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Abstract 
Streptococcus pneumoniae (pneumococcus) is a pathogen and a commensal of the upper respiratory 
tract, which is a leading cause of child mortality. The development of a successful vaccine against 
pneumococcal carriage and disease and the ongoing challenge of antimicrobial resistant strains 
mean that there is an imperative to understand how the pneumococcal population responds to 
vaccine and antibiotic pressure. 
Strains of pneumococci with reduced susceptibility to penicillin and other antibiotics have emerged 
and are a cause of concern, though their clinical impact is unclear. I perform a meta-analysis to 
examine the impact of antibiotic non-susceptibility on the risk of mortality and show that a 
meningitis infection with penicillin non-susceptible pneumococci increases the risk of mortality two 
fold. 
I then examine why some serotypes of pneumococcus are more likely to carry resistance than 
others. Using a mathematical model I generate the hypothesis that serotypes with a long duration of 
carriage are more likely to have a high prevalence of antibiotic resistance than those with a short 
duration of carriage. Using maximum likelihood estimation, I show that in children less than two 
years of age, penicillin resistance only occurs in those serotypes whose duration of carriage is 
nineteen days or more.  
Having considered the circumstances under which antibiotic resistance carries a selective advantage 
in a pneumococcal serotype, I then consider the effect that the spread of an advantageous gene has 
on the genetic diversity in a generalised bacterial population. Most simple models predict that when 
a novel allele arises in a bacterial population that is fitter than other alleles at that locus, it and its 
descendents will increase in frequency and sweep to fixation in the population. In the absence of 
recombination, all genetic diversity at all loci other than those within the sweeping genotype is lost.  
I consider whether asymmetric recombination can prevent the loss of diversity over the whole 
genome.  I show that asymmetric recombination, when occurring at rates estimated to date from 
bacterial populations, is not frequent enough to prevent the extinction of alleles from the wild-type 
population. Finally, I analyse sequence data sampled from carried pneumococci to examine the 
impact of vaccination on genetic diversity in a pneumococcal population, an example of a selective 
event in a pneumococcal population.  
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1 Introduction 
Streptococcus pneumoniae is a normal resident of the human upper respiratory tract where it is 
carried asymptomatically. It is an occasional but important human pathogen which can cause a wide 
range of disease (1). Streptococcus pneumoniae, also referred to as the pneumococcus, is a causative 
agent of diseases such as acute otitis media, meningitis and pneumonia (2). It has been estimated 
that 11% of all deaths of children under five in the year 2000 were caused by pneumococcal disease 
(3). 
The development of a successful vaccine against pneumococcal carriage and disease and the 
ongoing challenge of antimicrobial resistant strains mean that there is an imperative to understand 
how public health interventions affect the evolution of the pneumococcal population. The aim of 
this thesis is to examine the impact of antibiotic resistance and vaccination on pneumococcal 
population genetics. In this chapter I review relevant aspects of the biology, epidemiology and 
clinical impact of the pneumococcus. 
1.1 Biology  
1.1.1 Capsular Polysaccharide 
The pneumococcus produces an outer polysaccharide capsule, which is exposed on the surface of 
the pneumococcal cell, and provides a target for host immune response. Currently over 90 serotypes 
have been described, each with an immunochemically distinct capsular polysaccharide (CPS). Each 
CPS is composed of a series of repeated units of simple sugar structures (monosaccharide) linked 
together by glycosidic bonds, the repeated units being linked together and attached to the cell wall 
of the pneumococcus (4,5). Antigenic diversity between serotypes is due to the number and nature 
of monosaccharide structures, the type and configuration of the linkages between monosaccharides, 
non-sugar  composition and features such as acetylation (the addition of an acetyl group to a 
monosaccharide), and the form of linkages between repeated units. The CPS of some serotypes are 
relatively simple in structure, such as serotypes 3 and 37, whereas others are more complex, such as 
serotypes 6A and 15C (4). 
The pneumococcal capsular serotype is synthesised by the Wzx/Wzy-dependent pathway (with the 
exception of serotypes 3 and 37 which are synthesised by the synthase pathway).  The Wzx/Wzy-
dependent pathway involves the synthesis of the repeated units of the CPS, its translocation across 
the cytoplasmic membrane, and its polymerisation and linkage to the cell wall (6). As illustrated in 
Figure 1.1, the genes required for the synthesis of CPS through the Wzx/Wzy-dependent pathway 
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are located in a cluster of genes called the capsular biosynthetic locus (cps). The cps locus is at the 
same position on the pneumococcal chromosome in each serotype, bounded by two genes (dexB 
and aliA) which play no part in the synthesis of the capsule (4). Published sequences of cps loci have 
shown that although CPS are structurally diverse, the cps locus has a number of common features 
shared among serotypes. The first four genes of the locus (designated as wzg, wzh, wzd and wze 
using the Bacterial Polysaccharide Gene Naming (BPGN) scheme) are highly conserved between 
serotypes and are present at the 5’ end of the cps locus. In most serotypes the 5th gene encodes the 
initial sugar phosphate transferase WchA (also known as cpsE), which is responsible for the linkage 
of an activated glucose phosphate to the lipid carrier. The next section of the locus, downstream 
from the 5th gene, is a serotype specific region. In each serotype this region contains 
glycosyltransferase (GT) genes, the CPS repeat unit polymerase gene (wzw) and the CPS repeat unit 
flippase gene (wzx) and genes that encode acetyl transferases. Genes that code for sugar pathway 
proteins are often located at the 3’ end of the cps locus (7,8). 
14 
 
 
 
Figure 1.1 Schematic of the pneumococcal genome.  
Housekeeping genes (which code for metabolic function) characterised in the MLST scheme (aroE, gdh, gki, recP, spi, xpt, 
and ddl), the genes for PBPs, (pbp2x, -1a, -3, -2b, -2a, and -1b), the capsular locus flanked by the dexB and aliA genes, 
and the region around the capsular locus are depicted. Capsular loci are approximately 15 to 20kb in length, for example 
the capsular loci of serotypes 4 and 19A are 20.9 kb and 18.6 kb respectively. Reproduced from (8). 
 
1.1.2 Recombination 
Pneumococci are naturally competent bacteria, meaning that they can actively take free 
(extracellular) DNA from their environment, transfer it into the cell and incorporate it into their 
genome by homologous recombination (9).  The term ‘natural transformation’ has been coined to 
describe this process. Although detected over fifty years ago in laboratory experiments, the 
important role it plays in natural populations of pneumococci (those colonising the nasopharynx of 
humans) only came to light in the 1990s (10).   
Broadly, natural transformation occurs in three basic steps: association of free DNA with the 
competent pneumococcal cell, translocation of the DNA into the cytoplasm, and incorporation of the 
donor DNA into the genome.  Free double stranded DNA associates with competent cells to form a 
complex that is resistant to gentle washing though not to degradation by enzymes that digest DNA 
(DNase) (9). Pneumococci can potentially take up any free DNA (11), although the probability of 
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integration of a DNA strand decreases as genetic divergence between the donor and recipient 
increases (10).  
Recombination plays an important role in generating genetic diversity in the pneumococcal 
population. Unlike mutation where changes in the nucleotide code may result in the novel allele 
being non-functional, homologous recombination is expected to introduce functional sequences into 
the recipient pneumococcal genome as the donor DNA comes from a functional pneumococcus. In 
addition several independent fragments (1-5% of the genome) can be taken up per pneumococcal 
cell allowing novel combinations of genes to arise and the simultaneous substitution of components 
of protein complexes can occur in one transformation event (11).  Homologous recombination 
allows pneumococci to transfer DNA from pneumococci and closely related oral streptococci that 
share the same ecological niche (the human nasopharynx) (12). Thus it provides an extremely 
important mechanism allowing the rapid evolution of the pneumococcal genome (10).  Two well 
studied and clinically important aspects of pneumococcal evolution where homologous 
recombination has played an integral role are: firstly, the creation and spread of antibiotic resistant 
genes; and secondly, capsular polysaccharide switching between strains, which will be examined in 
more detail in Section 1.2.  
1.1.1 Carriage and disease 
The upper respiratory tract is the ecological niche for many bacterial species which colonise the 
nasopharynx within the first months of life. A broad variety of organisms, including the 
pneumococcus, Moraxella cattarrhalis, Haemophilus influenzae, Neisseria meningitidis and 
Staphylococcus aureus will colonise an individual in their lifetime, commonly resulting in 
asymptomatic carriage, or more rarely disease (13).  
i. Biology of carriage 
Adhesion is the initial event in asymptomatic carriage, and requires adherence of a pneumococcal 
cell to the epithelial lining of the respiratory tract (14). Adhesion of the pneumococcus to the 
epithelial lining is mediated by pneumococcal cell wall associated surface proteins which bind to the 
cell surface carbohydrates of the host (15). Pneumococci have a phase shift which allows them to 
exist in a transparent and an opaque state; pneumococci in transparent phase state have thick cell 
walls but sparse capsules, while in the opaque state have thin walls but thicker capsules. Animal 
models of nasopharyngeal carriage have demonstrated that acquisition of nasopharyngeal carriage 
is achieved more readily with transparent phase state pneumococci (16). As the transparent state 
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has thick cell walls but a sparse capsule, it is thought that this allows the sub-capsular proteins on 
the cell wall to attach to the epithelial lining more efficiently (17).   
The duration of asymptomatic carriage in an individual is age and serotype dependent, and although 
not fully understood, may be influenced by interactions between pneumococci and host immune 
effectors (18).  Immune mediated clearance from the nasopharynx involves both antibody 
dependent and independent mechanisms of immunity. The antibody independent mechanisms are 
thought to involve a T cell response which results in the recruitment of neutrophils to the site of 
carriage and the subsequent clearance of asymptomatic carriage (19,20). Although the role of the 
polysaccharide capsule in carriage is unclear, heavily encapsulated serotypes can avoid being 
destroyed by phagocytes (18). 
During the first two years of a child’s life there may be multiple instances of pneumococcal carriage 
with the same serotype or multiple different serotypes (21). In animal models of carriage there is no 
clear evidence that carriage of one serotype prevents subsequent carriage by the same serotype 
(22), although some mouse models of carriage show some evidence of immunity to re-infection (23). 
Thus, although it is observed that the incidence of pneumococcal carriage declines with age, the role 
of specific and natural human immune response (in particular in the context of exposure to multiple 
serotypes) is unclear (24).  However as I will later describe, there is good evidence that immunity 
artificially induced by serotype specific vaccines is protective against carriage of certain serotypes.  
ii. Epidemiology of carriage 
Person to person spread of pneumococcal carriage is thought to be through direct contact between 
individuals (25). Transmission and carriage prevalence are highest in young children (24). Although 
carriage prevalence varies between studies there is a common pattern: infants can be colonised in 
the first few weeks after birth, and the prevalence of carriage rises during the first year of life (1,14). 
In most studies prevalence of carriage declines after the age of four and decreases further into 
adulthood (26).  
There is some evidence that in healthy populations other risk factors additional to age determine the 
frequency of carriage. Independent determinants for nasopharyngeal carriage include ethnicity, 
crowding and socioeconomic factors (24). In young children, day care visits are significantly 
associated with carriage, and there is evidence of genotypic clustering of isolates among day care 
attendees, suggesting that transmission occurs among day care attendees (14,27). In a study of 
carriage in children under the age of three, children who attended day care had a mean prevalence 
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of carriage of 58%, while children who did not attend day care had a mean prevalence of carriage of 
37% (27).  
Studies from low income settings have shown that prevalence is higher in both children and adults in 
these settings compared to high income settings (21). In a study carried out in the Gambia, 
researchers followed a cohort of infants from birth to 11 months. During this time all the infants 
carried pneumococci  in the nasopharynx at least once, the mean prevalence of carriage was 85% in 
children under 11 months (21). In contrast, in a longitudinal household study carried out in the 
United Kingdom which followed children and their households for 10 months, only 86% of children 
carried pneumococci in the nasopharynx at least once. The mean prevalence of carriage was 36% in 
children under two years of age (26).  
However, within high income countries some communities have been found to have an increased 
risk of carriage. Studies of Native American and Native Alaskan communities in the United States 
have shown increased prevalence of carriage in all age groups (28). A study of White Mountain 
Apache and Navajo children in the United States found that 92% of 410 children surveyed acquired 
carriage of pneumococcus at least once during the study period, while the mean prevalence of 
carriage in children under two was 75% (29). This mean prevalence of carriage is two to three times 
higher than studies of similarly aged non-Native American children in the United States (30).  
iii. Biology and risk factors of disease 
Compared to the prevalence of asymptomatic carriage, pneumococcal disease is a rare consequence 
of acquisition of pneumococcal carriage (31). Pneumococci can cause symptomatic infections of the 
mucosa of the auditory canal (otitis media), the upper respiratory tract (sinusitis) or the lower 
respiratory tract (pneumonia) (24).  Pneumococcal infection can also result in invasive pneumococcal 
disease (IPD), defined as isolation of pneumococci from blood, cerebrospinal fluid (CSF), or other 
normally sterile sites (32). In contrast with asymptomatic carriage, the polysaccharide capsule is 
known to be a key virulence factor which is associated with disease.  The majority of pneumococci 
isolated from the blood or lungs are opaque phase organisms with a thick capsule and such 
organisms have been shown to be more efficient at causing invasive disease in rodents (33). The 
denser capsules of the opaque state provide greater protection against opsonisation and killing 
through phagocytosis (17).  
Risk factors for pneumococcal disease are increased age, underlying chronic illness in adults (34,35). 
In children day care centre attendance is a risk factor for disease, as day care attendance increases 
the risk of carriage and thus the risk of disease (36).  Serotype is also an important risk factor for 
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disease. Some serotypes have been shown to be more likely to cause disease than others (31). For 
example, in the United States seven serotypes, 4, 6B, 9V, 14, 18C, 19F, and 23F, were shown to be 
responsible for over 70% of the cases of IPD in the pre-vaccine era (37). In a study of IPD and 
carriage the authors showed significant differences in the rate of IPD per carriage acquisition. 
Serotypes 4, 14, 7F, 9V and 18C were associated with rates of 120 IPD cases per 100,000 acquisitions 
of carriage, and serotypes 23F 6A, 16F, 6B and 15B/C were associated with < 10 IPD cases per 
100,000 acquisitions (31).  
1.2 Interventions 
1.2.1 Vaccination 
Two types of vaccine against pneumococcal disease are currently licensed for use, a 23 valent 
polysaccharide vaccine, and multi-valent conjugate capsular polysaccharide vaccines. The 23 valent 
polysaccharide vaccine was licensed for use in 1983 and provides protection from invasive disease 
caused by serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 
22F, 23F, and 33F (37). Vaccine effectiveness in preventing IPD caused by the constituent vaccine 
serotypes has been shown to be 77% in adults over 60 (38,39). While there is evidence that this 
vaccine is effective in preventing disease in the elderly and adults with chronic disease, the vaccine 
does not protect children from IPD.  Pneumococcal polysaccharide capsules do not elicit a strong 
immune response in children (40), however by conjugating the polysaccharide capsule to a carrier 
protein a stronger immune response can be achieved. Thus, the pneumococcal vaccine currently 
used to prevent IPD in children is the seven valent conjugate polysaccharide vaccine (PCV7) (40). This 
vaccine will be replaced by a higher valent conjugate vaccine in the near future (2,41). 
i. Impact of the polysaccharide conjugate vaccine 
PCV7 provides protection from IPD caused by seven serotypes, 4, 14, 6B, 19F, 18C, 23F and 9V. 
Antibodies are raised against each of the polysaccharide capsules and so the vaccine is serotype 
specific (42). These serotypes were chosen for inclusion in the vaccine as together they were 
responsible for the majority of IPD in the United States prior to the year 2000 (40). In randomized 
control trials the vaccine was shown to be 98% effective in preventing IPD caused by the seven 
constituent serotypes (42).  In the United States the rate of disease caused by any vaccine serotype 
was 156 per 100,000 in children under the age of two in 1998-1999, after vaccination was 
introduced this rate fell to 33.6 per 100,000 children in 2001 (43). In the United States the 
introduction of PCV7 has resulted in a net reduction of IPD in all age groups, both in children 
vaccinated and in older adults. In all age groups IPD caused by all serotypes dropped from an 
average of 24.3 cases per 100,000 persons in 1998 and 1999 to 17.3 per 100,000 in 2001. In children 
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under the age of two the rate of disease caused by all serotypes declined from 188 cases per 
100,000 in 1998 and 1999 to 59 per 100,000 in 2001 (P<0.001) (43).  
The decline in IPD in unvaccinated groups is due to indirect or herd effects, as vaccination with PCV7 
has led to a decline in nasopharyngeal carriage of the seven vaccine serotypes in vaccinated children 
(44). A community randomised trial has shown that unvaccinated siblings of vaccinated children are 
less likely to be colonised with vaccine serotypes (45). As the highest levels of carriage prevalence 
and transmission are found in young children, PCV7 vaccination has resulted in a decline in disease 
caused by PCV7 serotypes in all age groups because the majority of transmission events in older age 
groups is assumed to occur due to contact between young children and older individuals (41).  
Vaccination has not resulted in a decline in asymptomatic carriage in children, rather PCV7 
vaccination leads to a reduction in nasopharyngeal carriage of vaccine serotypes (VT) while creating 
immunological and consequently selective pressure for an increased prevalence of non-vaccine 
serotypes (NVT).  A consequence of this has been serotype replacement (41). Serotype replacement 
in nasopharyngeal carriage has been demonstrated in a series of studies of children in 
Massachusetts communities. The authors collected samples from nasopharyngeal carriage in the 
period before and after the introduction of vaccination and demonstrated a significant decline in the 
prevalence of VT serotypes and concomitant increase in the prevalence of NVT serotypes in carriage 
(46-48). Invasive disease among children and adults caused by NVT serotypes has significantly 
increased in the United States post-vaccination, and the majority of IPD  among children under five 
years of age is now due to non-vaccine serotype 19A (49,50). 
Recombination plays an important role in allowing the survival of genotypes associated with vaccine 
serotypes. In the wake of PCV7 vaccination there was concern that acquisition of an NVT capsule 
through recombination by a pneumococcal strain capable of causing invasive disease would 
negatively impact on the effectiveness of any serotype-specific vaccine (51). Immunization by PCV7 
results in immunity against the capsular serotype, therefore genotypes associated with vaccine 
serotypes can survive in a vaccinated community though capsular switching. This is when the genes 
encoding one type of polysaccharide capsule are replaced, via transformation and recombination, 
with the genes encoding a different type of capsule (51). Capsular serotypes have a stable 
association with distinct genotype (52), however capsular switching from one serotype to another 
has previously been demonstrated (53-55). Capsular switching has been demonstrated in serotype 
19A (an NVT) after the implementation of PCV7 vaccination. Researchers have shown that a 
genotype previously associated with serotype 4 (a VT) has been found associated with the NVT 
capsule 19A (49,51,56). Authors have characterised these strains and demonstrated that the 
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association of serotype 19A capsule with the serotype 4 genotype arose as a result of a putative 
recombination event in 2003 (51).  
1.2.2 Antibiotic treatment and resistance 
The first line treatments for pneumococcal disease are β-lactam antibiotics such as penicillin. When 
such treatment fails the recommended second line treatments are third generation cephalosporins 
and vancomycin (57,58).  
i. Mechanism of resistance 
β-lactam antibiotics inhibit bacterial growth through binding to the cell wall synthesising enzymes, 
penicillin binding proteins (PBP), and therefore interfere with the synthesis of the pneumococcal cell 
wall during growth and division. Pneumococci develop resistance to β-lactam antibiotics through 
alterations to the PBPs which reduce their affinity to this class of antibiotics (59). Six PBPs have been 
described in the pneumococcus: 1a, 1B, 2x, 2a, 2b and 3 (60). Resistant strains show a mosaic 
structure in genes encoding 2b, 2x and 1a PBPs (61-63). A mosaic gene structure is where genes are 
constituted of regions identical to a susceptible gene interwoven with regions with a divergent 
nucleotide structure (61).  Highly divergent regions within the PBP genes of the resistant 
pneumococci contrast with the uniformity of the nucleotide sequences of other genes, and with the 
uniformity of the PBP  genes in penicillin susceptible pneumococci (60).  Thus, it is thought that 
altered PBP genes have arisen by localized interspecies recombination, involving the PBP genes of 
closely related streptococci (12,61).   
PBP alterations occur in a stepwise fashion, which confer different degrees of resistance to the 
antibiotic class. Pneumococci with no PBP alterations are fully susceptible to β-lactam antibiotics, 
primary alterations in the PBPs result in reduced susceptibility, which through further alterations can 
progress to intermediate susceptibility, and finally full clinical resistance (59,64). Although 
intermediately susceptible strains are less susceptible to antibiotics, diseases caused by such strains 
are successfully treated through increasing the dosage of β-lactam antibiotics, with the exception of 
meningitis (65). 
For individuals where treatment with β-lactam antibiotics is not possible (for example due to 
allergy), antibiotics from the macrolide class such as erythromycin are used. Although chemically 
distinct, macrolide, lincosamine and streptogramin antibiotics all bind to a ribosomal subunit and act 
as protein synthesis inhibitors (59). A number of mechanisms which confer resistance to these 
antibiotics have been described. For example the acquisition of an erythromycin ribosomal 
methylation gene (erm) results in a posttranscriptional modification of the 23S subunit of ribosomal 
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RNA, which blocks the binding of the macrolide to the ribosome. Expression of the gene results in 
high-level resistance to macrolide, lincosamines and streptogramin B (66). Another mechanism of 
resistance is through acquisition of genes encoding an efflux pump. Acquisition and expression of 
the mefA gene allows the pneumococcus to effectively excrete the antimicrobial reducing 
intracellular erythromycin, azithromycin and clarithromycin to ineffective concentrations (67). In 
contrast to β-lactam resistance, macrolide resistance via these mechanisms is absolute, and cannot 
be overcome by increasing the dosages of antibiotics (59,68,69). Macrolide resistance determinants 
are found on mobile genetic elements (transposons), which unlike PBP genes are not a normal 
component of the bacterial genome (70). 
ii. Spread of antibiotic resistance 
An antibiotic resistant phenotype can spread in the host population though transmission. For 
example many multi-drug resistant strains of 23F isolated from different countries have related 
genotypes, identical mosaic PBP genes and the same serotype suggesting global clonal spread (71). 
In section 1.1.2 I briefly referred to the fact that recombination was an important factor in the 
creation and spread of antibiotic resistance in pneumococci. I have already discussed the role of 
recombination in creating mosaic genes that confer penicillin resistance, but recombination also 
allows pneumococci to spread resistance horizontally through the population. When homologous 
recombination transfers a gene from one genotype to another, the PBP gene does not change. Thus 
it can be assumed that identical PBP genes found in multiple genotype or serotypes have spread 
horizontally through recombination rather than arising independently multiple times (72). 
Research into the evolution of antibiotic resistance has largely focused on the influence of treatment 
on prevalence of resistance. Cohort studies of invasive disease have shown that antibiotic use 
increases the risk that the patient will be infected with a resistant strain of pneumococcus (36). At a 
national level there is a remarkable correlation between antibiotic use in a nation and prevalence of 
pneumococcal resistance. The ESAC study calculated outpatient antibiotic consumption in Europe 
between 1997 and 2003. This study showed wide variation in antibiotic use in different countries 
and seasonal trends in usage. When the total consumption of all antibiotics was compared between 
countries, consumption was found to vary by a factor of 3 between the country with the highest 
usage (31.4 daily doses per 1000 inhabitants  per day in Greece) and the country with the lowest (9.8 
daily doses per 1000 inhabitants per day in the Netherlands) (73). In a study of 26 European 
countries Goossens et al. (74) showed that the prevalence of resistance in invasive disease and 
found a significant association between penicillin use and prevalence of penicillin resistance in IPD 
(74).  
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iii. Cost of resistance 
Antibiotic resistance is often assumed to be associated with reduced fitness (the capability of a 
genotype to survive and reproduce) (75). This cost may arise because additional DNA is synthesized 
by the resistant bacteria when resistance is encoded on plasmids or transposons. There is also an 
energetic cost to the bacterium from the maintenance of antibiotic transport mechanisms such as 
efflux pumps. It is also possible that changes in the PBPs of resistant pneumococci have a negative 
effect on their function, thus decreasing the fitness of resistant pneumococci (70).  If resistance is 
associated with reduced fitness, it has been proposed that a reduction in antibiotic use would 
benefit fitter susceptible strains of pneumococci enabling them to outcompete resistant strains over 
time (75).  Estimation of the cost of antibiotic resistance in pneumococci has to date examined the 
fitness of resistance strains in vitro and in mouse models of infection. For example a study which 
investigated the relative fitness of gemifloxin resistant strains found that resistant strains had an 
increased generation time when compared to susceptible strains (76). To date there has been no 
examination as to whether resistant pneumococci have reduced fitness in their natural habitat 
(human nasopharynx).  However promising research has shown that a dramatic reduction in 
antibiotic use results in an associated reduction in resistant pneumococci, suggesting that resistance 
is associated with a fitness cost and consequently a reduction of community antibiotic use can result 
in the out competition of resistant strains by sensitive strains (77). 
It should be noted that the interaction between antibiotic resistance, fitness and virulence can be 
more complex. In some bacterial species, there is evidence that ‘compensatory mutations’ can 
restore wild-type fitness to strains which carry antibiotic resistance (78,79). Much of the research 
into the effect of antibiotic resistance on fitness has been restricted to the laboratory, there is a real 
need to examine the impact (or lack of impact) of antibiotic resistance on fitness in the human 
nasopharynx.  
1.2.3 Mathematical models of interventions 
i. Mathematical models of antimicrobial resistance 
Previous research into the spread of antibiotic resistance has examined the role of different factors 
that influence the prevalence of antibiotic resistance in bacterial populations. Both generalised and 
pathogen specific epidemiological mathematical models of drug resistance have been published 
which examine community and hospital acquired infections. In each model the major selective 
pressure driving increasing prevalence of antibiotic resistance is the volume of drug use (80).  
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Studies such as these present the patterns of emergence and establishment of drug resistance in 
clinical community settings as being similar and consistent. After the introduction of antibiotic 
treatment a long period of very low prevalence of resistance is followed by a phase of rapid increase 
and the slow approach to an equilibrium level <100% (80-83).  Studies which are most appropriate to 
understand the evolution of resistance in pneumococcal populations are those that examine the 
spread of resistance in the community.  The emergence and establishment of penicillin resistance in 
pneumococci in Iceland has been characterised in this way (82). The authors simulated the evolution 
of antibiotic resistance and constructed a population genetic framework embedded in a 
transmission model which showed that penicillin resistance increased over time in a community 
following the form of a sigmoid curve. The authors then fitted the model to the prevalence of 
resistance in pneumococcal infection in Iceland over a number of years. During the 1980s the first 
pneumococcal resistant isolates were identified in Iceland and the frequency of resistance rose 
rapidly. In response, antibiotic consumption by children was reduced by 12.7% between 1992 and 
1995. As a result of the intervention, resistance peaked in 1993 at 19.8% and then declined (82). 
These mathematical models quantified the relationship between resistance and treatment rates; 
they identified a threshold treatment rate over which the prevalence of resistance increases rapidly 
to the equilibrium level (81-83).  
More recent research has explored why sensitive strains can persist in pneumococcal populations, 
even under constant treatment over a long period of time. An unusual characteristic of the impact of 
antibiotic use in the pneumococcal population has been the maintenance of antibiotic sensitive 
strains over a long period of time, this runs counter to predictions from simulations of the spread of 
antibiotic resistance in most mathematical models. In the study of penicillin resistance in Iceland, 
peak prevalence of resistance was 19.8%. Austin et al. (80-83) estimated that equilibrium penicillin 
resistance in this population would be ~20% if there was no reduction in antibiotic use. The authors 
overcame the problem of explaining coexistence in a mathematical model by explicitly incorporating 
strain difference between resistant and sensitive strains. The sensitive strain was less transmissible 
than the resistant strain (even in the absence of antimicrobial use), but better at superinfection (80-
83). However there is no empirical evidence to support this assumption. Thus, although Austin et al. 
(80-83) successfully fitted the mathematical model to data, the assumptions that underlie the model 
structure are unproven and the problem of explaining the mechanism of co-existence remains 
unsolved. This problem is significant as it undermines mathematical model based predictions in 
public health management and highlights a fundamental gap in our understanding of the dynamics 
of antimicrobial resistance. 
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Lipsitch et al. developed a suite of mathematical models of the pneumococcal system to examine 
the conditions under which sensitive strains can be maintained in the population (84,85). The initial 
model considered the scenario of single carriage in which the hosts may carry one strain or the 
other. This model was unsatisfactory as it predicted that the sensitive or resistant strain would be 
competitively excluded and so does not adequately describe the pneumococcal population (86). A 
second model allowed dual carriage but predicted a stable equilibrium even in the absence of 
antibiotic treatment or when the competing strains were indistinguishable in fitness, which is clearly 
not a realistic result (87).  
ii. Mathematical model of vaccine impact 
An integral part of simulating the impact of vaccination on the pneumococcal population is 
simulating the stable coexistence of serotypes before and after vaccination. To date a satisfactory 
mathematical model which achieves this has not been developed. This is largely due to the fact that 
the mechanism maintaining many serotypes in the population is not understood. Different serotypes 
have many biological differences (88), these include, duration of carriage, invasiveness, accessibility 
of surface determinants (89), and antimicrobial resistance (90). What isn’t clear is which if any of 
these mechanisms are responsible for the maintenance of multiple serotypes in the population over 
time (84). 
In the absence of this information a model with an explicit coexistence mechanism can only produce 
tentative predictions as to the impact of vaccination on serotype prevalence and coexistence. 
However such models can provide a useful tool to understand the impact of vaccination on a multi 
strain system (84). The majority of mathematical models which consider vaccination in a multi-strain 
system have considered viral infections (91-94). The dynamics of multiple strain infection, re-
infection and transmission may be very different for a bacterial system given the differing immune 
reactions to the two organisms. Lipsitch considers the impact of a serotype specific pneumococcal 
vaccine using a mathematical model of a bacterial multi strain system. Using the model, the author 
showed that in a two serotype system the reduction in carriage from the vaccinated serotype will be 
exceeded by an increase in carriage from the non-vaccine serotype (86). Models of multi strain 
systems predict the competitive exclusion of vaccine serotypes in the population-a prediction that 
has been largely borne out by the changes in serotype prevalence in carriage (48).  
 
1.3 Typing pneumococci  
To understand the clinical impact, epidemiology, population and evolutionary biology of 
pneumococcal populations it is vital to index the variation between strains of pneumococci. Broadly 
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two distinct methods are currently utilised. The first identifies antigenic variation in the 
pneumococcal population and the second examines other genetic variation. 
1.3.1 Antigenic typing 
As I have discussed in previous sections the capsular polysaccharide of the pneumococcus is an 
important identifier which is associated with the likelihood of disease, antibiotic resistance or 
vaccine protection. A typing method which identifies different serotypes is therefore clinically 
important. Antigenic typing mechanisms identify the reaction of antibodies to a bacterial antigen. In 
the case of the pneumococcus this is the capsular polysaccharide (95). 
Currently the most common method of determining the serotype of a pneumococcal isolate is the 
quellung reaction.  This is a biochemical reaction in which anticapsular antibodies bind to the capsule 
of a bacterium together with India ink, causing the capsule to swell and its outlines to become 
clearly demarcated. The capsule can then be identified through microscopy (96). For certain 
common serotypes this method has been advanced so that multiple serotypes can be identified in a 
semi automated fashion using a multiplex immunoassay with distinct labelled microspheres 
conjugated to serotype specific antibodies (97). Although the quellung reaction is the gold standard 
for serotype discrimination it does have disadvantages. The high cost of antisera, the requirements 
for technical skills and the complexity in interpretation limit its ease of use in all settings (98).  PCR 
techniques to identify the capsular polysaccharide have been developed (99,95), however these 
have not been developed for comprehensive surveillance and so, to date, the standard technique 
used in the surveillance of pneumococcal isolates from disease or carriage is the quellung reaction. 
Antigenic typing of pneumococci has been used to identify the variation in serotypes causing 
invasive disease. This has allowed capsular polysaccharide vaccines to be designed so that they 
maximise their impact against serotypes which most commonly cause invasive disease.  In addition 
surveillance of the serotypes causing invasive disease allows us to examine the impact of vaccination 
campaigns. 
1.3.2 Molecular typing 
As I have discussed in previous sections, the identification of capsular switching and the transfer of 
antibiotic resistant genes between serotypes has highlighted the importance of identifying 
pneumococcal genetic diversity within a serotype.  To do so a tool is needed to provide a suitable 
level of discrimination to distinguish between pneumococcal isolates of the same serotype. 
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Multi Locus Sequence Typing (MLST) was developed as a tool for clinical microbiologists and 
epidemiologists who require a suitable typing mechanism to compare strains of interest from 
different regions, countries and over time (100). This requires a typing scheme with a high level of 
discrimination so that all isolates assigned to a type are likely to have shared a recent common 
ancestor and isolates from a more distant common ancestor are not assigned to the same type 
(101). 
Global and long term epidemiological research requires a typing mechanism that characterises 
regions of the genome where variation is accumulating very slowly, is likely to be selectively neutral 
(or not subject to frequent convergent selection leading to homoplasies), and where the mechanism 
underlying the generation of variation is well understood (102). For this reason MLST identifies 
sequence variation in housekeeping genes which encode essential metabolic functions. Compared to 
nucleotide sequencing of a gene under selection only a small number of alleles at each locus can be 
identified using this method, however high level discrimination between strains is achieved by 
characterising variation at multiple loci (100).  
The MLST scheme used to identify a pneumococcal strain characterises sequence variation at seven 
housekeeping genes: ddl, spi, recP, aroE, gdh, gdh, gki and xp (103). Alleles are identified by 
obtaining the nucleotide sequences of internal fragments of each gene. The gene fragments are 
amplified from chromosomal DNA using PCR with appropriate primers and then sequenced. For each 
gene fragment the nucleotide sequences are then compared to all previously identified sequences at 
that locus and assigned an allele number. Newly identified sequences are assigned a new allele 
number and isolates with identical sequences are assigned the same allele number. For each strain 
the combination of seven allele numbers defines its sequence type (ST), this profile is then added to 
the mlst.net internet database (100) 
The first benefit of MLST is that high discrimination can be achieved when characterising a strain, 
while allowing researchers to identify lineages of isolates over a long period of time or wide 
geographic area (100). The second is that a multi locus typing scheme is particularly appropriate to 
examine pneumococcal strains where recombination plays an important role in the generation of 
genetic variation (104). Homologous recombination can obscure the relationship between two 
closely related strains and lead to inconsistent relationships between strains inferred through 
sequencing a single gene. The use of MLST means that relationships identified between strains are 
more robust; if the alleles at the majority of loci in two strains are identical, a recombination event 
at one locus does not obscure the relationship between two strains (105). MLST has proven 
extremely useful in examining the population genetics of pneumococcal populations (106,105). It 
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has allowed researchers to identify globally distributed antibiotic resistant clones of pneumococcus 
(107,102) but also gain a greater understanding of the evolution of strains in asymptomatic carriage 
(108).  
1.4 Aims of thesis 
The overall aim of this thesis is to examine the impact and evolution of antibiotic resistance and the 
impact of strong selective pressure on the population structure of S. pneumoniae.  
To achieve this overall aim I will examine four questions in the course of this thesis: 
 What is the added burden of mortality associated with antibiotic resistant pneumococci? 
Research into the burden of pneumococcal disease has shown that pneumococcal pneumonia, 
meningitis and bacteraemia are responsible for a significant burden of mortality in children under 
five. Surveillance of the prevalence of penicillin resistance has shown that in some countries more 
than 50% of isolates are resistant to penicillin. In Chapter 2 I will carry out a systematic review and 
meta-analysis to examine whether antibiotic resistance (primarily penicillin resistance) contributes 
an added burden of mortality.  
 How and why are antibiotic resistant strains distributed among serotypes? 
Even if resistance to antibiotics in the pneumococcus does not have an obvious impact on mortality 
in invasive disease at this time, treatment failure in non-invasive and invasive disease leads to the 
use of antibiotics which are more expensive to administer.  It is important then to study and 
understand the distribution of antibiotic resistance in pneumococcal populations, and what gives 
rise to it. Given that the serotypes of the pneumococcus have distinct characteristics and antibiotic 
resistance is known to associate more frequently with some serotypes than others I will use a 
mathematical model and analysis of serotype prevalence to examine how and why antibiotic 
resistance is distributed among the serotypes. This will be described in Chapters 3 and 4. 
 What effect does the spread of advantageous alleles have on genetic diversity in the 
population? 
The growing collection of MLST data provides an opportunity to understand how the spread of 
evolutionary advantageous alleles affects the genetic diversity in the pneumococcal population. I will 
carry out a review of the bacterial and eukaryotic population genetics literature to examine whether 
current techniques have adequately described the impact of selection on a bacterial population like 
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S. pneumoniae where homologous recombination plays an important role in generating and 
maintaining diversity. Chapter 5 will detail the results of the review and provide a comparison 
between a model incorporating eukaryotic type recombination and one incorporating bacterial type 
recombination. I shall construct and simulate a stochastic model of a selective sweep of 
advantageous alleles through a bacterial population. This research will be reported in Chapter 6. 
 How does vaccination impact on diversity assessed by MLST in the pneumococcal population? 
Use of the pneumococcal conjugate vaccine has significantly changed the distribution of serotypes in 
disease and carriage. In Chapter 7 I will take insights from the mathematical model of a simple 
selective sweep and analyse whether the predictions of this model can adequately describe the 
selection in the pneumococcal population which arose as a result of vaccination. 
29 
 
 
2 The impact of pneumococcal antibiotic resistance on mortality: a 
review and meta-analysis 
2.1 Introduction 
The threat from antimicrobial resistance has long been illustrated as an arms race between the 
development of effective antibiotic therapy and the evolution of drug resistance. Antimicrobial 
resistant pathogens are generally thought to result in infections with higher morbidity and mortality 
than similar infections with antibiotic sensitive pathogens. This increased negative clinical impact is 
most likely due to a lack of suitable treatment, as a delay in the treatment of the infection can be 
detrimental to the patient. As penicillin resistant pneumococcal infection can still be successfully 
treated with a number of antibiotics, an infection with a penicillin resistant organism is not 
necessarily characterised as clinically costly at the current time (109). However, given that resistant 
pneumococci are common (110), it is important to estimate whether resistance already adversely 
impacts on a patient’s survival. 
Pneumococcal infections are classed as susceptible to an antibiotic when the recommended 
therapeutic dosage will successfully clear an infection, intermediately resistant  when a higher 
dosage of the same antibiotic can still successfully clear an infection and resistant to an antibiotic 
when no dosage of the antibiotic can clear an infection.  Several studies have investigated the 
differences in mortality rates of infections with antibiotic susceptible and non-susceptible 
(intermediately and fully resistant organisms) pneumococci, to assess the impact of antibiotic 
resistance in pneumococcal infections. These studies have not produced consistent results. Some 
cohort and case-control studies have suggested that there is no significant impact of pneumococcal 
non-susceptibility on mortality (18). However a meta-analysis of the impact of penicillin non- 
susceptible  pneumococcal (PNSP) pneumonia found that there was a significant increased risk of 
mortality associated with  PNSP infections (109). Some authors have criticised this interpretation 
(110,111), pointing out that pneumococcal pneumonia was treated with antibiotics other than 
penicillin in the majority of cases studied. Furthermore, when a patient was recorded as receiving 
discordant therapy (when a patient is treated with penicillin although the infection is caused by 
PNSP pneumococci) there was no increased adverse effect when compared to patients treated with 
a concordant therapy (109,111). They suggest that any association between PNSP pneumonia and 
increased mortality is a result of confounders associated with PNSP infections and not due to 
resistance itself (112,113). 
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Such confounders make it difficult to distinguish between: a) an association between antibiotic 
resistance and poor outcome and b) causality between resistance and poor outcome. Possible 
confounders include age, underlying disease and severity of disease. A patient who has an 
underlying medical condition or is of advanced age may have a greater risk of death from a 
pneumococcal infection than a younger individual with no underlying medical condition (114). A 
patient with an underlying condition may also be more likely to previously be prescribed antibiotics 
(for any infection, not necessarily pneumococcal). As prior antibiotic therapy is associated with an 
increased risk of colonisation with a resistant pneumococcal strain (OR 4.0) (115), such a patient is 
more likely to carry asymptomatically, or suffer from a symptomatic infection, with a resistant strain.  
Assessing the impact of PNSP and resistant infection in pneumococcal disease is further complicated 
by the range of pneumococcal disease and the ability of antibiotics to penetrate the site of infections 
differently. For example, it is known that penicillin penetrates the cerebral spinal fluid (CSF) poorly, 
so much higher dosages of penicillin are needed to be effective in the treatment of meningitis 
compared to pneumonia or bacteraemia (116). Thus, it is important then to examine each invasive 
disease syndrome separately. 
As I mentioned in the above, a meta-analysis which examined pneumococcal pneumonia was 
published, however no comparable study on meningitis or bacteraemia has been published. In 
recent years the possible impact of penicillin non-susceptibility on meningitis has been highlighted 
by Klugman et al. (112), who noted that penicillin is often the treatment of choice for meningitis in 
Sub-Saharan Africa (112,116). There is a need therefore to carry out an analysis of the impact of 
penicillin non-susceptibility in pneumococcal meningitis.  
2.1.1 Aims 
In order to estimate the impact of resistance on IPD I will perform a systematic review and meta-
analysis. I will examine the impact of resistance on mortality as mortality is an outcome that can be 
easily compared across studies and is most widely reported. Given that treatment of pneumococcal 
infection has changed in developed countries in response to increasing prevalence of resistance, I 
hypothesise that the impact of resistance on mortality will be most keenly felt in those countries 
whose routine treatments have not changed in response to resistance.  
To examine this I will: 
 Carry out a systematic review of all IPD,  
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 Examine the impact of resistance on mortality in three major syndromes: meningitis, 
bacteraemia and invasive pneumonia, 
 Attempt to examine the impact of known confounders. 
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2.2 Method 
2.2.1 Literature search terms and strategy 
The search terms used in the systematic search of PubMed are outlined in Table 2.1. The search 
strategy was made up of four sections: A) Organism B) Study type, C) Resistance, D) Outcome and E) 
Exclusions. The search was conducted on papers published up to March 2009. When a group of 
studies was collected from the systematic search results, further studies were identified through 
reading the reference lists of collected papers. 
Where appropriate I used PubMed MeSH terms which increase the breadth and success of the 
search. MeSH is the United States National Library of Medicine’s controlled vocabulary used for 
indexing articles for PubMed/MEDLINE.  MeSH terms are assigned by hand to journal articles 
submitted to PubMed. They provide a consistent way to retrieve information where different 
terminology may be used to describe the same topics or concepts (117). For example using 
Streptococcus pneumoniae as a MeSH term will return articles where “Streptococcus pneumoniae”, 
“S. pneumoniae”, “pneumococcus” etc. are MeSH subheadings that have been assigned to the text. 
In contrast searching for “Streptococcus pneumoniae” as a conventional search term will return only 
articles where the phrase Streptococcus pneumoniae is present in the text.  
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Table 2.1 Search Terms 
Search component Search Terms Result 
Organism/Syndrome "Pneumonia"*MeSH Major Topic+ OR “Pneumonia, Ventilator-
Associated"[MeSH] OR "Pneumonia"[MeSH] OR "Pneumonia, 
Bacterial"[MeSH] OR "Pneumonia, Pneumococcal"[MeSH] OR 
"Pneumococcal Infections"[MeSH] OR "Meningitis, 
Pneumococcal"[MeSH] OR "Streptococcus pneumoniae"[MeSH] 
OR "Otitis"[MeSH]  
97418 
AND Study type 
 
"Clinical Trials as Topic"[MeSH] OR "Clinical Trials as Topic"[MeSH] 
OR "Evaluation Studies as Topic"[MeSH] OR "Evaluation 
Studies"[Publication Type] OR "Epidemiologic Studies"[MeSH] 
OR "Clinical Trial"[Publication Type]  
14938 
AND Drug resistance 
 
"Drug Resistance"[MeSH] OR "Drug Resistance, Multiple, 
Bacterial"[MeSH] OR "Drug Resistance, Bacterial"[MeSH]  
1102 
AND Outcome 
 
mortality OR “short term mortality”  354 
AND Exclusion 
 
"Pneumococcal Vaccines"[MeSH Major Topic] 349 
 
i) Inclusion criteria 
Studies were eligible for inclusion if they reported or allowed calculation of the mortality for antibiotic 
resistant, non susceptible and sensitive pneumococcal infections. All studies of IPD were included as long as 
the study identified that the infection was caused by Streptococcus pneumoniae and death was a result of the 
pneumococcal infection. I also included cohort and case control studies, both prospective and retrospective, 
and infections from all age and patient groups.  
ii) Screening and article retrieval 
To determine whether articles were eligible for further review the title and abstract of the article 
was read at the search stage. If not relevant the article was screened out at this stage. Articles that 
only contained the following types of data listed below were excluded at this stage: case reports, 
vaccine safety studies, nasopharyngeal carriage studies, animal model studies, studies of species 
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other than S. pneumoniae. If an article was eligible for further review it was retrieved electronically 
and when this was not possible a hard copy was obtained from Imperial College Library. 
iii) Exclusion criteria and variables recorded 
I reviewed the whole text of the retrieved articles and excluded those that did not fit the pre-defined 
inclusion criteria. Articles were excluded if they did not report S. pneumoniae specific rates of 
disease or mortality. Studies which lacked adequate data to form a contingency table describing 
survival and antibiotic specific resistant disease status were also excluded. 
iv) Location and year of study 
The country or countries included in the study was recorded. If a study was carried out in more than one 
country but the authors did not report separate results for each country, all country names were noted and 
the reported data were recorded. I noted the year of publication of the article and the time period during 
which the study was undertaken. 
v) Study design and population 
I recorded whether data collection was prospective or retrospective, whether the study could be classified as 
case control or a cohort study and what statistical model had been used to analyse data. I also noted the age 
range and size of the study population and the disease inclusion criteria and antibiotic resistance tested in the 
study.  
vi) Study outcomes 
The principal outcome of interest recorded was mortality. I noted whether the mortality definition recorded in 
the study was “in hospital mortality”, “30 day mortality” or all mortality.  In order to calculate contingency 
tables for mortality I recorded the number of cases and number of deaths for study participants with a 
resistant or susceptible infection. Where available I also recorded the length of stay in hospital and costs 
associated with treatment for resistant and susceptible infections. I also collected data on the antibiotic 
treatment used where this was stated. Where an adjusted mortality Odds Ratio (OR) had been calculated in a 
study using a statistical model this was recorded. 
vii) Antibiotic resistance 
I recorded what antibiotic resistance had been tested for and the susceptibility breakpoints that had 
been used in testing.  
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2.2.2 Statistical methods 
The initial meta-analysis was based on the unadjusted OR calculated from raw deaths and survival 
data collected from the studies. ORs and 95% confidence intervals for individual studies were 
calculated and pooled using the Review Manager software package (RevMan 5.0) (118). A fixed 
effects model was used to pool the effect estimates. Crude ORs were weighted using the Mantel-
Haenszel weighting method. Forest and funnel plots based on the data were formed using the 
RevMan software. All sub-group analysis was also carried out using RevMan software. 
When calculating ORs for penicillin susceptibility I compared the number of deaths among patients 
with a PNSP infection to deaths among patients with penicillin sensitive S. pneumoniae (PSP) 
infections. In line with the pre-2008 (Clinical and Laboratory Standards Institute) CLSI MICs, PSP 
isolates were isolates with a minimum inhibitory concentration (MIC) of ≤0.06 µg/mL and PNSP 
isolates were those with a MIC of over 0.1 µg/mL. For isolates tested for cefotaxime resistance, I 
compared the number of deaths in the group infected with isolates with an MIC over 0.25µg/ml to 
those with an MIC below this. I calculated separate ORs for each resistance type. In these analyses I 
only considered “in hospital” deaths or deaths that occurred thirty days after diagnosis with S. 
pneumoniae infection. I calculated pooled estimates of adjusted OR by combining the separate 
estimates of inverse variance-weighted log OR from each study. I carried out subgroup analysis 
where appropriate. I calculated pooled ORs for each syndrome and study country. 
2.3 Results 
2.3.1 Search results 
The systematic literature search was carried out until 30th March 2009. The search generated 1102 
results when restricted to those that reported mortality data and studies which carried the MeSH 
term “Pneumococcal Vaccine” as a major topic the number of results generated was 349. I reviewed 
the title and abstract of these studies and collected 65 studies suitable for further review. From the 
review of the full text of these papers I excluded 35 papers. References of excluded studies and their 
reasons for exclusion are presented in Table 2.2. The most common reason for exclusion at this 
stage was that the study did not have resistance related mortality data. Other studies were excluded 
as they were serotype surveillance studies and reviews with no original data.  
Thirty papers were selected that had data suitable for inclusion in the review and I also included ten 
suitable papers from review of the bibliographies of systematically searched papers. A summary of 
the characteristics of these studies is presented in Table 2.3. The most common study country was 
the United States where thirteen studies were carried out. The earliest study started in 1979 and the 
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most recent study finished in 2005. Included in the meta-analysis were ten bacteraemia studies, 
eight studies of meningitis, twelve studies of pneumococcal pneumoniae, one study of 
pneumococcal peritonitis, one study of endocarditis and nine studies of mixed invasive 
pneumococcal infection (IPnI). The largest study size had 3452 patients with PSP infection and 741 
patients infected with PNSP infection. The smallest study had 64 patients in total.  
The most common antibiotic susceptibility analysed was penicillin non-susceptibility. The other 
antibiotic studied was cefotaxime. When the initial treatment regime was reported in the study 
penicillin was the least common form of treatment. Penicillin was reportedly used to treat patients 
with pneumonia and other IPDs (188) and one study in Hong Kong reported its use in the treatment 
of bacteraemia (166). Both African studies included, reported that treatment of patients with 
meningitis was with penicillin (176,112). 
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Table 2.2 Excluded Studies  
Author, Year of Publication Article References Reason for rejection 
(Chomarat et al. 2002), (Echave 
et al. 2003), (Fernandez 
Guerrero et al. 2003), (Garcia-
Lechuz et al. 2007), (Gentile et 
al. 2003), (Jette and Lamothe 
1989), (Laupland et al. 2004), 
(Leelarasamee, Dhiraputra, and 
Hunnangkul 1999), (Levin et al. 
2003), (Mattei, Falleiros-
Carvalho, and Cavalcante 2008), 
(Rendi-Wagner et al. 2004), 
(Siegel 1999), (Watanabe et al. 
2000), (Woolfson et al. 1997), 
(Yanagihara et al. 2004), (Yaro 
et al. 2006) 
(119), (120), (121), (122), (123), (124), 
(125), (126), (127), (128), (129), (130), 
(131), (132), (133), (134) 
No information on resistance related 
mortality 
(Chen et al. 2006), (Friedland 
and Klugman 1992), (Ramos et 
al.  1996), (Sirinavin et al. 2003),  
(Sanz Herrero et al. 2003),  (Wu 
et al. 2000) 
(135), (136), (137), (138), (139), (140) Text unavailable 
(Tan 2003), (Tleyjeh et al. 2006) (141), (142) Review 
(Ispahani et al. 2004), (Sjostrom 
et al. 2006) 
(143), (32) Serotype Study 
(Rowland and Turnidge 2000) (144) No deaths in the study group 
(Hoffman et al. 2003) (67) Mouse Model 
(Wandi, Kiagi, and Duke 2005) (145) Mixed Bacterial Study 
(Huang et al. 2007) (146) Incorrect Species 
(Madhi et al. 2000) (147) HIV Comparison Only 
(Yu and Baddour 2004) (148) Comment 
(Dylewski and Davidson 2006) (149) Case Report 
(Sun, Nicolau, and Kuti 2006) (150) Economic Analysis 
(Isozumi et al. 2007) (66) Genotyping study 
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Table 2.3 Studies included in meta-analysis  
 
Author, Year of 
Publication 
 
 
Reference 
 
Country Study Type Age
(i)
 Syndrome Period of Study Antibiotic Initial Treatment Regime Study Size 
(Ailani et al. 2002) (151) USA Retrospective Case Control 53
a
 Pneumonia 1993-1999 Cephalosporin Cephalosporin 78 
(Arditi et al. 1998) (152) USA Prospective Cohort 9
a
 Meningitis 1993-1996 Penicillin Cephalosporin 180 
(Aspa et al. 2004a) (153) Spain Prospective Cohort 16 to 97 Pneumonia 1999-2000 Penicillin … 638 
(Capdevila et al. 2001) (154) Spain Retrospective Case Control 14 to 65 Peritonitis 1979-1998 Penicillin … 90 
(Castillo et al. 2000) (155) USA Retrospective Cohort 1 to 83 Bacteraemia 1991-1998 Penicillin … 281 
(Choi and Lee 1998) (156) Korea Retrospective Cohort 0 to 15 IPnI 1985-1996 Penicillin 
Penicillin, Vancomycin, 
Macrolide 
72 
(Ewig et al. 1999) (159) Spain Prospective Cohort 26 to 82 Pneumonia 1996-1998 Pen and Ceph Macrolide 101 
(Falco 2004) (160) Spain Prospective Cohort 62.8
b
 Pneumonia 1997-2001 Penicillin Penicillin, Ceftriaxone 247 
(Feikin et al. 2000) (157) USA Prospective Cohort 0 to 85 IPnI
ii
 1995-1997 Penicillin … 12194 
(Fiore et al. 2000) (161) USA Retrospective Cohort 2 to 94 Meningitis 1994-1996 Cefotaxime Vancomycin 109 
(Friedland and Klugman 
1992) 
(162) South Africa Prospective Cohort 3-16 Meningitis 1989-1991 Penicillin Penicillin 79 
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Author, Year of 
Publication 
 
Reference 
 
Country Study Type Age
(i)
 Syndrome Period of Study Antibiotic Initial Treatment Regime Study Size 
(Gomez et al. 1995) (163) Spain Prospective Cohort 12 to 84 Bacteraemia 1989-1993 Penicillin … 71 
(Gomez-Barreto et 
al. 1999) 
(164) Mexico Prospective Cohort 0 to 8 Meningitis 1994-1998 Penicillin … 38 
(Gomez-Barreto et 
al. 2000) 
(165) Mexico Prospective Cohort 2 to 4 IPnI 1994-1998 Penicillin Ceftriaxone 49 
(Ho et al. 2006) (166) Hong Kong Retrospective Cohort 
10 to over 
70 
Bacteraemia 1995-2001 Penicillin Penicillin 173 
(Iannini et al. 2007) (167) USA Retrospective Cohort 33 to 80 Pneumonia 2004-2005 Erythromycin … 122 
(J Kellner 1999) (170) Canada Case Control 0 to 15 Meningitis 1991-1999 Penicillin Ceftriaxone 75 
(Jehl 2002) (168) France Prospective Cohort 65
a
 Pneumonia 1998-2000 Penicillin Macrolide 465 
(Kaplan et al. 1998) (169) USA Prospective Cohort 0 to 18 IPnI 1993-1996 Penicillin Ceftriaxone 1291 
(Kim et al. 2002) (34) South Korea Retrospective Cohort 18 to 90 Bacteraemia 1996-2001 Penicillin … 151 
(Kumashi et al. 2005) (171) USA Retrospective Cohort 34 to 72 Bacteraemia 1998-2002 Penicillin Fluoroquinolones 122 
(Ma, 2002) (172) Taiwan Retrospective Cohort 0 to14 IPnI 1990-2000 Penicillin … 72 
(Maddox and Winter 
2003) 
(173) UK Retrospective Cohort 0 to 98 Bacteraemia 1998-2000 
Penicillin & 
Macrolide 
Erythromycin 106 
(Martinez et al. 
2002) 
(158) Spain Prospective Cohort 18 to 79 Endocarditis 1978-1998 Penicillin … 63 
(Maugein et al. 2003) (174) France Survey 0 to over 70 Bacteraemia 1997 Penicillin … 438 
(Metlay, 2002) (175) USA Retrospective Cohort 53a Pneumonia 1994 Penicillin … 192 
(Molyneux et al. 
2002) 
(176) Malawi 
RCT(Dexamethasone 
treatment) 
2 months- 
15 years 
Meningitis 1997-2001 Penicillin 
Penicillin & 
Chloramphenicol 
188 
(Moroney et al. 
2001) 
(177) USA Case Control 56.8
b
 Pneumonia 1994-1996 Cefotaxime Ceftriaxone 255 
40 
 
Author, Year of 
Publication 
 
Reference 
 
Country Study Type Age
(i)
 Syndrome Period of Study Antibiotic 
Initial Treatment 
Regime 
Study Size 
(Mufson, Chan, and 
Stanek 2007) 
(178) USA Retrospective Cohort 18 to 96 Pneumonia 1983-2003 Penicillin Cephalosporin 185 
(Pagliano et al. 2007) (179) Italy Prospective Cohort 0 to 7 Meningitis 1997-2005 Penicillin Cephalosporin 64 
(Pallares et al. 1995b) (180) Spain Prospective Cohort 19 to 70 IPnI 1994-2000 Penicillin 
Ceftriaxone and 
Penicillin 
456 
(Pallares et al. 2002b) (181) Spain Prospective Cohort 19 to  over 70 IPnI 1994-2000 Cephalosporin Ceftriaxone 429 
(Quach et al. 2002) (182) Canada Case control 0 to 18 IPnI 1989-1998 Penicillin Ceftriaxone 144 
(Sangthawan 2003) (183) Thailand Prospective Cohort 52.5
b
 Pneumonia 1998-2001 Penicillin … 46 
(Song 2004) (184) 9 Asian countries Prospective Cohort 60.8
b
 Pneumonia 2000-2001 Penicillin 
Penicillin, 
Cephalosporin 
233 
(Turett et al. 1999) (185) USA Retrospective Cohort 0 to 102 Bacteraemia 1992-1996 Penicillin … 456 
(Wasier et al. 2005) (186) France Retrospective Cohort 0 to 9 Meningitis 1990-2003 Penicillin Vancomycin 49 
(Winston et al. 1999) (187) USA Case control 30 to 58 IPnI 1994-1996 Penicillin … 476 
(Yigla 1995) (188) Israel Prospective Cohort 60.2
b
 Pneumonia 1989-1990 Penicillin Penicillin 22 
(Yu et al. 2003) (189) Multi-Country Prospective Cohort 15-97 Bacteraemia 1998-2001 Penicillin Cephalosporin 844 
i) Study population age is in the form of a range or a)median age and b)mean age 
ii) IPnI 
iii) Italicized  text are studies included through bibliographic rather than systematic searches 
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2.3.2 Unadjusted ORs 
I extracted the number of cases and deaths for antibiotic non-susceptible and susceptible infection. 
These were inputted into the RevMan software package which was used to calculate individual and 
pooled ORs. Results were obtained from 3371 non-susceptible infections and 9559 susceptible 
infections. 580 deaths occurred in the non-susceptible infection group and 1206 deaths occurred in 
the susceptible infection group. The pooled OR for all studies was 1.30 (CI 1.16-1.46).  
Three studies examined the effect of cefotaxime resistance only. Results were obtained from 92 
resistant infections and 287 susceptible infections. There were 13 deaths in the group of patients 
infected with cefotaxime resistant pneumococcus and 48 deaths in the group of patients infected 
with cefotaxime susceptible pneumococcus. Analysed separately from the PNSP isolates the pooled 
OR for these three studies is 0.89 (CI 0.45, 1.76).  
The remaining studies analysed the effect of PNSP infection on mortality. There were 2753 patients 
with PNSP infection. 526 of these patients died in hospital or within 30 days of diagnoses. 8500 
patients were infected with penicillin susceptible bacteria, 1066 of these patients died. The pooled 
OR for these studies is 1.49 (CI 1.32, 1.69).  
2.3.3 Sub-group analysis 
As the effect of cefotaxime resistance was only reported in three studies I restricted further 
subgroup analysis to penicillin susceptibility only. I grouped the studies by country and syndrome. 
Shown in Figure 2.1, IPnI and pneumococcal pneumonia had the closest estimated ORs to the 
average with ORs of 1.27 (CI 1.04 -1.55) and 1.53 (CI 1.28 – 1.84) respectively. Bacteraemia 
infections had a pooled OR of 1.03 (CI 0.78-1.36). Meningitis infections had a pooled OR of 1.54(CI 
1.01-2.34).  
I also analysed the studies by country or region where appropriate. This is illustrated in Figure 2.2 
which shows the unadjusted ORs for studies carried out in regions or countries. Spain and the United 
States were analysed distinct from other studies from Europe or the Americas. Asian, other 
European and North and South American were analysed regionally. The lowest value of pooled OR is 
0.67 (CI 0.13-3.41) and was reported by studies carried out in Canada. The pooled OR for the two 
African studies was 2.25 (CI 1.29-3.94), which was the highest found from the sub regional analysis.  
However, any apparent regional effects were insignificant once syndrome and treatment biases 
were accounted for. Different syndromes were unevenly distributed between regions, for example, 
there were no studies of pneumococcal meningitis reported from Spain, but there were four 
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pneumonia studies. There was a small difference between OR for pneumonia from Spanish and 
United States studies, the pooled OR for pneumococcal pneumonia from United States studies was 
1.52 (CI 0.87, 2.66) whereas that for Spanish studies was 1.85 (CI 1.38-2.49), though the difference is 
not statistically significant. There were only two studies from Africa, one from Malawi and another 
from South Africa. The study from Malawi is data extracted retrospectively from a randomised 
control trial of dexamethasone use in the treatment of children with bacterial meningitis (112,176). 
The study from South Africa was a small prospective cohort of children with pneumococcal 
meningitis (162).  Both these studies reported that patients infected with PNSP meningitis had an 
increased risk of death compared to a PSP infection.  
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Study or Subgroup
8.1.1 Meningitis
Arditi 1998
Fiore 2000
Friedland 1992
Gomez-Barreto 1999
Kellner 2002
Molyneux 2002
Pagliano 2007
Wasier 2005
Subtotal (95% CI)
Total events
Heterogeneity: Chi² = 7.13, df = 7 (P = 0.42); I² = 2%
Test for overall effect: Z = 2.01 (P = 0.04)
8.1.2 IPnI
Choi 1998
Feikin 2000
Gomez-Barreto 2000
Kaplan 1998
Ma 2002
Pallares 2002
Quach 2002
Winston 1999
Subtotal (95% CI)
Total events
Heterogeneity: Chi² = 3.10, df = 7 (P = 0.88); I² = 0%
Test for overall effect: Z = 2.30 (P = 0.02)
8.1.3 Pneumonia
Ailani 2002
Aspa 2004
Ewig 1999
Falco 2004
Iannini 2007
Jehl 1995
Metlay 2000
Moroney 2001
Mufson 2007
Pallares 1995
Sangthawan 2003
Song 2004
Yigla 1995
Yu 2003
Subtotal (95% CI)
Total events
Heterogeneity: Chi² = 14.47, df = 13 (P = 0.34); I² = 10%
Test for overall effect: Z = 4.33 (P < 0.0001)
8.1.4 Peritonitis
Capdevila 2001
Subtotal (95% CI)
Total events
Heterogeneity: Not applicable
Test for overall effect: Z = 1.39 (P = 0.16)
8.1.5 Endocarditis
Martinez 2002
Subtotal (95% CI)
Total events
Heterogeneity: Not applicable
Test for overall effect: Z = 0.75 (P = 0.45)
8.1.6 Bacteraemia
Castillo 2000
Gomez 1995
Ho 2006
Kim 2002
Kumashi 2005
Maddox 2003
Maugein 2003
Turett 1999
Subtotal (95% CI)
Total events
Heterogeneity: Chi² = 11.81, df = 7 (P = 0.11); I² = 41%
Test for overall effect: Z = 0.20 (P = 0.85)
Total (95% CI)
Total events
Heterogeneity: Chi² = 46.14, df = 39 (P = 0.20); I² = 15%
Test for overall effect: Z = 4.49 (P < 0.00001)
Test for subgroup differences: Not applicable
Events
2
2
13
1
1
22
1
9
51
3
101
11
4
10
8
1
6
144
1
42
8
16
6
28
10
15
8
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7
18
3
45
262
5
5
7
7
2
6
21
18
8
2
24
8
89
558
Total
35
22
30
11
29
45
10
16
198
32
741
25
221
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55
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65
1206
26
229
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66
87
202
44
98
52
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19
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7
195
1355
21
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24
24
34
23
81
74
44
7
133
19
415
3219
Events
12
13
11
4
3
45
1
14
103
1
383
7
15
5
23
3
31
468
3
50
3
23
1
48
32
18
16
85
5
13
5
90
392
18
18
15
15
23
8
38
17
11
36
65
64
262
1258
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146
87
49
27
42
143
54
32
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40
3452
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1062
26
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108
411
5253
52
409
52
181
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148
157
133
359
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105
15
598
2534
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43
39
39
158
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84
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303
402
1306
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Weight
0.9%
1.0%
1.0%
0.4%
0.5%
2.3%
0.1%
0.8%
7.0%
0.2%
24.1%
0.8%
1.0%
0.8%
2.4%
0.3%
1.6%
31.2%
0.4%
6.0%
0.6%
1.9%
0.3%
7.4%
2.3%
2.4%
1.6%
6.3%
0.5%
2.5%
0.4%
7.0%
39.6%
1.9%
1.9%
1.7%
1.7%
1.6%
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4.4%
2.6%
1.3%
0.7%
6.7%
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18.7%
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M-H, Fixed, 95% CI
0.68 [0.14, 3.17]
0.57 [0.12, 2.73]
2.64 [0.99, 7.08]
0.57 [0.06, 5.81]
0.46 [0.05, 4.70]
2.08 [1.05, 4.12]
5.89 [0.34, 102.88]
1.65 [0.49, 5.54]
1.54 [1.01, 2.34]
4.03 [0.40, 40.79]
1.26 [1.00, 1.60]
1.91 [0.58, 6.23]
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1.00 [0.10, 9.93]
1.25 [0.50, 3.12]
1.27 [1.04, 1.57]
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1.61 [1.03, 2.52]
2.67 [0.67, 10.65]
2.20 [1.08, 4.48]
2.52 [0.29, 21.72]
0.72 [0.43, 1.20]
1.07 [0.48, 2.39]
1.40 [0.67, 2.92]
1.33 [0.53, 3.33]
1.97 [1.30, 2.98]
2.57 [0.67, 9.86]
1.16 [0.54, 2.49]
1.50 [0.24, 9.46]
1.69 [1.13, 2.53]
1.48 [1.24, 1.77]
0.43 [0.13, 1.40]
0.43 [0.13, 1.40]
0.66 [0.22, 1.96]
0.66 [0.22, 1.96]
0.37 [0.08, 1.64]
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0.89 [0.48, 1.67]
1.13 [0.53, 2.42]
1.47 [0.55, 3.99]
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0.81 [0.48, 1.36]
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1.30 [1.16, 1.46]
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Study or Subgroup
8.1.1 Meningitis
Arditi 1998
Fiore 2000
Friedland 1992
Gomez-Barreto 1999
Kellner 2002
Molyneux 2002
Pagliano 2007
Wasier 2005
Subtotal (95% CI)
Total events
Heterogeneity: Chi² = 7.13, df = 7 (P = 0.42); I² = 2%
Test for overall effect: Z = 2.01 (P = 0.04)
8.1.2 IPnI
Choi 1998
Feikin 2000
Gomez-Barreto 2000
Kaplan 1998
Ma 2002
Pallares 2002
Quach 2002
Winston 1999
Subtotal (95% CI)
Total events
Heterogeneity: Chi² = 3.10, df = 7 (P = 0.88); I² = 0%
Test for overall effect: Z = 2.30 (P = 0.02)
8.1.3 Pneumonia
Ailani 2002
Aspa 2004
Ewig 1999
Falco 2004
Iannini 2007
Jehl 1995
Metlay 2000
Moroney 2001
Mufson 2007
Pallares 1995
Sangthawan 2003
Song 2004
Yigla 1995
Yu 2003
Subtotal (95% CI)
Total events
Heterogeneity: Chi² = 14.47, df = 13 (P = 0.34); I² = 10%
Test for overall effect: Z = 4.33 (P < 0.0001)
8.1.4 Peritonitis
Capdevila 2001
Subtotal (95% CI)
Total events
Heterogeneity: Not applicable
Test for overall effect: Z = 1.39 (P = 0.16)
8.1.5 Endocarditis
Martinez 2002
Subtotal (95% CI)
Total events
Heterogeneity: Not applicable
Test for overall effect: Z = 0.75 (P = 0.45)
8.1.6 Bacteraemia
Castillo 2000
Gomez 1995
Ho 2006
Kim 2002
Kumashi 2005
Maddox 2003
Maugein 2003
Turett 1999
Subtotal (95% CI)
Total events
Heterogeneity: Chi² = 11.81, df = 7 (P = 0.11); I² = 41%
Test for overall effect: Z = 0.20 (P = 0.85)
Total (95% CI)
Total events
Heterogeneity: Chi² = 46.14, df = 39 (P = 0.20); I² = 15%
Test for overall effect: Z = 4.49 (P < 0.00001)
Test for subgroup differences: Not applicable
Events
2
2
13
1
1
22
1
9
51
3
101
11
4
10
8
1
6
144
1
42
8
16
6
28
10
15
8
55
7
18
3
45
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5
5
7
7
2
6
21
18
8
2
24
8
89
558
Total
35
22
30
11
29
45
10
16
198
32
741
25
221
31
55
36
65
1206
26
229
57
66
87
202
44
98
52
145
19
128
7
195
1355
21
21
24
24
34
23
81
74
44
7
133
19
415
3219
Events
12
13
11
4
3
45
1
14
103
1
383
7
15
5
23
3
31
468
3
50
3
23
1
48
32
18
16
85
5
13
5
90
392
18
18
15
15
23
8
38
17
11
36
65
64
262
1258
Total
146
87
49
27
42
143
54
32
580
40
3452
24
1062
26
130
108
411
5253
52
409
52
181
35
263
148
157
133
359
27
105
15
598
2534
43
43
39
39
158
48
135
77
84
99
303
402
1306
9755
Weight
0.9%
1.0%
1.0%
0.4%
0.5%
2.3%
0.1%
0.8%
7.0%
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2.3.4 Adjusted ORs 
Few studies reported adjusted ORs calculated from a statistical model. This was because antibiotic 
resistance was rarely a significant indicator of mortality in the univariate analysis. Table 2.4 presents 
the adjusted ORs them for the impact of PNSP infection on mortality for the four studies which 
reported. Where studies reported ORs no confidence intervals were reported. Where the ORs are 
reported they are consistent and within the confidence interval of the pooled unadjusted OR found 
by the meta-analysis.  The studies had all been adjusted for age, but only two had adjusted for 
underlying illness. None of the models found PNSP infection to be a significant indicator of mortality 
once the model had been adjusted for confounding variables.  
Table 2.4 Adjusted OR 
 Reference OR P Value Variables Adjusted 
(Winston et al. 1999) (187) 1.25 0.82 Age, Gender, Homelessness 
(Yu et al. 2003) (189) 1.42 0.19 Age, Critical Illness, Immunosupression, Chronic Disease 
(Feikin 2003) (190) 1.3
 
NS Age 
(Pallares et al. 1995) (180) 1.3 0.84 Age 
PNSP infections vs. PSP Infections 
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2.4 Discussion 
This systematic review and meta-analysis examined published literature to analyse whether patients 
infected with an antibiotic resistant strain of S. pneumoniae had an increased risk of mortality 
compared with patients infected with antibiotic sensitive strains.  One finding of the systematic 
search was that the majority of studies recorded whether the pneumococcal isolate was PNSP or 
PSP. Thus, this meta-analysis examined whether PNSP infections had an increased risk of mortality 
compared to PSP infections.  
2.4.1 Impact of PNSP is syndrome dependent 
The impact of PNSP infections varied dependent on the syndrome (pneumonia, bacteraemia and 
meningitis) assessed.  Therefore, I will interpret the pooled ORs of each syndrome in turn. 
i. Invasive pneumonia  
The synthesis of published studies on mortality for patients with invasive pneumococcal pneumonia 
showed an association between PNSP pneumonia and an increased risk of mortality (OR 1.48, 95% CI 
1.24-1.77). I also considered a subgroup of studies which grouped invasive pneumonia with 
bacteraemia; referred to as non meningeal IPnI. The combined OR for these studies also showed an 
association between PNSP IPnI and an increased risk of mortality (OR 1.27 CI 1.04-1.57). These 
results are consistent with the result of a previous meta-analysis on the effect of antibiotic resistant 
pneumococcal pneumonia (142).  
The results from both sub-groups indicate an association between PNSP and increased risk of 
mortality, however it is not necessarily appropriate to interpret this as a causative relationship 
between PNSP infection and excess mortality. A number of studies in the meta-analysis did not 
appropriately control for confounding from age or severity of underlying illness or increased age 
within the study, which are in turn associated with increased severity of pneumonia. A common 
feature of the cohort and case control studies which considered pneumococcal pneumonia was that 
the patient populations examined ranged in age from young adults to the elderly, and the 
populations were not stratified by age (159,160,168,172,180,183,184,188,189,191,192). Previous 
research has shown that PNSP infection is associated with increased age as well as underlying 
medical conditions (193), so any apparent association between PNSP infection and increased 
mortality could be an association between age or underlying illness and increased risk of mortality. 
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In those studies where an OR was calculated using a regression model which allows the authors to 
control for confounding, PNSP infection was never found to have a significant negative impact on 
mortality once confounders such as underlying illness and age were controlled for (187,194) . The 
results of the multivariate models indicate that any association between PNSP and increased risk of 
mortality is a function of the known associations between underlying disease and antibiotic 
resistance, these underlying factors increase the risk of mortality independent of the susceptibility 
status of the infecting strain.  
If there is no significant causal association between PNSP infection and increased mortality, then it 
follows that discordant therapy is unlikely to have a negative impact. Most studies examining 
pneumococcal pneumonia reported that patients were not treated with penicillin. The most 
common reported treatment was cephalosporin(159,160,168,172,183,184,188,189,191,195,196) . In 
those studies where patients were treated with penicillin, there was no increased risk of mortality 
and thus, no evidence for the negative impact of discordant therapy (34,188). 
ii. Bacteraemia 
The combined OR for studies of bacteraemia was 1.03 (95% CI 0.77, 1.37). This indicates that PNSP 
bacteraemia is not associated with a higher risk of mortality than patients with PSP bacteraemia. 
This is a reasonable interpretation as while all studies tested the bacteria for penicillin susceptibility 
the treatment of choice was a third generation cephalosporin or vancomycin. Therefore patients did 
not experience a delay in treatment. (189). Only one other study reported the treatment regime of 
the patients. Ho et al. reported that the majority of patients in their study were initially treated with 
penicillin (197). This study did not report any negative impact of treatment on mortality.  
iii. Meningitis 
The combined OR for all studies which examined patients with meningitis was 1.54 (95% CI 1.01-
2.34). This indicates that PNSP meningitis infections are associated with an increased risk of 
mortality compared to PSP infections. Unlike the studies examining bacteraemia and pneumonia, 
the patient population included in the meningitis cohorts were all children, thus age was a not a 
confounding factor in these studies. If this association was a true indication of the negative impact of 
PNSP meningitis one would expect to see a negative impact of discordant therapy. 
The recommended initial treatment in the United States, Europe for pneumococcal meningitis is 
third generation cephalosporin or vancomycin. In studies carried out in the US and Europe analysed 
in this meta-analysis, patients were treated with third generation cephalosporin or vancomycin. In 
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all these studies the authors reported the association between PNSP infection and mortality.  The 
combined OR for these studies was 0.96 (95% CI 0.47- 1.94) (152,161,198,186,179). This indicates 
that if patients are initially treated with appropriate therapy PNSP infection carries no excess risk.  
When patients are not treated with concordant therapy the outcome is very poor. Studies carried 
out in Africa reported that patients with PSP and PNSP meningitis were treated with penicillin 
(162,176) , the patients with PNSP meningitis had over twice the risk of mortality compared to 
patients with PSP meningitis (OR 2.25, 95% CI 1.29-3.94) (162,176).  
2.4.2 PNSP meningitis places an excess burden of mortality in regions with routine penicillin 
use 
Klugman et al. highlighted that penicillin and chloramphenicol remains widely used in the treatment 
of meningitis in developing countries (112). The possible clinical impact of an increased mortality 
due to PNSP meningitis is dependent on the prevalence of PNSP pneumococci in carriage and 
disease in a region. Currently national systematic surveillance systems of the prevalence and 
incidence of PNSP pneumococci are largely restricted to Europe and North America (199), though 
the SENTRY surveillance system was established in 1997 to monitor the prevalence of antimicrobial 
resistance in clinically relevant pathogens in the United States, Canada, Europe, Latin America, and 
the Asia-Pacific region (200). Such surveillance systems estimate the prevalence of antibiotic 
resistance (particularly to penicillin and erythromycin) in invasive disease isolates and indicate that 
PNSP is a global problem. PNSP has been shown to be of clinical relevance in studies carried out in 
Sub-Saharan Africa. In one such study 70% of isolates from respiratory infections in South Africa 
were intermediately resistant to penicillin (136) and in another study in rural Malawi 17% of cases of 
pneumococcal meningitis were intermediately resistant to penicillin (112). A survey of published 
literature found that the average prevalence of intermediate penicillin resistance from studies in 
Central Africa was 13% (201).  
Although it was known for some time that meningitis was responsible for much child mortality 
worldwide, this has been quantified systematically in a recent study. O’Brien et al. calculated the 
burden of disease caused by S. pneumoniae in children younger than 5 years, and estimated that in 
2000, 14.5 million episodes of serious pneumococcal disease occurred worldwide (203).   The 
greatest number of cases occurred in Asia, while the greatest number of cases per head of 
population under the age of five occurs in Africa (3). An estimated 43,100 cases of pneumococcal 
meningitis occurred in the African region (as defined by WHO region) and the incidence rate is 
estimated as 38 cases per 100,000 children under 5 (203). Thus, given that pneumococcal meningitis 
is a serious public health problem in Africa, and the clinical impact of PNSP meningitis is so severe if 
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incorrectly treated there is an urgent need to survey the prevalence of PNSP at a national level in 
this region and to allow physicians resources to efficiently treat meningitis with appropriate 
concordant therapy. 
2.4.3 Penicillin is still an effective treatment for many episodes of pneumococcal pneumonia 
and bacteraemia 
All studies used in this analysis calculated the susceptibility of the infection to penicillin treatment 
using the CLSI guidelines published prior to 2008. Before January 2008 isolates susceptible to 
penicillin were defined as those with a MIC of ≤0.06 µg/ml. As I stated in the introduction the effect 
a dosage of penicillin has on an infection depends on the site of treatment (65). If a drug is to be 
clinically effective then the concentration at the site of infection (blood stream, lungs or central 
nervous system) must exceed the MIC of the isolate 95% of the time. As penicillin penetrates poorly 
into the cerebrospinal fluid, the dosage of penicillin at the site of infection for meningitis will be 
much less than an infection in the lungs or blood stream. Thus a dosage of penicillin which may be 
suitable for treatment of a PNSP bacteraemia will be not suitable to treat PNSP meningitis. This 
explains the effects of treatment seen in this meta-analysis.  
In January 2008 the CLSI guideline MICs were changed to reflect the true clinical impact of penicillin 
non-susceptibility, MICs for penicillin non-susceptibility in meningitis remained the same while the 
MICs for non-meningitis infections when treated intravenously were increased (18). The results of 
this meta-analysis are supportive of this change. Only studies examining PNSP meningitis infections 
reported a negative outcome as a result of discordant therapy, while patients infected with PNSP 
meningitis or bacteraemia showed no increased risk of mortality as a result of treatment with 
penicillin. On this basis these revised breakpoints penicillin administered intravenously is still an 
effective treatment for most invasive pneumonia and bacteraemia.  
Mortality is one important but narrow definition of impact and cost, and due to a paucity of study I 
did not attempt to quantify the increased cost of treatment or length of stay of patients with PNSP 
infection.  A consequence of the unnecessary use of third generation cephalosporin and vancomycin 
to treat pneumococcal pneumonia and bacteraemia is that an unnecessary economic cost is being 
imposed on health systems.  
A caveat to the optimistic analysis above is the problem of truly penicillin resistant pneumococci. 
While in resource rich settings these can still be effectively treated with alternative therapy such a 
third generation cephalosporin and vancomycin, these alternative treatments may not be routinely 
available in resource poor settings. The incidence of pneumococcal pneumonia in children under 5 in 
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the year 2000 is estimated as 3,397 per 100,000 in Africa and 2,911 per 100,000 in South East Asia 
(202). An increase in the prevalence of penicillin resistant infections could result in an increased rate 
of mortality or greatly increased economic burden due to treatment provision. 
2.5 Conclusion 
At the outset the aim of this meta-analysis was to examine the impact of antibiotic resistance on the 
risk of mortality. The results showed that penicillin non-susceptibility increased the risk of mortality 
two fold when patients with non-susceptible meningitis were treated with penicillin.  
Firstly this result demonstrates the importance of treatment guidelines for clinicians that take 
account of the effect of non-susceptibility on treatment. Such guidelines are influenced by the 
prevalence of resistance seen in patients and so are dependent on accurate surveillance of antibiotic 
resistance. In countries where penicillin treatment of meningitis is routine due to lack of awareness 
of the prevalence of PNSP, or lack of resources to treat routinely with more treatment, such as third 
generation cephalosporin or vancomycin, the risk of death increases two fold for a patient with PNSP 
meningitis compared to a patient with PSP meningitis. 
Secondly these results warn of the impact of the loss of third generation cephalosporins as effective 
treatment of meningitis due to development of resistance to this antibiotic. They show that once 
effective treatment options are all but exhausted antimicrobial resistance will result in an increased 
risk of mortality.  
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3 Explaining heterogeneous prevalence of resistance among 
serotypes: Hypothesis and Mathematical Model 
3.1 Introduction  
In the previous chapter, I showed that PNSP infection can be clinically costly. In pneumococcal 
meningitis, the probability of death is doubled for patients with a PNSP infection inappropriately 
treated with penicillin. Although the impact of antibiotic non-susceptibility can be overcome by 
changing treatment regimen, this is not always possible and so patients may still be inappropriately 
treated, especially in resource poor settings. Thus, interventions to prevent the emergence and 
spread of antibiotic resistance are necessary and so understanding how antibiotic resistance evolves 
in a pneumococcal population is of direct public health importance. In this chapter I will shift focus 
onto the study of the basic mechanisms which regulate the spread of antibiotic resistance at the 
population level. 
Broadly, the question of what determines the prevalence of resistance is separate from that of 
understanding how genetic mechanisms of resistance evolved in the first place. The prevalence of 
resistance is determined by a trade-off on the one hand between selective pressure exerted by 
human consumption of antibiotics, and on the other the biological cost of resistance which reduces 
the ability of resistant strains to spread. The details of this trade off are quantitative and specific to 
each case. We will therefore need a detailed mathematical model of resistance and antibiotic 
consumption in the pneumococcal population to help interpret trends. 
3.1.1 Antibiotic consumption occurs independently of carriage 
The majority of carriage and transmission of pneumococci occurs amongst children under the age of 
two. The majority of episodes of carriage do not lead to disease (204). Infants and children under 
two years of age have very high rates of antibiotic consumption (205) and these high rates of 
antibiotic consumption, combined with high rates of carriage, place a selective pressure on 
pneumococci to develop and maintain antibiotic resistance. Resistant strains of pneumococcus 
maintained in the carriage population can then occasionally cause invasive disease in all age groups, 
so prevalence of resistance in invasive disease is related to that found in carriage.  
Because antibiotic consumption occurs independently of carriage, mathematical models of 
resistance in the pneumococcus will differ in an important respect from models of resistance in 
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obligate pathogens where treatment occurs in direct response to infection.  For the pneumococcus 
antibiotic consumption and carriage should be modelled as uncoupled independent processes. 
3.1.2 The importance of serotype 
Previously published surveys of pneumococcal carriage have reported uneven distributions of 
antibiotic resistance among serotypes. Some serotypes are more likely to carry antibiotic resistance 
than others and this pattern is conserved among surveys from different countries and settings (90). 
Broadly 6B, 9V, 14, 19F, 23F, 6A and 19A are frequently associated with antibiotic resistance and 
serotypes 3, 18C, 15A and 1 are more rarely associated with antibiotic resistance (90).   
This phenomenon has been illustrated particularly well in a recently published study of 
pneumococcal invasive disease in Spain, which compiled surveillance of IPD from 1979 to 2007 
(193). This survey examined the prevalence of PNSP in invasive disease (which is the prevalence of 
isolates that were intermediately susceptible to penicillin and those which were resistant). During 
the 1990s the prevalence of PNSP was stable at 42% for all isolates. However serotypes 1, 3, 4, 5, 7F 
and 8 had no reported penicillin non-susceptibility, whereas serotypes 6B, 9V, 14, 19F and 23F were 
90 -100% PNSP (193).  
This simple but striking observation leads us to consider which aspects of serotype biology could 
explain these observed heterogeneities in resistance. 
The three important characteristics of serotypes to consider are: 
 Invasiveness, 
 Serotype-specific age distribution of carriage and disease, 
 Prevalence and duration of carriage. 
 
i. Invasiveness 
As discussed previously, certain serotypes are more likely to cause disease than others.  The relative 
attack rates (relative invasiveness of a serotype) of pneumococcal serotypes were measured using 
national UK surveillance data on IPD and serotype-specific acquisition rates collected from a 
longitudinal study of carriage.  This study found significant differences between attack rates. For 
example serotypes 4, 13, 7F, 9V and 18C were associated with 120 invasive disease cases /100,000 
acquisitions and serotypes 23F, 6A, 19F, 16F, 6B and 15B/C were associated with 10 invasive disease 
cases /100,000 acquisitions (31). However, differences in a serotype’s invasiveness does not seem to 
be a plausible biological mechanism to explain differences in resistance since, as discussed above, 
there is no strong link between antibiotic consumption and carriage.  
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ii. Age 
Traditionally serotypes thought to be particularly associated with carriage in children have been 
characterised as ‘childhood’ serotypes. Serotypes which are commonly isolated from the 
nasopharynx of children would be under greater antibiotic pressure than serotypes isolated more 
commonly from adults, as children consume more antibiotics. Therefore any study which looks for 
an association between serotypes and resistance should be stratified by age to avoid spurious 
associations. The impact of age will be explored in Chapter 4. 
 
iii. Serotype prevalence and duration 
Authors have frequently noted that the more prevalent serotypes have a higher prevalence of 
antibiotic resistance (193,56). This in turn is linked to the duration of time a serotype is carried in an 
individual; serotypes that are carried for a longer time are more likely to be present in the sampled 
population. Previous studies have consistently shown that different serotypes are carried for 
different amounts of time in the host (206,207,31,208). Although there is variation in serotype-
specific duration of carriage estimated from different studies, certain serotypes are consistently 
characterised as having a short duration of carriage (such as serotype 4, (31,209,210)) or a long 
duration of carriage (such as serotype 6A (31,209,210)). Different serotypes are also present at 
different prevalences in the population (206,207,31,208).  
 
Recently an interesting biological mechanism which explains differences in serotype duration has 
been discovered (18). In the study, the authors hypothesised that serotypes that had less complex 
capsular polysaccharide structures may be more successful at evading the immune system, and so 
persist longer in the host and at higher prevalence in the population. Weinberger et al. showed that 
serotypes with less complex polysaccharides were more heavily encapsulated and that heavily 
encapsulated serotypes were less susceptible to clearance by the immune system of the host (18). 
When the authors compared their findings to published data on serotype prevalence and carriage 
duration, heavily encapsulated serotypes were found to have longer durations of carriage and to be 
more prevalent in the population (18). 
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3.2 Hypothesis - distribution of antibiotic resistance amongst serotypes 
Taking previously published knowledge of serotype characteristics, a hypothesis was developed to 
explain the distribution of antibiotic resistance among serotypes. Figure 3.1 illustrates schematically 
the effect of antibiotic resistance on two serotypes with two different durations of carriage (the 
period of time between acquisition and natural clearance by the immune system). The natural 
duration of carriage is thought to be the same in a resistant and sensitive strain of the same 
serotype in the absence of antibiotic consumption. When an individual consumes an antibiotic, the 
sensitive strain is cleared from the nasopharynx and has its duration of carriage cut short. The 
resistant strain is carried for its natural duration, irrespective of antibiotic use. As the resistant strain 
is carried longer than the sensitive strain, the resistant strain has more opportunity for transmission 
and thus becomes more prevalent as a constituent strain of the serotype. The fitness advantage of a 
resistant strain is thus the average difference in carriage duration between it and the sensitive 
strain.  
From Figure 3.1, I hypothesise that the relative fitness advantage is greatest in serotypes with longer 
durations of carriage. Therefore a serotype with a long duration of carriage gains a larger advantage 
in being resistant than a serotype with a short duration of carriage. As a result, one would expect 
there to be a positive relationship between the duration of carriage of a serotype and the presence 
of antibiotic resistance.  
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Figure 3.1 Relative impact of resistance.  
This illustrates the relative fitness advantage of a resistant strain (red) when it is a serotype (A) with a long duration of 
carriage (time between acquisition and natural clearance) compared to a serotype (B) with a short duration of carriage. 
 
As I discussed in the introductory chapter, antibiotic resistance is often associated with reduced 
fitness of the resistant strain compared to the sensitive strain (211). In communities where antibiotic 
use is absent or rare, the reduced fitness of the resistant strain means that they are outcompeted by 
sensitive strains. Conversely, for a resistant strain to become established in a community, the fitness 
advantage of antibiotic resistance must be greater than the fitness cost of resistance. On the other 
hand, because the genetic mechanism(s) of resistance are independent of serotype (59,212), the 
cost of resistance is plausibly assumed to be constant. This means that there should be a threshold 
fitness advantage (duration of carriage in this hypothesis) below which antibiotic resistance is not 
maintained in the population.  
 
In species of bacteria where there is no difference in the duration of carriage between different 
strains, fitness advantage is the same in each strain. Previous mathematical models of antibiotic 
resistance examined these types of bacterial populations, where the fitness advantage of resistance 
is constant in all bacteria in carriage (14-17).   
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3.2.1 Aims of chapter 
I will investigate whether the hypothesis outlined in the previous paragraph can adequately describe 
the distribution of antibiotic resistance among serotypes in the pneumococcal population. In this 
chapter I will explore the hypothesis using two mathematical models. I will: 
 Explore the relationship between the duration of carriage of a serotype and the prevalence of 
resistance. 
 Quantify the impact of antibiotic consumption on this relationship. 
 Examine the interaction between the fitness (cost of resistance), the duration of carriage of a 
serotype and the rate of consumption of antibiotics. 
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3.3 Mathematical model of antibiotic resistance 
In section 3.2, I outlined a hypothesis which provides an explanation for the heterogeneous 
distribution of antibiotic resistance among serotypes. In this section I explore that hypothesis using a 
mathematical model, and quantify what serotype characteristics promote the maintenance of 
antibiotic resistance. The aim is to make more precise the intuitive arguments outlined in 3.2. 
3.3.1 Model Structure  
I use two deterministic transmission models of pneumococcal carriage developed previously 
(213,214). Both models are highly idealised representations of the strain structure within one 
serotype, with two strains of pneumococci, one susceptible to antibiotics and the other resistant. In 
both models pneumococci can be cleared from the host naturally and sensitive strains can also be 
cleared through exposure to antibiotics. These models describe transmission of strains within a 
single serotype. I then vary the natural duration of carriage of the serotype to simulate the 
characteristics of different serotypes. I do not consider the dynamics of multiple serotypes co-
existing which, though relevant and interesting, would make the models too complex and intractable 
at this stage. Although this is a model of carriage rather than disease, for the sake of exposition I will 
use ‘infection’ as short hand to refer to carriage and acquisition of carriage for the remainder of the 
chapter. 
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Figure 3.2 Schematic illustration of two theoretical models.  
X indicates susceptible individuals, Is those infected with a sensitive strain, Ir those infected with a resistant strain and Isr 
are individuals infected with both strains. Infection with one strain is indicated by an arrow, recovery is indicated with a 
dot dash arrow and consumption of antibiotics is indicated with a dashed arrow. In model A dotted arrows indicate re-
infection. In model B there are two additional classes Iss and Irr, where individuals are infected with two strains. Super-
infection from a single to a double infection is indicated with a dotted arrow and from a dual infection to a dual 
infection with a small dashed arrow Reproduced from (84,85). 
 
In previous work, Lipsitch et al. and Colijn et al. (213,214) analysed the theoretical foundations of 
multistrain epidemic models, and discovered that great care needs to be taken to avoid introducing 
spurious dynamics that arise from subtle choices in model structure. They suggested that a 
‘structurally neutral’ model is defined by the condition that strain frequencies should not be under 
any selection when all parameters governing fitness are equal. Selection should only arise due to 
differences in fitness between strains. This condition leads to biologically counterintuitive model 
structures such as the Iss term in model B (see Figure 3.2). Both model A and B are examples of 
structurally neutral models. I consider both here as given current knowledge there are no grounds to 
distinguish between them. 
i. Model A 
The simpler of the two models, Model A, is illustrated in Figure 3.2 (A) and the equations of the 
model are shown as equation group 3-2. In this model individuals may be infected with a single 
strain or co-infected with both resistant and sensitive strains.  As shown in Figure 3.2 (A) the basic 
model contains four types of individuals: X (susceptible), Is (infection with a sensitive strain), Ir 
(infection with a resistant strain) and Isr (co-infection).  
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Individuals are infected with a sensitive strain proportional to rate constant βs and to the prevalence 
of individuals infected with a sensitive strain (Is) or individuals with dual infection (Isr). The rate of 
infection with a resistant strain is proportional to its rate constant βr and the prevalence of 
individuals infected with a resistant strain (Ir) or individuals infected with two strains (Isr).  
Individuals infected with both strains may transmit either strain on contact with a susceptible 
individual or individual infected with one strain.  The force of infection (  is: 
3-1 Model A, forces of infection 
                                                                                                                                                   
                                                                                                                                                    
In this model q = ½, meaning that dually infected individuals are equally infectious as the average 
infectiousness of singly infected hosts with the sensitive or resistant strain alone. A singly infected 
individual may become dually infected upon contact with the competing strain.  
Re-infection with a second strain is less efficient than the initial infection. This is modelled through 
the parameter k. Re-infection with a second strain occurs at a per capita rate of k times less likely 
where k is a number between ½ and 1. When k is within this range the model simulates partial 
resistance to super-infection, re-infection and co-infection play a role in the dynamics of the model. 
The impact of this on transmission is that individuals carrying a single strain (Is or Ir) are partially 
protected against super infection with a second strain.  
If a host infected with two strains (Isr), is super infected with a “new infection” sensitive strain that 
host is then defined as a singly infected individual with a sensitive strain (Is). A resistant strain can 
also replace a sensitive strain in the same way. With probability c= ½, re-infection of a dually 
infected individual replaces the same strain, resulting in no change. Dually infected individuals have 
the same infectiousness as singly infected individuals so that q =c= ½. The choice of q =c= ½ 
means that the structural neutrality of the model is conserved (84). 
 
An individual in class Is , Ir or Isr returns to the susceptible class X at rate . This is the natural rate of 
clearance, defined as the inverse of the natural duration of carriage. Sensitive and resistant strains 
have the same natural duration of carriage in the absence of antibiotic consumption. 
Antibiotic consumption is simulated in this model through the consumption rate τ. An individual 
infected with a sensitive strain may return to the class X and individuals in class Isr may return to 
class Ir through antibiotic consumption. In the second case antibiotic consumption clears the 
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sensitive strains carried by the individual. Antibiotic consumption is assumed to be instantaneously 
effective therefore it can be considered as a drug mediated recovery rate.  
The following set of equations describes the dynamics of Is, Ir, and Isr with time: 
3-2 Model A 
  
  
  
  
ii. Model B 
Model B is an unusual transmission model, as it allows both co-infection and co-transmission of 
resistant and sensitive strains (214,213). It builds upon model A in two ways, firstly re-infection may 
result in individuals having two “copies” of a single strain (states Iss and Irr) and secondly this model 
allows dual transmission of two strains in a single transmission step.  
As shown in Figure 3.2(B), Model B contains four types of individuals: X (susceptible), Is (infected 
with a sensitive strain), Ir (infected with a resistant strain) and Isr (dual infection). Building upon 
model A the model now has two additional states Iss and Irr. 
Infection with a sensitive strain is proportional to rate constant βs and the prevalence of individuals 
infected with a sensitive strain (Is) or dually infected individuals (Isr and Iss). The rate of infection with 
a resistant strain is proportional to its rate constant βr and the prevalence of individuals infected 
with resistant strain (Ir) or co-infected individuals (Isr and Irr). 
Extending Model A, Model B allows acquisition of two strains in a single transmission step. 
Susceptible individuals (the X class) may enter the dual infected class (Isr, Iss or Irr) on contact with a 
dual infected individual (those who are Isr, Iss or Irr). In this case transmission of a single strain can 
occur with probability   . The transmission of a sensitive strain from a dually infected 
individual occurs with probability . The equations for acquisition of carriage are shown in equation 
set 3-4. Those dual infected individuals are q times as infectious with each of their strains. When q = 
½ as both Model A and Model B a dual infected state is as infectious as a singly infected state.  The 
set of equations describing the dynamics of the model are presented below: 
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3-3 Model B 
  
  
  
  
  
  
3-4 Model B, force of infection 
  
  
  
  
  
  
  
As discussed in the initial outline of the hypothesis (section 3.2), antibiotic resistance is thought to 
carry an associated fitness cost. Models A and B can incorporate a fitness cost at the initial 
transmission stage; in these models β (the probability of infection on contact by the number of 
contacts) of the resistant strain is less than that of the sensitive strain. This makes it harder for a 
resistant strain to transmit in the population relative to the sensitive strain.  
In model B there is a second method of incorporating a fitness cost in a dually infected person the 
sensitive strain is more likely to transmit than the resistant strain. When a dually infected individual 
(Isr) is in contact with a susceptible individual (X) and a single infection is transmitted (with 
probability ), a sensitive strain is transmitted with probability ρs and resistant strain is 
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transmitted otherwise. In both models it is assumed that the cost of resistance does not change with 
the serotype, therefore the cost of resistance is independent of the duration of carriage. 
3.3.2 Parameters and simulations 
Previous work with this model investigated the parameter space which allows the coexistence of 
susceptible and resistant strains of pneumococci (85). Within these restrictions I defined a set of 
plausible parameters. Where a parameter was available from published literature I used this in the 
model; if this was not possible I simulated the model for a range of values. The parameters for this 
model are shown in Table 3.2.  
The range of carriage duration was informed by previous published work. As carriage duration has 
been shown to vary for different serotypes, I ran simulations for a range of carriage duration values 
estimated from a carriage study of children in Kenya (described in more detail in Chapter 4, Table 
4.1). From this study the duration of carriage of a serotype ranged from 9 to 52 days. 
Previous research using this model has examined a fixed duration of carriage and consequently fixed 
transmission parameters (213). An essential part of the research presented here is to examine the 
impact of variable rates of carriage, therefore transmission parameters varied with the duration of 
carriage. 
Previous research has shown that prevalence of pneumococcal infection (asymptomatic carriage) in 
children under three years of age varies considerably in different communities (205,21,215). For the 
simulations presented in this analysis, I chose to simulate transmission, and thus a value of βs was 
chosen so that the prevalence of infection (proportion of individuals in any infected state) was 
maintained at 26%. This is the prevalence of infection when individuals in the population consume 
antibiotics at a rate of 1/3 per person per month. These prevalence and antibiotic consumption 
estimates are taken from a community in the United States (205). 
The relationship between transmission and duration of any infection can be expressed though R0 in a 
community with no antibiotic consumption, where R0 is the number of secondary infections, from a 
primary infection in a fully susceptible population and D  is the duration of infection. 
3-5 Relationship between β, R0 and duration of infection 
  
R0 was maintained at a constant value of 1.5, which maintained a prevalence of infection of 33% 
when antibiotic consumption was zero. The values of βs varied from 4.22 to 1.01 per person per year 
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for corresponding duration of infection of 2 to 56 days, in order to maintain a constant value of R0. 
When the antibiotic consumption rate was 1/3 per person per month, the prevalence of infection 
(carriage) varied from 26%-0.16%, for these parameters. 
I used antibiotic consumption rates estimated from studies of children in day care. This study found 
that children under three years of age consumed antibiotics (specifically penicillin) at an average rate 
of 1/3 per person per month, and children under five consumed penicillin at an average rate of 1/12 
per person per month (205).  These were taken as the upper and lower bounds of consumption in 
this analysis.  
As there is no conclusive evidence of values of the transmission cost of antibiotic resistance in 
carriage, I simulated a range of parameter values, though I assume that the parameter value for the 
cost of resistance is not related to the duration of carriage. In Model A and Model B, the 
transmission parameter of the resistant strain (βr) is proportional to the transmission parameter of 
the sensitive strain βs so that: 
3-6 Relationship between βr and βs 
  
where the parameter  f  is varied between 0.5 and 1.  
In Model B the default assumption is that the cost of resistance is comparable at both single and 
double transmission, so that:  
3-7 Model B cost of resistance 
  
Table 3.1 Cost of resistance relationship between parameters  in model A and model B 
f  
 
 
0.5 0.660 0.5  
0.6 0.600 0.6  
0.7 0.588 0.7  
0.8 0.555 0.8  
0.9 0.525 0.9  
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In Model B,  the probability of infection with a sensitive strain on contact with an Isr individual was 
varied between 0.52 and 0.6 with corresponding values for the f parameter presented in Table 3.2. 
As part of the sensitivity analysis I varied between 0.5 and 0.6 while keeping f constant and then 
varied f  between 0.7 and 1 while keeping constant. 
I constructed the model using differential equations in Berkley Madonna. I ran the model for 50 
simulated years, with a timestep of 1 day. In each simulation one resistant and one sensitive 
individual were added to a population of fully susceptible individuals.
 67 
 
Table 3.2 Parameter Table for Model A and Model B 
Parameter Value/Range Units Description Comments 
βr f βs Per person 
per year 
Transmission parameter 
for the resistant strain, 
assumes resistant strain 
is never more 
transmissible than the 
sensitive strain 
 
f 0.75-1 Proportion Fitness proportional cost. 
assumes resistant strain 
is never more 
transmissible than the 
sensitive strain 
Computed 
τ  1/12-1/3  Per person 
per month 
Drug mediated recovery 
rate 
(30) 
µ  
  
Per person 
per month 
Natural recovery rate  
Duration of 
carriage 
9-52 Days Number of days between 
acquisition and natural 
clearance 
(208) 
k ½ Per capita 
rate 
1-partial immunity Assumption 
c ½ 
 
Proportion fraction of dual infected  
returning to IS ( or IR) 
upon re-infection with S 
(or R) 
Necessary for 
structurally neutral 
model in simple model 
when strains are 
indistinguishable (84). 
ρsingle ½ Proportion Probability that a single 
(rather than dual) 
infection is transmitted 
Assumption  
ρs ½-1 Proportion Probability that S is 
transmitted when a 
dually infected individual 
transmits single infection  
Assumption 
q ½ 
 
Proportion Relative infectiousness 
with each strain for 
dually infected (Isr) 
Necessary for 
structurally neutral 
model in simple model 
when strains are 
indistinguishable (84). 
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3.4 Results  
3.4.1 Results from Model A  
This section presents results from Model A, a transmission model of pneumococcal asymptomatic 
carriage, referred to as infection in the description of the model. The effect of antibiotic 
consumption, serotype specific carriage duration and cost of resistance are investigated and 
presented in the following sections. Unless otherwise indicated, the parameters in the simulations 
presented here are as described in Table 3.1 and Table 3.2. 
i. Relationship between antibiotic consumption and treatment 
In Model A, increasing the rate of antibiotic consumption increases the prevalence of antibiotic 
resistance in the model population. Figure 3.3 shows the proportion resistant described by equation 
3-8 plotted against duration of carriage for three antibiotic consumption rates: low (1/12 per person 
per month), medium (1/6 per person per month) and high (1/3 per person per month). 
3-8 Proportion resistant 
  
At the low rate of antibiotic consumption the prevalence of resistance is zero; at medium and high 
consumption rates the prevalence of resistance can reach 100% for some durations of carriage.  
Increasing the rate of antibiotic consumption increases the prevalence of resistance; a serotype with 
a carriage duration of 35 days will have a prevalence of resistance of 100% if antibiotic consumption 
is at a rate of 1/3 per month, while if consumption is at a rate of 1/6 per person per month 
prevalence of resistance is 50%. 
ii. Relationship between serotype carriage duration and prevalence of resistance 
Shown in Figure 3.3, at the medium and high antibiotic consumption rates (1/6 per person per 
month and 1/3 per person per month) the relationship between duration of carriage and prevalence 
of resistance is positive. For the lowest rate of antibiotic consumption (1/12 per person per month), 
antibiotic resistance is absent at all carriage durations.  
Increasing the rate of antibiotic consumption reduces the duration of carriage under which antibiotic 
resistance is zero. At the rate of antibiotic consumption documented in children under three (1/3 per 
person per month), serotypes with a duration of carriage of under 20 days do not maintain 
resistance. At a lower rate of antibiotic consumption (1/6 per person per month) this threshold of 
carriage duration is 32 days.  
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Figure 3.3 Proportion resistant; effect of treatment.  
In this figure duration of carriage in days is plotted against the proportion of pneumococci that are resistant to 
antibiotics. The proportion resistant is calculated as shown in equation 3-8. This is shown for a population with low 
antibiotic use (1/12 per person per month) when resistance is 0% in the population; (dashed line), a usage rate of 1/6 
per person per month (dotted line) and 1/3 per person per month (solid line).  The fitness of the resistant strain was 80% 
of the fitness of the sensitive strain in these simulations, k=0.5 and the simulation ran for 150 years to ensure that 
equilibrium had been reached.   
 
iii. Cost of resistance 
As illustrated in Figure 3.3 there is a positive relationship between the duration of carriage and the 
prevalence of antibiotic resistance. I also showed that the prevalence of antibiotic resistance at each 
point of duration of carriage increases as the rate of antibiotic consumption increases. I then 
explored what effect the cost of resistance has on the prevalence of resistance within this model. 
Figure 3.4 shows the relationship between   , and the prevalence of resistance. This figure 
shows that simulations where the rate of antibiotic consumption is varied from 1/12 per person per 
month to 1/3 per person per month, while the duration of carriage is constant at 31 days. 
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Figure 3.4 Cost of resistance: rates of antibiotic consumption.  
This figure shows the relative fitness of the resistant strain (where 0 is unable to transmit and 1 is as fit as the sensitive 
strain) plotted against the proportion of resistant bacteria. In these simulations the duration of carriage was 31 days, the 
re-infection probability k=0.5 and the simulation ran for 150 years. The figure shows rates of antibiotic consumption of 
1/3 per person per month (solid line), 1/6 per person per month (dotted line) and 1/12 per person per month (dashed 
line). 
 
 
Figure 3.5 Cost of resistance: duration of carriage.  
This figure shows the relative fitness of the resistant strain plotted against the proportion of resistant pneumococci. In 
these simulations the rate of antibiotic consumption was 1/3 per person per month, k=0.5 and the simulation ran for 
150 years. This figure shows duration of carriage of 42 days (solid line), 31 days (dotted line) and 9 days (dashed line).
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These simulations illustrate that when  , no resistant strains remain in the model 
population when the rate of antibiotic consumption is 1/3 per person per month and under. At low 
rates of antibiotic consumption (1/12 per person per month) when   the resistant strain 
does not persist in the population. I then examined the interaction between the duration of carriage 
and fitness where the rate of antibiotic consumption was constant at 1/3 per person per month. 
Figure 3.5 shows the results of simulations where the duration of carriage was 9, 31 and 42 days. 
This figure shows that resistant strains are present at high prevalence in the population when   
, when the duration of carriage is 42 days and . If the duration of carriage is 
9 days resistance does not persist if  . 
iv. D5: cost of resistance and impact of antibiotic consumption 
As shown in Figure 3.3, Figure 3.4 and Figure 3.5, there is a consistent relationship between the rate 
of antibiotic consumption, the cost of resistance, duration of carriage and prevalence of antibiotic 
resistance. To further quantify this relationship I estimated D5, which is the lowest duration of 
carriage (in number of days) of a serotype where at least 5% of pneumococci are resistant to 
antibiotics. The estimates of D5 for different costs of resistance and rates of antibiotic consumption 
are presented in Table 3.3.  
Table 3.3  D5 (Lowest duration of carriage in days with 5% of strains resistant to antibiotics) 
 Rate of Antibiotic consumption 
 1/3 per person per month 1/6 per person per month 1/12 per person per month 
  Model A Model B Model A Model B Model A Model B 
0.9 9 9 15 14 30 30 
0.8 22 22 33 35 > 52 > 52 
0.7 38 36 > 52 > 52 > 52 > 52 
0.6 > 52 > 52 > 52 > 52 > 52 > 52 
0.5 > 52 > 52 > 52 > 52 > 52 > 52 
 
The lower bound for duration of carriage examined was 9 days and the highest was 52 days as these 
are realistic durations estimated from carriage. Therefore in Table 3.3, when D5 > 52, resistance was 
not seen at levels above 5% for any duration of carriage up to 52 days.  For example when the cost 
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of resistance was 0.5 in Model A and Model B resistance was below 5% for all levels of antibiotic 
consumption.  
3.4.2 Results from Model B  
In this section I present the results from the more complex Model B, which allows dual transmission 
and multiple co-infected and super-infected states. Unless otherwise indicated I assume that the 
fitness of a strain transmitting from a singly infected individual is the same as transmission from a 
co-infected individual. This means that dually infected individuals are not any more infectious than 
singly infected individuals and is true for resistant and sensitive strains. 
i. Relationship between serotype carriage duration and prevalence of resistance 
The relationship between the duration of carriage of a serotype and the prevalence of antibiotic 
resistance in the Model B population is presented in Figure 3.6. This figure also presents the impact 
of antibiotic consumption on this relationship.   
In this analysis the fitness of the sensitive strain relative to the resistant is described by the equation: 
  .  
This corresponds to parameters f = 0.8, and  = 0.56.  
The results from this analysis are very similar to those from Model A with f=0.8. At the medium and 
high antibiotic consumption rates (1/6 per person per month and 1/3 per person per month) the 
relationship between duration of carriage and prevalence of resistance is positive, and for the lowest 
rate of antibiotic consumption (1/12 per person per month) antibiotic resistance is absent at all 
carriage durations.  
Increasing the rate of antibiotic consumption increases the prevalence of resistance at each carriage 
duration; the results predict that a serotype with a carriage duration of 35 days will have a 
prevalence of resistance of 100% if antibiotic consumption is at a rate of 1/3 per person per month. 
If consumption is at a rate of 1/6 per person per month the prevalence of resistance is 59%. 
Increasing the rate of antibiotic consumption also reduces the duration of carriage under which 
antibiotic resistance is zero. At the rate of antibiotic consumption documented in children under 
three (1/3 per person per month), serotypes with a duration of carriage of under 20 days do not 
maintain resistance. At a lower rate of antibiotic consumption (1/6 per person per month) this 
threshold of carriage duration is 31 days.  
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Figure 3.6 Model B, proportion resistant; effect of treatment.  
Duration of carriage in days is plotted against the proportion of pneumococci that are resistant to antibiotics. The 
proportion resistant is calculated as : 
 
This is shown for a population with low antibiotic use (1/12 per person per month) where resistance is not present in the 
population (dashed line), a usage rate of 1/6 per person per month (dotted line) and 1/3 per person per month (solid 
line).    , k=0.5 and the simulation ran for 150 years. 
 
ii. Cost of resistance 
As illustrated in Figure 3.6 there is a positive relationship between the duration of carriage and the 
prevalence of antibiotic resistance. The prevalence of antibiotic resistance at each duration of 
carriage increases as the rate of antibiotic consumption increases. I then explored what effect the 
cost of resistance has on the prevalence of resistance within this model.  
Figure 3.7 shows the relationship between the relative fitness of the sensitive strain and the 
prevalence of resistance. In this analysis, I assumed that the fitness cost of antibiotic resistance 
would affect the resistant strain at transmission from a singly infected or co-infected individual. 
These simulations illustrate that when a resistant strain transmits less than half as well as the 
sensitive strain no resistant strains remain in the model population when the rate of antibiotic 
consumption is 1/3 per person per month and under. At low rates of antibiotic consumption (1/12 
per person per month), a resistant strain must be almost as fit as the sensitive strain in order to 
persist in the population.  
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Figure 3.7 Model B, cost of resistance: effect of treatment.  
This figure shows the relative fitness of the resistant strain plotted against the proportion of resistant pneumococci. In 
these simulations the duration of carriage was 31 days, the re-infection probability k=0.5 and the simulation ran for 150 
years. This figure shows duration of carriage of 1/3 per person per month (solid line), 1/6 per person per month (dotted 
line) and 1/12 per person per month (dashed line). 
 
 
Figure 3.8 Model B, cost of resistance: duration of carriage.  
This figure shows the relative fitness of the resistant strain plotted against the proportion of resistant pneumococci. In 
these simulations the rate of antibiotic consumption was 1/3 per person per month, the re-infection probability k=0.5 
and the simulation ran for 150 years. This figure shows duration of carriage of 42 days (solid line), 31 days (dotted line) 
and 9 days (dashed line).  
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Figure 3.8 shows simulations where the duration of carriage is varied from 9 to 42 days, while the 
rate of antibiotic consumption is constant at 1/3 per person per month. Like the results from Model 
A, when the duration of carriage of the pneumococcus is 9 days the resistant strain must be as fit as 
the resistant strain to persist in the population. As the duration of carriage increases the cost of 
resistance that a resistant strain can carry while persisting in the population increases. The lower 
bound of cost for the resistant strain is 0.5. When the cost of resistance is greater, the resistant 
strain cannot persist for pneumococci carried for 42 days. 
iii. D5: cost of resistance and impact of antibiotic consumption  
As I showed in the results from Model A, there is clearly a consistent relationship between the rate 
of antibiotic consumption, the cost of resistance, duration of carriage and prevalence of antibiotic 
resistance. To further quantify this relationship I estimated D5 for Model B. The estimates of D5 for 
different costs of resistance and rates of antibiotic consumption are presented in Table 3.3. When 
the cost of resistance is consistent with Model A the values of D5 are consistent (within two days) 
within Model A. 
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3.5 Exploration of key model assumptions and sensitivity analysis 
Both models are an extremely simplified simulation of the complex process of transmission of 
pneumococci in a group of young children. Each model contains some key assumptions that I will 
discuss in this section. 
i. Strain neutrality  
Models A and B are ‘structurally neutral models’, meaning that in the absence of antibiotic 
consumption the resistant and sensitive strains are equally fit. In Model A this is achieved by keeping 
parameters c and q at 0.5, while Model B is a true ‘structurally neutral’ model. For this reason I 
chose to keep parameters c and q constant at 0.5 throughout all the analysis.  
ii. Strain-specific immunity 
In Models A and B strain specific immunity is incorporated through the parameter k. In analysis of 
Models A and B, to examine parameters under which the coexistence of resistant and sensitive 
strains was possible, the authors showed that strain-specific immunity was an important parameter 
governing co-existence (85). In  Model A, an individual infected with strain S can be re-infected with 
strain R and become co-infected in state Isr therefore the transition term of Is to Ir is: 
Equation 3-9 Transition term Is to Ir in Model A 
 
In Model A it is assumed that an individual infected with both strains may be infected again with one 
of those strains. When this happens one strain will be ‘knocked out’ and the host will become singly 
infected, e.g. an Isr individual may become Is on infection with an S strain. This occurs at the same 
rate as secondary infection, with half of all infections being undetectable as the infecting strain will 
be the same as that ‘knocked out’. In a second scenario, an individual infected with strain S are less 
likely to become infected with an S strain than an R strain (and the converse is true). In this case 
‘knocking out’ a strain becomes less likely and the transition term from Isr to Is would be: 
Equation 3-10 Transition term Isr to Is 
   
where  and  
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In previous analyses the authors showed that decreasing ‘knock-outs’ by reducing the value of k0, 
increases the probability of co-existence of sensitive and resistant strains. I performed the same 
analysis but examine whether decreasing k0, changes the value of D5. 
Table 3.4 D5 in days for changing values of k0  
fa Model A Model B 
0.5 22 23 
0.75 22 23 
1 22 22 
a f=k0/k 
Where τ=1/3 per person per month, 
 
 
 
Previous work has shown that decreasing ‘knock out’ may increase the probability of co-existence 
(85) but as Table 3.4 shows, does not greatly change the duration of carriage above which resistant 
strains persist in the population. 
iii. Cost of resistance in Model B 
In Model B, the cost of resistance is applied to a resistant strain in two ways, firstly (like Model A) the 
transmission rate constant of the resistant strain is less than that of the sensitive strain so that: 
   
The cost of resistance is also applied on transmission from a co-infected individual. When one strain 
is transmitted from a co-infected individual a sensitive strain is transmitted with probability ρs. 
When ρs > 0.5, a sensitive strain is more likely to be transmitted from a co-infected individual than a 
resistant strain. 
In the simulations presented in this chapter I have assumed that both forms of resistance are applied 
equally at each stage. This assumes that within-host competition between strains is equal to the 
between-host competition. Figure 3.9, shows that when the duration of carriage is at intermediate 
levels (21 days in Figure 3.9), changing the value of ρs changes the persistence of resistance within 
the strain. As the value of ρs increases the proportion of resistant strains decreases; under the 
parameters presented in Figure 3.9 when ρs > 0.56, and therefore   , no resistant strains 
are present. 
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Figure 3.9  sensitivity analysis.  
Value of ρs is plotted against the proportion resistant strains for  and duration of carriage of 9 days (dashed 
line), 21 days (dotted line) and 42 days (solid line). In each simulation antibiotic consumption is 1/3 per person per 
month.  
 
Table 3.5 D5 for changing values of  relative to   
g Antibiotic consumption per person per month 
 
1/3 1/6 
1 22 35 
0.8 22 >52 
0.7 23 >52 
0.6 24 >52 
0.5 24 >52 
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To further quantify the impact of varying ρs, while  is constant, I calculated D5, when                 
 , the results of which are presented in Table 3.5.  When  is twice as 
small as  , the value of D5 is increased by two days in simulations where the population has a high 
rate of antibiotic consumption (1/3 per person per month). At the lower rate of antibiotic 
consumption (1/6 per person per month) when   is smaller than  , D5 increases from 35 days 
to being greater than 52 days. 
iv. Transmission from a co-infected individual 
In Model B the parameter  is the probability that on contact with a co-infected or super-
infected individual (Isr, Irr or Iss) there is transmission of one strain. All simulations presented in this 
analysis have  =0.5, which is the symmetric form of the model (i.e. 50% of the time a single 
strain is transmitted from a dual infected individual). When using this model to explore the 
coexistence of sensitive and resistant pneumococcal strains Colijn et al. found that decreasing 
, thus increasing the probability of dual transmission, increased the level of stable co-
existence of sensitive and resistant strains (85).  
Increasing co-existence could allow resistant strains to persist at low prevalence but at durations of 
carriage lower than expected at symmetry. To investigate this I varied , while keeping the 
relative fitness of the sensitive strain and antibiotic consumption constant at 0.8 and 1/3 per person 
per month respectively.  As   increases (decreasing the probability that a single strain will be 
transmitted), the value of D5 increases from 15 days when   is 0.1 to 25 days when   is 
0.9.  
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3.6 Conclusions 
In section 3.2, I outlined a hypothesis that provides an explanation of the uneven distribution of the 
prevalence of antibiotic resistance among pneumococcal serotypes. Using two deterministic models 
of pneumococcal transmission, I examined the relationship between carriage duration and the 
prevalence of resistance within a serotype.  
i. There is a positive relationship between duration of carriage and prevalence of resistance 
In the introduction to this chapter I described research which had consistently shown that 
pneumococcal serotypes differ in their duration of carriage (21,26,31). I then outlined the hypothesis 
in section 3.2, that the relative fitness advantage of an antibiotic resistant strain is greatest in 
serotypes with long durations of carriage. Thus, there should be a positive relationship between the 
duration of carriage and the prevalence of antibiotic resistance. When I used two mathematical 
models to quantify this relationship, both models consistently predicted that a serotype with long 
duration of carriage was more likely to be antibiotic resistant.  
ii. There is a threshold duration of carriage under which antibiotic resistance does not persist 
The fitness cost associated with antibiotic resistance arises from alterations in the pneumococcus 
associated with mechanisms of resistance. As these mechanisms are serotype independent the cost 
of resistance is assumed to be constant. Therefore, as I outlined in section 3.2, there should be a 
threshold duration of carriage under which the cost of resistance outweighs the benefit and so no 
antibiotic resistance persists. This threshold was a consistent feature of Models A and B and was 
robust to sensitivity analysis. 
iii. The threshold of carriage is consistent for a given rate of antibiotic consumption and cost of 
resistance 
The threshold duration of carriage (D5 in the analysis) was very sensitive to the parameter values 
used for the rate of antibiotic consumption and the cost of resistance in both models. Broadly D5 
decreased as antibiotic consumption increased, and, increased as the cost of resistance increased. 
The value of D5 was consistent in both models for a given rate of antibiotic consumption and fitness 
cost. This relationship can be used to inform data analysis as I will describe in the next chapter.   
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4 Analysis of pneumococcal populations from invasive disease and 
carriage  
4.1 Introduction 
The mathematical model described in Chapter 3 allowed me to explore the hypothesis that there is a 
positive relationship between the prevalence of resistance in a serotype and the duration of carriage 
of that serotype. The relationship between duration of carriage and prevalence of resistance can be 
described approximately by a sigmoid curve, with a threshold of carriage duration under which 
resistant pneumococci do not persist in the model population. The persistence of resistant 
pneumococcal strains at intermediate carriage durations is determined by the level of treatment and 
the fitness cost of resistance. In this chapter I describe a test of the hypothesis explored by the 
mathematical model using a collection of S. pneumoniae isolates from invasive disease. 
4.2 Data sets  
4.2.1 Invasive Disease Data 
I analysed data collected as part of the Active Bacterial Core Surveillance (ABCS) which is part of the 
United States Centers for Disease Control and Prevention’s Emerging Infections Program that has 
conducted active, population and laboratory based surveillance of invasive pneumococcal infection 
(defined as isolation of the bacteria from a usually sterile site such as blood, cerebrospinal fluid (CSF) 
or pleural fluid) since 1995.  
Cases of pneumococcal invasive disease are recorded at least monthly through active 
communication with all microbiology laboratories which serve acute care hospitals. Using a 
standardized case reporting form information is recorded on patient demographic characteristics, 
clinical syndrome and geographic location to the county level (216).  
Isolates are characterized at a reference laboratory through antimicrobial susceptibility testing using 
CLSI guidelines (217) and serotyping (50). The dataset used in this study has information on 
demographic and geographic characteristics, antimicrobial susceptibility and serotype data. I 
extracted the frequency of each serotype, the distribution of susceptibility to penicillin and 
erythromycin in that serotype, the age of the patient from whom it was isolated and the year of 
isolation.  
I have assumed that the consumption of oral antibiotics is the primary driver of antibiotic resistance 
in pneumococci, thus I have interpreted the MICs of each isolate in line with CLSI guidelines for oral 
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antibiotics. MIC cut offs for susceptible, intermediate and resistant isolates are presented in Table 
4.1. 
Table 4.1 Former and current Clinical and Laboratory Standards Institute Penicillin and erythromycin minimum inhibitory 
concentration (MIC) breakpoints  
 
 
 
 
 
 
 
In 2000 the PCV7 pneumococcal vaccine was added to the childhood vaccination schedule. In order 
to examine vaccination effects I analysed ABCS data collected before the year 2000 in the first 
instance.  In further analysis I then repeated the analysis on isolates collected after the year 2000. 
4.2.2 Duration of carriage data 
I analysed data on the serotype specific duration of carriage which had been collected from the Kilifi 
Epidemiologic and Demographic Surveillance Study (Epi-DSS). Carried out in Kilifi, Kenya the Kilifi Epi-
DSS is a longitudinal recording of residents in a well-defined geographic area around Kilifi District 
Hospital and is updated through continuous census for vital events every four months. Children 
younger than five years of age were randomly recruited from the Epi-DSS and a nasopharyngeal 
sample was collected with a swab at the beginning of the study. Children whose swabs were positive 
for pneumococcal carriage were re-sampled on approximately the 1st 2nd, 4th, 8th, 16th and 32nd days 
from the first sample and monthly thereafter. Sampling stopped when they observed two 
consecutive swabs which were negative for the original serotype or negative for any pneumococcal 
growth (whichever came sooner) (208). The estimates of duration of carriage from this study are in 
Figure 4.1. 
  MIC
a
 µg/ml, by susceptibility category 
 Period, syndrome 
and route of administration 
 
Susceptible Intermediate Resistant 
 Before January 2008 
Penicillin All syndromes and routes ≤ 0.06 0.12 - 1 ≥2 
From January 2008 to present 
 
Meningitis, via intravenous administration 
≤ 0.06 None  ≥0.12 
Non-meningitis syndrome, 
via intravenous administration 
≤ 2 4  8 
 Non-meningitis syndrome, 
Oral administration  
≤ 0.06 0.12 - 1  ≥2 
Erythromycin Any syndrome any route ≤ 0.25  ≥1 
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Figure 4.1 Duration of carriage per serotype.  
The mean carriage duration in days is the middle point on each bar, upper end of the black bar is the upper 95% 
confidence bound while the lower grey bar is the lower confidence bound. This is plotted for the serotypes sampled. 
 
4.3 Description of statistical models and statistical techniques 
From the mathematical model presented in Chapter 3, I observed a relationship between the 
duration of carriage and prevalence of resistance that can be approximately described by a sigmoid 
curve. A curve that can follow this relationship is described by equation 4-1. In equation 4-1 the 
prevalence of antibiotic resistance  is determined by the mean duration of carriage D,  dependent 
on the threshold parameter D50 and parameters which govern the shape of the curve  and . The 
null hypothesis, where  D50 = 0 and the prevalence of antibiotic resistance is independent of the 
duration of carriage is described by equation 4-2, where α is the mean prevalence of antibiotic 
resistance.  To allow comparison with the parameters estimated from the mathematical models 
presented in Chapter 3, the parameter D5 is calculated from the estimated values of α,γ and D50, this 
is described by 4-3.                                                                                             
4-1 Statistical model 
        
4-2 Null hypothesis 
 or equivalently  
                       
 84 
 
4-3 D5: Duration of carriage at which prevalence of resistance is 5% 
                                                                                                                                       
The null hypothesis is nested within the sigmoid model, thus both models are fitted to data using the 
maximum likelihood method.  
Due to sampling effects, a small sample of a serotype is less likely to have resistant isolates present 
even if these resistant isolates are present in the population the sample comes from. Thus the 
likelihood calculations (shown in 4-4) include the frequency of each serotype as well as the 
prevalence of resistance from data and the model prediction. Using a ‘generalised reduced gradient 
algorithm’ optimisation algorithm, the parameters are varied until values are found which maximise 
the likelihood of the observed data. All analysis was carried out in Excel. 
 
4-4 Likelihood equations 
 
                                                                                                                                                                 
        
Where: 
 
 
 
 
 
Using maximum likelihood estimation, I estimated the parameters which determine the functional 
form of each model.  
I then tested whether the second model described by 4-1 is a better fit to the data than the null 
model, 4-2. Using the likelihood ratio test (shown in 4-5), which is based on the value of the log 
likelihood ratio at the null value of the parameter, I tested the strength of the evidence against the 
null model. If the second model is a statistically significantly better fit than the null model, the 
corresponding P value derived from the   distribution with 2 degrees of freedom is  P  < 0.05. 
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4-5 Likelihood ratio statistic 
   
To assess the goodness of fit of the sigmoid model, the likelihood for the saturated model (which 
assigns for a parameter for each serotype) was calculated and compared to the sigmoid model using 
the  as above. This result was statistically significant in all cases, indicating that the sigmoid 
model does not fully account for the variance seen in the dataset. Such unexplained variation is 
known as extra-Binomial overdispersion. Standard errors and therefore CIs from the sigmoid and 
null model were adjusted for overdispersion by using an overdispersion adjustment factor. This is 
the square root of the model deviance divided by the degrees of freedom.   
A possible confounder of any relationship is the age of the patient, as all serotypes are not equally 
likely to cause invasive disease in each age group. To examine this confounder I fitted the model to 
samples from the children under two years of age only and then from samples of those aged over 
two.  
Another important influence of serotype distribution is the implementation of the 7 valent 
pneumococcal carriage vaccine (PCV7) which provides immunity against colonization of certain 
serotypes: 4, 9V, 14 19F, 23F, 18C, 6B. This vaccine was included in the United States childhood 
vaccination schedule in 2000 and caused significant changes in serotypes circulating in carriage and 
causing invasive disease (48,146,47). To account for this I fitted the data against samples collected 
before 2000, and those collected after 2000. 
4.4 Results  
4.4.1 Preliminary data analysis 
Table 4.2 shows the frequency of each serotype in the ABCS dataset before 2000 and the estimated 
duration of carriage of each serotype estimated from the Kenyan nasopharyngeal carriage study. As 
this table shows there is a wide variation in the frequency that each serotype is isolated from 
invasive disease.  Serotype 14 is the most common serotype isolated from both age groups, while 
some serotypes present at low frequencies in those over two (serotypes 35C and 2 for example) are 
not isolated from invasive disease in those under two. 
Frequency distributions were calculated for penicillin and erythromycin susceptibility from the ABCS 
dataset. These were then stratified for age; under two years and over two years. Figure 4.2 shows 
the distribution of susceptibility to penicillin among each serotype of pneumococci isolated from 
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patients younger than two years of age (Figure 4.2 (A)) and older than two years of age (Figure 4.2 
(B)). Figure 4.3 (A) and (B) presents the prevalence of erythromycin resistance in invasive disease 
occurring before 2000 in patients younger than two years of age Figure 4.3 (A) and those older than 
two years of age Figure 4.3 (B). 
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Table 4.2 Frequency and carriage duration of serotypes in patients under and over two years of age 
Serotype Frequency Mean Carriage duration (days) 95% Confidence Interval 
 
< 2 years > 2 years 
 
 
19F 315 432 52 44 - 62 
6A 149 502 46 38 - 58 
6B 347 700 46 36 - 55 
23B 7 17 33 25 - 50 
11A 4 223 32 25 - 45 
23F 224 865 31 24 - 41 
35B 7 71 29 22 - 40 
15A 3 23 28 20 - 40 
21 1 3 27 19 - 39 
10A 9 66 27 18 - 39 
14 1027 1539 24 16 - 38 
13 0 45 23 16 - 37 
34 0 23 21 15 - 35 
19A 89 335 19 15 - 34 
35A 0 3 19 14 - 32 
16F 5 66 18 14 - 31 
18C 231 387 18 13 - 31 
15C 11 36 18 12 - 28 
15B 10 71 18 12 - 28 
07C 0 8 17 12 - 28 
004 200 1257 17 10 - 27 
23A 4 58 14 10 - 26 
3 18 552 11 8 - 25 
20 0 65 10 8 - 24 
1 12 302 9 7 - 18 
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Figure 4.2 Prevalence of penicillin resistance pre 2000 in invasive disease isolates from individuals (A) under two years of 
age and (B) over two years of age.  
The serotypes are ranked from longest to shortest carriage duration from top to bottom. Green sections are the 
percentage sensitive (MIC break point of ≤0.06 ), orange intermediate (MIC break point of 0.12-1 µg/ml,) and resistant 
red. Resistance is defined as pneumococci with an MIC break point of ≥2 µg/ml,. 
 
B 
A 
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Figure 4.3 Prevalence of erythromycin resistance pre 2000 in invasive disease isolates from individuals (A) under two 
years of age and (B) over two years of age.  
The serotypes are ranked from longest to shortest carriage duration from top to bottom. Green sections are the 
percentage sensitive and resistant red, resistance is defined as pneumococci with an MIC to erythromycin of ≥1 µg/ml,. 
 
B 
A 
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Penicillin resistance and erythromycin resistance are unevenly distributed among the serotypes. In 
pneumococci isolated from patients aged less than two years, serotypes 1, 15B and 15C are all 
susceptible to penicillin. Although more than half of pneumococci of serotype 14 isolated from 
children less than two years of age were resistant to erythromycin, no erythromycin resistance is 
reported in serotypes 1, 23A, 15A, 15B, 15C, 10A, 21, or 35B. 
4.4.2 Statistical analysis 
Using maximum likelihood estimation I analysed whether the null hypothesis (that the prevalence of 
resistance to antibiotics is randomly distributed among serotype) or the sigmoid model (a sigmoid 
curve) best describe the distribution of antibiotic resistance among serotypes. In the first instance I 
analysed pneumococcal isolates collected before the introduction of vaccination in 2000. Figure 4.4 
(A) shows the prevalence of penicillin resistance in patients less than two years of age collected 
before 2000 plotted against the duration of carriage. The frequency of each serotype is plotted with 
its 95% CI, in the same figure are the null model (plotted as a dashed line) and the sigmoid model 
(plotted as an unbroken line) fitted to the data. The functional form of the relationship in the model 
has been determined through maximum likelihood estimation of the parameters as described in the 
previous section. The sigmoid model fitted a sigmoid functional form when fitted to data using 
maximum likelihood methods. Parameter estimates are presented in Table 4.3. From the null model, 
the estimated value α, of the mean prevalence of penicillin resistance is 0.25 (95% CI 0.18-0.23). 
In the sigmoid model, α is estimated to be 0.32 (95% CI 0.27-0.38), the parameter D50, 20.44 (95% CI 
19.06-21.91) days. The sigmoid model (sigmoid curve) was found to fit significantly better to data 
than the null hypothesis and P  < 0.001. 
Although the sigmoid model fits significantly better than the null model, it does not fully account for 
variance in the data as the saturated model fits significantly better to the data than the sigmoid 
model. Therefore, all reported CIs are adjusted for overdispersion. 
To examine whether the hypothesis held for a separate class of antibiotics, I repeated the analysis 
examining the distribution of erythromycin resistance among serotypes.  Presented in Figure 4.5 is 
the prevalence of erythromycin resistance in pneumococci isolated from invasive disease in 
individuals under (A) and over two years of age (B), plotted against the duration of carriage. In both 
age groups the sigmoid model (a sigmoid curve) fits significantly better to data than the null 
hypothesis. Parameter estimates are presented in Table 4.4, in both age groups the prevalence of 
erythromycin resistance was higher than penicillin. In the analysis from the sample of isolates from 
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those under two, the value of the mean prevalence of erythromycin resistance (α) estimated by 
fitting the null model was 0.32 (95% CI 0.23-0.42) and by fitting the sigmoid model was estimated as 
0.42 (95% CI 0.34-0.51). The estimate of D50 was slightly though not significantly lower than those 
values estimated for penicillin resistance.  
The values of D5 were calculated by using estimated parameters in the equation presented in 4-3. 
The value of D5 for penicillin resistance was calculated as 18.78 days, and for erythromycin 
resistance, 16.39 days.  
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Figure 4.4 Prevalence of penicillin resistance. Mean proportion of serotypes penicillin resistant with 95% confidence 
bounds, plotted against the duration of carriage. A) Serotypes from surveillance of invasive disease in individuals under 
2 years of age collected before 2000, B) Serotypes from surveillance of invasive disease in individuals over 2 years of age 
collected before 2000. The solid line plots the curve from sigmoid fitted to the prevalence of penicillin resistance (MIC ≥ 
2), the dashed line, the null hypothesis.  
A 
B 
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Figure 4.5 Prevalence of erythromycin resistance. 
Proportion of serotypes erythromycin resistant with 95% confidence bounds, plotted against the duration of carriage. A) 
Serotypes from surveillance of invasive disease in individuals under 2 years of age collected before 2000, B) Serotypes 
from surveillance of invasive disease in individuals over 2 years of age collected before 2000. The solid line plots the 
curve from sigmoid fitted to the prevalence of penicillin resistance (MIC ≥ 2), the dashed line, the null hypothesis.
A 
B 
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Table 4.3 Maximum likelihood analysis: Association between prevalence of penicillin resistance (MIC ≥2) and serotype duration of carriage 
 
Pre 2000 Post 2000 
 
Patients under 2 years of age Patients over 2 years of age Patients under 2 years of age Patients over 2 years of age 
 Null  Sigmoid Null  Sigmoid Null  Sigmoid Null  Sigmoid 
α (95% CI) 0.25 (0.18-0.33) 0.32 (0.27-0.38) 0.14 (09-0.21) 0.23 (0.18-0.30) 0.25 (0.16-0.35) 0.37 (0.26-0.50) 0.13 (0.06-0.2) 0.25 (0.17-0.34) 
D50 (95% CI)  
20.44 (19.06-
21.91)  
20.61(18.66-
22.74) 
 
18.84 (17.09-
19.90) 
 
18.84 (17.95-
19.69) 
γ (95% CI) 
 
19.98 (11.79-
36.94)  
15.53 (7.92-
30.55) 
 
26.85 (7.80-
61.65) 
 
55.72 (16.93-
179.67)  
D5   
18.78  
 
18.94  
 
17.58  
 18.38  
lnull -1506.14  
-3101.45 
 
-1179.56  
-5090.84 
 
 
lsigmoid  
-1369.94 
 
-2648.93  -1064.16  
              -
4047.77 
lsaturated  
-1311.94 
 
-2430.89  -918.42  -3402.52 
P value (lnull and 
lsigmoid comparison)  
P < 0.001 
 
P < 0.001  P < 0.001  P < 0.001 
P value (lsigmoid 
and lsaturated 
comparison) 
 
P < 0.001 
 
P < 0.001  P < 0.001  P < 0.001 
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Table 4.4 Maximum likelihood analysis: Association between prevalence of erythromycin resistance (MIC ≥1) and serotype duration of carriage 
 
Pre 2000 Post 2000 
 
Patients under 2 years of 
age 
Patients over 2 years of age 
Patients under 2 years of 
age 
Patients over 2 years of age 
 
Null Sigmoid Null Sigmoid Null Sigmoid Null Sigmoid 
α (95% CI) 
0.32 (0.23-
0.42) 
0.42 (0.34-
0.51) 
 
0.16 (0.1-
0.24) 
 
0.29 (0.19-
0.43) 
0.32 (0.24-
0.44) 
0.39 (0.28-
0.51) 
0.23 0.14-
0.34) 
0.36 (0.24-1) 
D50 (95% CI)  
19.52 (18.29-
21.22) 
 
 
19.65 (15.99-
24.88) 
 
 
14.65 (2.52-
18.91)  
17.20 (12.24-
65) 
γ (95% CI) 
 
17.70 (9.57-
33.95) 
 
 
8.87 (3.01-
18.43) 
 
7.90 (0.58-
170)  
5.64 (1.13-
12.38) 
D5   
16.39   17.55   11.50  
 
12.54  
lnull 
-1364.97 
  
-1364.97 
 
 
-1179.56 
 
 
-5090.84 
  
lsigmoid  
-2460.309757 
 
 
-1223.215859 
 
 
-791.132 
  
-6375.27 
 
lsaturated  
-1147.72 
 
 
-2225.52 
 
 
-643.30 
  
-5331.95 
 
P value (lnull 
and lsigmoid 
comparison) 
 
P < 0.001  P < 0.001  P < 0.001 
 
P < 0.001 
P value 
(lsigmoid and 
lsaturated 
comparison) 
 
P < 0.001  P < 0.001  P < 0.001 
 
P < 0.001 
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4.5 Discussion and analysis limitations 
I have shown that the distribution of penicillin and erythromycin resistant pneumococci among 
serotypes is associated with the difference in serotype specific carriage duration. The relationship 
between duration of carriage prevalence of resistance was described by a sigmoid curve with a 
threshold fitness advantage (duration of carriage) below which antibiotic resistance was not 
maintained in the population. This suggests that the assumption that genetic mechanism(s) of 
resistance are independent of serotype (59,212) is correct and the cost of resistance is constant in 
each serotype. 
However analysis of antibiotic prevalence could be confounded by the impact of age or other 
effects. Exploration of the datasets revealed that serotype frequency varied among different age 
groups from the invasive disease isolates. The invasive disease dataset also showed serotype 
variation for different years due to the impact of a pneumococcal conjugate vaccination campaign.  
i. Age 
Certain serotypes are associated with infections in children. This age group is thought to be a higher 
consumer of penicillin and other antibiotics than older individuals (205). To examine whether age is 
a confounder I stratified each dataset into isolates from patients under and over two years of age. 
The sample of pneumococci isolated from invasive disease in individuals over two years and 
analysed to examine the relationship between the prevalence of resistance and duration of carriage 
are presented in Figure 4.4 (B). Parameter estimates for the prevalence of penicillin resistance are 
presented in Table 4.3. In the sample of individuals older than two years, the value of the mean 
prevalence of penicillin resistance (α) estimated by fitting the null model was 0.14 (95% CI 0.09-
0.21). In the sigmoid model, (α) 0.24 (95% CI 0.18-0.30), the parameter D50 was estimated at 20.61 
(95% CI 18.66-22.74) days. In this age group the sigmoid model fits significantly better to the data 
then the null model, P << 0.001.  
Figure 4.5 (B) presents the sample of pneumococci isolated from invasive disease in individuals over 
two years of age and analysed to examine the relationship between the prevalence of erythromycin 
resistance and duration of carriage. Table 4.4 presents the result for erythromycin analysis. The 
value of the mean prevalence of erythromycin resistance (α) estimated by fitting the null model was 
estimated at 0.23 (95% CI 0.22-0.24). In the sigmoid model, (α) is estimated as 0.29 (95% CI 0.19-
0.43) the parameter D50 was estimated at 19.65 (95% CI 15.99-24.88) days. In this as in the younger 
age group the sigmoid model fits significantly better to the data then the null model, P < 0.001. 
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As the analysis of both classes of antibiotics shows, in older patients the relationship between the 
duration of carriage and prevalence of resistance is described by a sigmoid curve. The prevalence of 
resistance is lower in this age group and the values of D5 and D50 are slightly though not significantly 
greater. 
ii. Pneumococcal conjugate vaccination campaign 
In 2000 the pneumococcal conjugate vaccine was introduced in the United States. This vaccine 
prevented carriage and invasive disease caused by serotypes: 4, 9V, 14 19F, 23F, 18C, 6B. This 
resulted in serotype replacement, where serotypes included in the vaccine declined in the 
population and are replaced by non-vaccine serotypes (48,47).  Presented in Table 4.3 and Table 4.4 
are the results of maximum likelihood analysis of isolates collected after the introduction of PCV7 
vaccination in 2000. In the case of both penicillin and erythromycin in each age group the sigmoid fit 
significantly better to data than the null, and P << 0.001. Although there are some differences in the 
parameter estimates calculated from the samples pre and post vaccination, the CIs of these 
estimates are overlapping.   
iii. Dataset suitability 
In this analysis I used two datasets for the majority of analysis, the prevalence of antibiotic 
resistance per serotype was calculated from a dataset compiled from surveillance of invasive disease 
in the United States and the duration of carriage of serotypes was taken from estimates of duration 
of carriage of isolates colonising healthy children in Kenya.  
The first and most obvious disadvantage of this approach is that these two datasets come from two 
very different settings. It is reasonable to expect that the prevalence of carriage and serotypes in 
circulation will differ between a high income country such as the United States and a low income 
country such as Kenya.  
A comparable study of carriage duration from a high income country comes from the UK (31). The 
major advantage of the Kenyan dataset is its size and thorough sampling regime. Due to this the 
dataset has a larger range of serotypes (with clearly defined confidence intervals) than the UK 
dataset. The smallest sampling interval in the UK dataset was two weeks, while in Kenya in the first 
week, samples were taken at daily intervals. Therefore in the UK the shortest duration of carriage 
estimated was four weeks (for serotype 9A) and there was the potential for researchers to confuse 
multiple incidences of short carriage with one incidence of long carriage (31). For these reasons the 
Kenyan dataset remains the best dataset available for this analysis. 
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The second problem that arises in comparing the two datasets is that one dataset comes from 
invasive disease and the other from carriage. As is shown in Figure 4.6 (A) the prevalence of 
serotypes in carriage differs from that in invasive disease. While the ABCS dataset would be 
unsuitable to study serotype frequency, as serotypes which are common in invasive disease may be 
rare in carriage, there is no evidence to suggest that the prevalence of antibiotic resistance in 
invasive disease is not similar to that in the wider pneumococcal population.  
Shown in Figure 4.6(B) the comparison of resistance prevalence in both datasets shows that the 
prevalence of resistance differs in the two datasets. However all isolates of serotypes 11A, 15B, 18C, 
23A are not resistant to penicillin in both datasets. This indicates that although the prevalence of 
penicillin resistance may be sample dependent, the presence or absence of resistance in certain 
serotypes forms a consistent pattern.  
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Figure 4.6 Comparison of invasive disease and carriage datasets. A) Proportion of serotype from carriage and invasive 
disease. Proportion of each serotype isolate from a study of healthy children collected in 2001 (white column) (48). Black 
bars show the proportion of that serotype in isolates from invasive disease in children under two, collected by the ABCS 
programme US, 1996-2000 (216). B) Prevalence of penicillin nonsusceptibility in the carriage dataset (white column) and 
the invasive disease dataset (black column). 
A 
B 
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4.6 Discussion and conclusion 
In this section I will examine some key insights from statistical analysis of invasive disease data, and 
interpret these with reference to predictions from the mathematical models presented in Chapter 3 
and, where appropriate, previous studies in published literature.  
i. The prevalence of penicillin resistance varies among age groups 
 From analysis of invasive disease data, the average prevalence of resistance was greater in samples 
from children younger than two years of age than from individuals over two years of age. This 
observation was true in the case of penicillin and erythromycin resistance. The most obvious 
explanation for this is increased antibiotic consumption in younger age groups. Surveys of antibiotic 
use in the community have shown that older age groups consume fewer antibiotics than children 
under two years of age (11). In both mathematical models presented in Chapter 3, increased 
antibiotic consumption resulted in increased prevalence of antibiotic resistance.  
This finding is consistent with previously published mathematical models which examined the 
impact of treatment on resistance (82,80). The results are also consistent with studies examining the 
association between antibiotic consumption and the prevalence of resistance in pneumococcal 
populations. Goossens et al. (74) compared the outpatient consumption of antibiotics in 26 
European countries with the prevalence of resistance in pneumococcal invasive disease. The authors 
used Spearman’s correlation coefficient and found a significant relationship between penicillin use 
and prevalence of penicillin resistance in IPD (74). 
The results from the mathematical model presented in Chapter 3 and data analysis presented in 
Chapter 4  strongly suggest that differences in antibiotic consumption between those patients age 
under and over two years are responsible for difference in the prevalence of resistance between 
those two age groups. 
ii. Estimates of D5 are consistent in different age groups 
The results of the mathematical model presented in Chapter 3 predict that different rates of 
antibiotic consumption will change the estimate of D5. Decreasing the rate of antibiotic consumption 
from a 1/3 to a 1/6 per person per month increases the value of D5 by over 10 days. In analysing the 
data in Chapter 4, I showed that although the prevalence of resistance decreased with age, the 
estimates of D5 did not decrease with age to the same degree. This would suggest that although a 
decrease in the rate of antibiotic consumption is associated with a decrease in the average 
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prevalence of resistance within a sub-population, the impact on the distribution of antibiotic 
resistance among serotypes is not as pronounced. Therefore it would be therefore interesting to 
examine populations with universally lower and higher antibiotic consumption rates than those 
studied to examine whether estimates of D5 from these populations varied as predicted by the 
mathematical model. 
iii. Estimate of D5 can be used to estimate the cost of penicillin resistance  
This analysis initially sought to explain the heterogeneous distribution of antibiotic resistance among 
serotypes. From analysis of the mathematical model it became clear that there was a consistent 
association between antibiotic consumption D5 and fitness cost of resistance. Thus, if the value of D5 
can be calculated from a sample of data this can be used to estimate the cost of resistance.  
Previous research into the fitness cost of antibiotic resistance in the pneumococcus has focused on 
estimating the impact of resistance on the growth rate in culture (211).This research has showed 
that antibiotic-resistant pneumococcal strains grow slower than sensitive strains in the absence of 
antibiotics. A method that allowed us to estimate the fitness cost of resistance on transmission in 
natural rather than laboratory populations of bacteria would greatly enhance our study of 
pneumococcal antimicrobial resistance.  
From the statistical analysis of IPD data I estimated a value of D5.  In analysis of penicillin resistance 
in children less than two years old D5 was estimated to be 18.78 days. In both mathematical models 
presented in Chapter 3 the value of D5 was estimated to range from nine to 35 days and the 
estimate was dependent on the cost of resistance and the rate of antibiotic consumption. Thus, if 
the rate of antibiotic consumption in a study sample was known, the suitability of the D5 estimate 
from data could be assessed and the cost of resistance could be estimated. 
A suitable estimate of the rate of penicillin consumption in children less than two years of age in the 
United States is not available. However, one study has estimated the rate of penicillin consumption 
in children under two attending a family practice in Massachusetts (205) and from the results of this 
study I calculated the antibiotic consumption rate of 1/3 per person per month. Although a local 
sample may not be completely representative of national trends, the rate of 1/3 per person per 
month is a plausible rate of consumption. For this rate of antibiotic consumption values of D5 
estimated from the mathematical model range from 9 to 38 days. The estimate of D5 from invasive 
disease is within this range of parameters (D5 = 18.78), which is consistent with a penicillin resistant 
strain being no less than 80% as fit as a penicillin sensitive strain. 
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4.7 Conclusion 
In conclusion, from analysis of a large sample of pneumococcal isolates from invasive disease, I have 
shown that the relationship between the duration of carriage of a serotype and the prevalence of 
resistance (to penicillin and erythromycin) can be described by a sigmoid curve. This relationship is 
consistent in different antibiotic classes, and is not disrupted by the introduction of pneumococcal 
conjugate vaccination in the year 2000. Although there are differences in the prevalence of 
resistance between different age groups, (those under and over two years of age), the relationship 
between the serotype-specific duration of carriage and prevalence of resistance is consistently best 
described by a sigmoid curve. I also estimated threshold parameters which predict the duration of 
carriage at which prevalence of resistance is 5% (D5), estimates of D5 are relatively consistent 
between age groups, ranging between 18 to 20 days.  
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5 Selection and Recombination in Bacterial Populations: literature 
review  
5.1 Introduction 
In the previous chapters I focused on when an adaptation like antibiotic resistance is beneficial to a 
bacterium like S. pneumoniae.  This chapter and the next are broader in scope and examine the 
impact of selection on population structure of a bacterial population and the role of homologous 
recombination.  
There is a large body of experimental and theoretical work describing the process of selection which 
focuses on either sexual or asexual organisms. Classical population genetics has provided an 
excellent theoretical framework with which to understand evolution in populations of sexually 
reproducing diploids or asexual haploids (220). Unfortunately bacteria do not fit neatly into either of 
these two ideal types being neither truly sexual nor asexual organisms. Unlike asexual organisms, 
bacteria can transfer and reassort genetic material through homologous recombination (221). In 
sexual organisms recombination is an obligate part of their lifecycle but bacteria reproduce by binary 
fission, not having to recombine every generation and so cannot be considered truly sexual 
organisms (222).  
As I introduced in the first chapter of this thesis, homologous recombination plays an important role 
in pneumococcal population genetics. Recombination occurs in three basic steps. Firstly, free DNA 
from another bacterium associates with the pneumococcal cell, secondly the free DNA enters the 
host cell cytoplasm and thirdly becomes incorporated into the genome (223). Recombination as 
described above results in replacement of a segment of the recipient chromosome with that from 
another bacterium of the same (or very similar) species. The size of the replaced DNA is thought to 
be small, but this is thought to vary according to the mechanism. The amounts replaced are not well 
established, although normally thought to be a few hundred base pairs of DNA to 30kb via 
transformation (14).   
In its most common form recombination in eukaryotic populations is a symmetric process, where 
genetic material is exchanged between two genomes. Recombination occurs during meiotic 
reproduction in a diploid population as part of meiosis a duplicated paternal chromosome is paired 
with its duplicated maternal homologue. As the nucleotide sequences of the maternal and paternal 
chromosomes are similar they can undergo a recombination event which in this context is called a 
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chromosome crossover. This process produces two hybrids, the chromosome of paternal origin 
which has incorporated some maternal DNA and the chromosome of maternal origin which has 
incorporated some paternal DNA (224).  Recombination can also occur in eukaryotic populations 
through gene conversion. This is an asymmetric process which occurs during meiosis in eukaryotic 
genomes. It occurs when a segment of DNA from one chromosome replaces the homologous section 
of DNA in the recipient chromosome. The donor chromosome remains unchanged while the 
recipient is now a hybrid chromosome (225,226). 
In eukaryotic populations a recombination event occurs at least once per chromosomal replication 
(7) and is an obligate part of the lifecycle (226). Bacteria do not have to recombine as part of their 
reproductive process and so it is not an essential part of their life cycle. The relative contribution of 
recombination and mutation to the generation of genetic diversity in bacterial populations varies in 
different bacterial types. The variation in the ratio of recombination to mutation can result in the 
generation of distinct structures of diversity in bacterial populations. In populations with low levels 
of recombination the population is highly clonal, consisting of individually evolving lineages (227). An 
example of this is an organism such as Mycobacterium tuberculosis, which is highly clonal, and its 
population structure suggests that recombination plays little role in its diversification (228,229). In 
bacterial populations with high ratios of recombination to mutation, such as Helicobacter pylori 
(102) clones cannot emerge as their genomes diversify too rapidly. The majority of bacterial 
populations are thought to have rates of recombination that lie between these two extremes (227).  
5.1.1 Aims 
Incorporating recombination in population models is one of the challenges of bacterial  
population genetics. Another is to generate models which are flexible enough that they can simulate 
the range of recombination rates seen in bacterial populations. Therefore, there is a need to 
generate models of selection that incorporate the unique characteristics of bacterial reproduction in 
order to understand the structure and variation in bacterial populations.  The aims of this chapter 
are to  
 Review the literature from the study of selection in bacterial populations in the laboratory and in 
theoretical models, 
 Review the literature from theoretical models which describe the impact of recombination 
during selection, 
 Examine the differences between a model of a selective sweep which incorporates classical 
recombination and one incorporating unidirectional or asymmetric recombination as seen in 
bacterial populations.  
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5.2 Review of selection in bacterial populations 
Laboratory populations of bacteria have been used along with other experimental systems such as 
fruit flies to test hypotheses about the selection process (230). Selection is thought to play an 
important role in shaping the genetic variation seen in natural bacterial populations. The role that 
selection is thought to play in bacterial populations has been greatly influenced by studies of 
laboratory cultures of bacteria undertaken since the 1950s (231,232). The term periodic selection is 
used in the literature to describe the process of the sequential occurrence and selection of adaptive 
bacterial types first observed in the continuous culture experiments of Atwood, Schneider and Ryan 
(233) and the chemostat experiments of Novick and Szilard (231,232). The term non specific 
selection was also used by Atwood to describe this process as the advantageous mutation occurred 
in an unknown gene that was not under study (233). However, periodic selection is the term most 
widely used to describe the phenomenon. The nomenclature is not ideal for two reasons. First, it 
suggests a distinct form of selection, when in fact it is used to describe a conventional process of 
asexual evolution which differs only in that the genes responsible for it are unknown. Second, the 
term implies a periodicity or regular recurrence of selective sweeps at predictable intervals, but this 
is not the case.  
Important assumptions of the asexual model of selection are: 
 As recombination is assumed to be absent, the advantageous mutation cannot be transferred 
onto another genetic background. This means that the whole genome is carried along with the 
advantageous mutant allele and the neutral markers on the genome used in experiments can 
represent the whole genome (234).   
 Following from the first assumption, two beneficial mutations can only be incorporated onto the 
one genome if the second beneficial mutation occurs on the genome of the first (235). Therefore 
each adaptive clone is derived from the one preceding it in the population.    
 A prediction that follows from the competitive exclusion principle is that when a population is 
growing under selection only one clone will be present at equilibrium (236). Therefore, other 
than during periods of adaptive shifts, when the parent population is being replaced by the 
mutant population, the population is assumed to be monomorphic.  
Selective sweeps have been studied using laboratory models of bacterial evolution, mathematical 
models and a limited study of genomic data from natural populations of bacteria. Given that 
recombination is an important force in shaping the genetic structure of populations (227), the rest of 
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this chapter will review the study of simple selection in bacterial populations to ascertain whether 
the conventional asexual model is an adequate description of the selection process. 
5.2.1 Review of previous studies of selective sweeps in laboratory bacterial populations 
Laboratory experiments can be divided into those which used a batch culture technique (Figure 5.1) 
and those that use a chemostat. The chemostat differs from batch culture techniques in that it is an 
open system where medium is continually renewed and excess medium with waste products and 
dead cells are removed, shown in Figure 5.2. In the chemostat the population is maintained at a 
constant cell density, while in batch culture techniques populations of bacteria are allowed enter 
stationary phase, when the growth rate is null, before being transferred to fresh medium. Further 
detail and discussion of the laboratory techniques described in this section are provided in Appendix 
A.   
 
Figure 5.1 Schematic diagram of batch culture technique.  
First a sample of founder culture is added to a flask containing growth medium with suitable nutrients, populations of 
bacteria are allowed to grow until they enter stationary phase (when the growth rate is null) before being transferred to 
fresh medium. This is repeated for the desired number of generations. 
 
i. Batch culture experiments 
Atwood’s original experiments used serial transfers of Escherichia coli culture, histidine dependence 
was used as a neutral marker to detect the effect of the selective sweep. Histidine is an amino acid 
and histidine dependant bacteria cannot grow on media which does not contain a source of 
histidine. The mutation for histidine independence is neutral if the bacteria are grown in an 
environment where histidine is provided. During the experiment changes in the genetic structure of 
the population are monitored through observing the change in the proportion of cells that are 
histidine independent. A small proportion of the cells in the population are histidine independent, it 
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is assumed that it is very unlikely that a mutation would arise on a cell which is histidine 
independent (see the glossary in Appendix A for further details). This experiment found a selective 
sweep occurring after 200 generations when the frequency of histidine independent cells declined in 
the population. This is assumed to correspond with the occurrence of an advantageous mutant in 
the histidine dependant population of cells which then expanded through the population. The 
histidine dependent cells isolated during the experiment were, when competed against each other, 
identical in fitness. When competed against the histidine independent cells they were found to be 
competitively superior. When the sweep had come to completion all the histidine dependant cells 
were competitively superior to the original histidine independent cells. Histidine independent cells 
isolated after the sweep were selectively identical to the dependent cells, suggesting that these cells 
had been derived from the sweep population rather than remaining from the original population. 
Two more sweeps of advantageous mutants occurred in the population, each having a higher 
maximum growth rate than the preceding population (233).  
These experiments were repeated using the same strains and media, though changing the culture 
conditions so that the experimental population alternated between growth and non-growth (237). 
The results of the experiment confirmed the findings of Atwood et al. (233) and showed that the 
adapted strains produced more acetate during growth. The authors then mapped genetic changes to 
the region containing genes responsible for the production of pyruvate dehydrogenase. They 
hypothesised that the glucose limited environment selected for mutations which allowed an 
enhanced ability to metabolise glucose efficiently.  
The experiment was repeated again but using different strains of E. coli and different neutral 
markers, and found a selective sweep occurred after 400 generations (238). Lenski et al. carried out 
a second serial culture experiment to investigate the long term trajectory of mean fitness in a 
population undergoing periodic selection (239). This was a long term serial culture experiment with 
limiting glucose, which was an environment that the bacterial cells were ill adapted to, with 12 
replicate cultures run for 2000 generations. In this experiment clones were not isolated at the end of 
each turnover but rather isolated every 100 generations. This method tracked changes in fitness 
over the 2000 generations. The relative fitness of the competing clones was estimated by 
performing a fitness assay (further described in the glossary in appendix A). In this case the clones 
were distinguished by their ability to grow on arabinose (a monosaccharide) and were distinguished 
by being grown on a specialist agar which resulted in the competitors forming different coloured 
colonies. Each clone was competed against the original strain, and it was found that the mean fitness 
of the isolated clones increased over time. The mean rate of the increase in fitness was calculated 
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using a least squares linear regression of mean fitness against time for each of the 12 populations 
over 2000 generations and over the first 1000 generations. The mean rate of the increase in fitness 
declined with time (239). There was no evidence found of fitness variation within the populations. 
There was no investigation as to how the advantageous mutants increased the fitness of the cells or 
any analysis as to the genomic changes occurring in the population. This limits our understanding of 
the impact of selection in the population. It was hypothesised that the increased fitness was due to a 
shorter lag phase on being transferred onto fresh medium, reduced mortality during stationary 
phase and greater affinity for limiting glucose (239). The study provided evidence for the populations 
converging on a single adaptive peak, where fitness of the clones increase over time, so that each 
new mutant is more fit that the original clone. At each time point tested, all isolates tested were 
equally fit, suggesting they were a homogenous population of clones. 
Early experiments performed using serial transfers of batch culture consistently show a 
characteristic pattern of multiple sweeps with transitive increasing relative fitness (238). Fitness is 
homogenous within populations outside of the periods of adaptive shift. The studies support the 
classical asexual model of selection but do not investigate the genetic structure of the population. 
More recent research by Rozen and Lenski found that two phenotypically distinct types of bacteria, 
evolved from a genetically homogenous starting culture and persisted in a stable equilibrium for 
20,000 generations, providing clear evidence for the maintenance of polymorphisms in E. coli under 
glucose limitation (240). This contradicts the classical model which predicts that only one type of 
clone will be present at equilibrium in the population.  
The two methods of characterising the population undergoing selection used in the previous studies 
- monitoring the neutral marker and using fitness assays to determine the relative fitness of the 
mutant to the ancestral strains - can provide good evidence that change is taking place in the 
population, but are limited in their ability to characterise that event (241).  Monitoring the frequency 
of a neutral marker does not allow the researcher to determine the origin of each new advantageous 
mutant. The data from past experiments (233,237,238,240,241) cannot rule out a more complicated 
model than the classical one which would allow non sequential mutation. In the multiple adaptive 
mutants model there is a reservoir of adaptive mutations in the population at varying frequencies 
(242). There will still be adaptive shifts in these populations but not necessarily in a sequential order, 
so the fourth advantageous clone may not contain the mutation that characterised the third 
dominant clone.  
 
 109 
 
ii. Chemostat experiments 
In the first chemostat experiment demonstrating periodic selection performed by Novick and Szilard, 
the first selective sweep occurred after thirty generations (231). This was in a chemostat 
environment where tryptophan was the limiting nutrient. The experiment was run for 500 
generations and six sweeps occurred during that time. In the experiment which used serial transfers 
of batch culture the first sweep did not occur until after 200 generations (233). The relative fitness 
coefficients of the two experiments also differed when estimated indirectly from the experimental 
data (rather than using fitness assays) (243). The selection coefficient for the advantageous mutant 
that emerged in the serial culture experiment of Atwood et al. was 0.37 and the selection coefficient 
for the first advantageous mutant occurring at thirty generations in the experiment of Novick and 
Szilard was 0.95 when estimated indirectly from the published data (231,233,243). Kubitschek 
postulated that the E. coli populations which were used in both experiments, though from different 
original cultures, were better adapted to the “feast and famine” environment of glucose-limited 
serial culture than the continuous growth environment of constant tryptophan limitation in the 
chemostat experiment of Novick et al. (243). A shorter time until the first sweep and increased 
fitness coefficients has been seen consistently in chemostat experiments, suggesting that the 
chemostat environment in which bacteria are growing continuously exerts much greater selective 
pressure than the batch culture environment. It was found that the advantageous mutants were 
more efficient at utilising substrate than the original population, without decreasing their maximal 
growth rate. In Dykuizen and Hartl’s experiment, in glucose-limited medium chemostat that was 
sampled every 100 hours, an increase in fitness was observed every 100 hours. In this experiment 
the selection was for isolates that utilised the chemostat nutrients more efficiently (244).  
 110 
 
 
Figure 5.2 Schematic of a chemostat.  
Chemostat, with a continuous inflow of nutrients (the feed) and outflow (the effluent). The rate of medium flow is 
controlled to keep the culture volume constant. In steady state, growth occurs at a constant rate and all culture 
parameters remain constant (culture volume, dissolved oxygen concentration, nutrient and product concentrations, pH 
and cell density. 
 
More recent work has identified stable polymorphisms which evolve repeatedly in originally 
homogenous populations growing on a single limiting resource. A genetically homogenous 
population of E. coli was shown by Rosenzweig et al. to evolve into a stable three clone polymorphic 
population. The study found evidence for the evolution of resource partitioning as a result of 
adaptations in the acetyl co-enzyme A synthase which allowed the co-existence of acetate scavenger 
bacteria and bacteria with a superior rate of glucose uptake (245). Further study has shown the 
repeated evolution of the acetate cross feeding polymorphism (246). Other work has confirmed the 
evolution of stable polymorphism in chemostat populations. Recent work has shown consistent 
evidence for the maintenance of polymorphisms in E. coli under glucose limitation (247-252). These 
studies have shown adaptive mutations in the mgl, mlc and malT loci (see the glossary in Appendix A 
for a brief explanation of gene cluster names) and that adaptive populations acquired multiple 
adaptive alleles rather than one single winner clone (40-45). In the experiments they used the 
traditional method of studying fluctuations in a neutral mutation which confers resistance to T5 
phage infection, but they also sequenced the genes on which they believed the adaptive mutation to 
be occurring - mgl, mlc and malT. The results of the experiments showed that although shifts in the 
T5 resistant population could be interpreted by the classical model as a series of selective sweeps, 
when the loci of interest were sequenced it was found that genotypic diversity was maintained in 
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the population, thus demonstrating that the classical model was incorrect. In the study by Majaran 
et al., it was found that a polymorphism existed where changes in the outer membrane proteins 
were detectable so that the bacterial population could be subdivided into five distinct groups. 
Sequencing also showed multiple branched clusters in the population (252).  
 
The studies of evolution in the laboratory described in the previous paragraph have revealed that 
the classical model of selective sweeps may not always hold, not even in the relatively simple 
environment of the chemostat or batch culture. They reveal much more genetic diversity than was 
previously seen in the original experiments in the 1950s. The more recent experiments have used 
genomic and biochemical techniques to characterise the population in the experiment while the 
earlier experiments used fitness assays and tracked the proportion of a neutral marker in the 
population. In experiments such as that by Dykuizen and Hartl (253), a detected change in fitness is 
equated with the replacement in the population of one bacterial type for another. This assumption 
leads to the conclusion that if a population is monomorphic in terms of fitness then there must only 
be one type of bacteria in that population. This is problematic as the types of fitness assays used in 
these experiments do not detect small changes in fitness and assume that if there is no detectable 
difference in fitness between two isolates then there is no genetic or phenotypic difference between 
those two isolates. In fact the two isolates could differ, but the difference in fitness between them is 
too small to be detected by the assay.  
Two assumptions underpin the experiments which used a neutral marker to track changes in the 
population. Firstly they assume that one gene can represent the whole genome, and secondly that a 
relatively small assayed proportion of the population is representative of the genomic structure in 
the whole population. The studies described above showed that just tracking the neutral marker did 
not reveal the diversity that was found when sequencing was carried out (247-252).  
All the experiments above assume that the bacterial populations are effectively asexual and that the 
neutral marker can be representative of the whole genome. No investigation took place considering 
whether the advantageous or the neutral marker could be separated from the genome on which it 
arose, or the role of recombination in the population. This is a valid assumption in these systems as 
there are no know mechanisms by which the chosen E. coli strains can exchange genes. In other 
bacteria this assumption is not valid (254).  
5.2.2 Mathematical models of selective sweeps in bacterial populations 
The way that bacteria in natural populations are distributed through space and time is likely to be 
different to that seen in the laboratory. Mathematical models provide an opportunity to model 
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selective sweeps in a variety of conditions that may provide insight into the role of periodic selection 
in natural populations of bacteria.  
The earliest mathematical depictions of the periodic growth curves observed in a chemostat were 
presented by Koch (255). Who constructed a deterministic model and investigated the ranges of 
selection and mutation parameters which generate periodic growth curves (255). It considered two 
subpopulations which have different growth rates. A deterministic model found parameter values 
for the selection coefficient which allowed the best fit of the model to dynamics seen in the 
laboratory. Using the model Koch found that an increase in the abundant type is independent of the 
mutation from rare to abundant type, as the amount of rare type compared to abundant type in the 
population is always too small to make a substantial difference. The mutation rate and selective 
advantage of new mutants were parameters that made a substantial difference. This model 
describes the fluctuation in neutral alleles as seen in the chemostat but does not attempt detailed 
analysis of the occurrence of mutations, their selective advantage, or the effect of the sweep on the 
genetic structure of the population.  
Deterministic models are not necessarily suitable for studying a process such as the recurrence of 
sweeps which may have a stochastic component such as the time before a sweep can occur. Berg 
constructed a model where the deterministic growth of a mutant variant is preceded by periods of 
stochastic delays in the appearance of novel advantageous mutants (256). In the model the early 
phase of appearance and growth of a new variant is modelled stochastically while the later phases 
when the new variant is at a sufficiently high number of cells is modelled deterministically. The 
model only considered the appearance of new variants that leave descendents. The time of 
appearance of a new variant was calculated from the mutation rate constant, the size of the 
population of the parental variant and the survival probability. This gives a distribution for 
appearance time. This was used to examine the impact of the stochastic delays on the fit of the 
simulated growth curves to experimental data. It was also used to calculate the hitchhiking 
probability, which is the probability that a neutral allele will be linked with and carried to fixation 
with an advantageous mutant. In this model hitchhiking by a weak or counter selected mutant takes 
place when the advantageous mutation occurs on the genome containing the weakly or counter 
selected mutant. The model assumed that bacterial growth is clonal and does not allow for the 
impact of recombination.  
The effect of periodic selection on E. coli population structure was investigated by Levin in a 
mathematical model which examined the effect of periodic selection on effective population size. 
The effective population size of a population is the number of individuals in a theoretically ideal 
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population that have the same magnitude of random genetic drift as the actual population. The 
actual size of a population (the number of individual bacteria in that population) can increase during 
a selection event. Therefore a clonal population of bacteria could be large in number but have a low 
amount of diversity and consequently a low effective population size. Levin’s model examined the 
relationship between rare recombination, periodic selection and the effective population size (257). 
Levin investigated whether rates of recombination in E. coli populations were sufficiently high to 
override the bottleneck effects of periodic selection and afford these populations relatively large 
effective population sizes. He found that the effective population size increased exponentially as the 
recombination rate increased. The model used parameters estimated for natural populations of E. 
coli and found that the reduction in genetic diversity on the genome as a result of selection was 
substantial. With these parameters populations of E. coli would have very small effective population 
sizes. Levin simulated the model using a narrow range of parameters which had been mostly 
estimated from experimental rather than natural populations of bacteria.  
The three models described in the preceding paragraphs have all addressed periodic selection in a 
chemostat or batch culture and attempted to model the observed growth curves (255,257,256). 
Majewski and Cohan’s model of bacterial evolution looks at the effects of global and local sweeps in 
a metapopulation structure (258). It examines the role of recombination within and between 
subpopulations and uses a coalescent model to simulate the evolution of a population into distinct 
sequence clusters called ecotypes, which constitute distinct ecological groups. Simulating the 
emergence of locally and globally beneficial mutations, it examines the potential of globally 
successful strains to sweep through the total population. When a globally beneficial mutant arises, it 
has the potential to reduce diversity in the whole population if the associated genome hitchhikes 
with the beneficial mutation.  
Based on their model Majewski and Cohan found that with low recombination rates globally 
adapted mutants reduce neutral sequence divergence between ecological groups, but that this is 
dependent on the size of the fragment transferred at each recombination event. The larger the 
recombining  fragment, the more effective the global sweep will be at reducing between population 
divergence. However, the model results provided evidence that global periodic sweeps would be 
able to homogenize subpopulations so that they are indistinguishable. When a global selection event 
occurs, the recombination rate between subpopulations needs to be above 10-7.8 for two 
subpopulations to homogenize, even when the recombining fragment size is greater than 10% of the 
genome. This threshold of recombination is higher than that currently estimated in most bacterial 
populations.  
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Central to the model is the assumption that periodic selection is an important evolutionary force in 
natural bacterial populations (259). As a result, the model fails to examine closely the effect of a 
selective sweep on a population for example the relationship between selective advantage, 
recombination rate and fixation time. This model of bacterial evolution has been suggested as one in 
which the purging effect of sweeps can be reconciled with the genetic diversity in bacterial 
populations. It has been suggested that bacteria live in distinct ecological niches and that locally 
advantageous mutations sweep to dominance within an ecotype or niche. Therefore, within a niche 
there is little diversity, but an abundance of niches allows the persistence of diversity over the wider 
bacterial metapopulation (258).  
A recent model of bacterial evolution developed by Levin and Cornejo, was used to explore the 
contribution of homologous recombination to the rate of adaptive evolution in bacterial populations 
and the conditions under which homologous recombination will provide a bacterial population a 
selective advantage over non-recombining or more slowly recombining populations (260). Using a 
semi-stochastic model of bacterial evolution, results of their simulations indicated that under broad 
conditions recombination occurring at rates in the range anticipated for bacteria like S. pneumoniae, 
E. coli, Haemophilus influenzae, and Bacillus subtilis will accelerate the rate at which a population 
adapts to environmental conditions. The authors measured the adaptation to environmental 
conditions as an increase in mean fitness (260). Though this study provides a mathematical 
counterpart to laboratory studies on the impact of recombination on population fitness, it was not 
concerned with the impact of recombination on diversity and divergence in the population. 
 
Like the previous model and simulations Johnsen et al. examine the impact of recombination on 
population fitness. The focus of the research was to examine why recombination is maintained in 
bacterial populations even though it is thought to carry a risk or fitness cost. The authors combined 
observations of growth in Bacillus subtilis populations with a mathematical model which simulated 
the population dynamics. From these observations they formulated the theory that recombination 
can be maintained in a population due to periods of non-growth when environmental factors (such 
as antibiotics) inhibit dividing cells. In Bacillus subtilis competent cells (cells that can take DNA from 
the surrounding environment into the cell to recombine with its genome) are non-growing. When 
attacked by an antibiotic these cells are not killed and so have a selective advantage over growing 
cells which are killed.  Thus the recombining cells are maintained in the population (261).  
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5.2.3 Eukaryotic models of recombination and selection 
The impact of recombination on the genetic diversity of a population undergoing a selective sweep 
has been studied comprehensively within eukaryotic population genetics. Theoretical models 
(262,263) and observations of the process in genomic samples (264) have led to a good 
understanding of the dynamics of selective sweeps in obligate sexually reproducing eukaryotes.  
A selective sweep was shown to have an impact on patterns of linked genetic variation and the 
phenomenon known as the hitchhiking effect. This was demonstrated with a simple two locus 
haploid model (developed by Maynard Smith and Haigh) where symmetric recombination (the 
reciprocal exchange of genetic information during a single cross over event) occurred at a variable 
rate (265). This model demonstrated that when there are low rates of recombination between a 
neutral and selected allele a neutral allele may sweep to fixation with the linked beneficial allele. The 
genomic pattern predicted by this model has been observed in eukaryotic genomes where a 
selective sweep may result in previously rare alleles becoming very common. The model can also be 
used to show that recombination can allow neutral alleles to “escape” a sweep: they remain in the 
population even if they are not linked to the selected allele. 
More recent work has concentrated on the effect of symmetric recombination on local linkage 
disequilibrium (LD). McVean et al. described LD between neutral alleles at two loci as arising because 
of correlations in the genealogical history of the two loci. Under the coalescent model, if the time to 
most recent common ancestor (MRCA) at locus x on the genome is informative about the MRCA 
locus y then the alleles at those loci should show significant LD (266). This study showed that a 
measure of LD was dependent on the correlations between coalescent time between two pairs of 
loci, which in turn depends on the rate of recombination between two loci (266). This result was 
used to examine the fate of two neutral loci situated near a locus that has undergone a selective 
sweep.  The theory was validated using stochastic simulations and showed that the effect of a 
selective sweep on patterns of genomic diversity (measured by LD) was highly dependent on the 
position of the neutral allele simulated relative to the selected gene. In fact, depending on the 
relative position of the loci a selective sweep could increase, decrease or eliminate linkage 
equilibrium (263).  Though the theory provided a comprehensive examination of the effect of 
symmetric recombination on a eukaryotic genome it failed to examine the impact of asymmetric 
recombination in the form of gene conversion which has been demonstrated to play a role in 
eukaryotic genomes. In the original model one of the results showed that two loci on the same side 
of the selected locus may show substantial LD whereas the expected LD on the opposite side of a 
selected locus is zero. When Wakefield et al. (267) extended the model to incorporate gene 
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conversion they showed that there may be substantial LD between two loci on opposite sides of a 
selective sweep (267). These models provide a robust explanation of genetic variability in eukaryotes 
although its predictions are not necessarily applicable to bacterial populations as they don’t 
explicitly model the effect of asymmetric recombination alone on the population. 
5.3 Two-Locus Model of a selective sweep with asymmetric recombination 
Although there has been substantial theoretical study of the role of symmetric recombination and 
the concurrence of asymmetric recombination, this has previously been carried out under the 
assumption that the recombination looked and behaved like that in a eukaryotic genome. 
Homologous recombination in bacteria differs from what is referred to as recombination in sexual 
eukaryotes in that it involves small regions of the genome, is not obligate with reproduction and 
rather than being a symmetric exchange of genetic material, it is a unidirectional transfer in which a 
small region of the chromosome of a recipient is replaced by homologous recombination with the 
corresponding region of a donor bacterium. In fact it is more similar to gene conversion as described 
in the model of Jones and Wakeley (267).  
In this section I will present the comparison of two locus models of a selective sweep in a haploid 
population. The first (developed by Maynard Smith and Haigh) incorporates asymmetric 
recombination (265).The second which I developed, differs from the earlier model of Maynard Smith 
and Haigh by incorporating asymmetric recombination. I will examine whether the mechanistic 
differences between asymmetric and symmetric recombination impact on the results predicted from 
a simple two locus model. The advantage of using a simple model to do this is that firstly the model 
structures can be easily compared by comparing differential equations and secondly the impact of 
parameter variation can be easily examined.  
The model in this chapter is developed as a ‘sample model’ to compare with previous work on this 
topic. I developed it to examine the impact of asymmetric compared to symmetric recombination 
and in the next chapter of this thesis I will use this model to examine the impact of asymmetric 
recombination on a selective sweep.  
Like the model of Maynard Smith and Haigh I simulated a simple population where genomes are 
defined at two loci (265). The model is parameterised by a variable recombination rate, selection 
coefficient and population size. Under the infinitely many alleles model (IAM) mutation always 
generates new alleles. Alleles which become extinct as a result of a selective sweep cannot re-occur 
in the post-sweep population through mutation. Thus, pre-existing alleles can only remain in the 
population if they are rescued into the genotype sweeping to fixation through recombination. I 
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adapted the simple two locus deterministic model to incorporate an asymmetric recombination 
process as occurs in bacterial populations.  
5.3.1 Methods 
i. Model Structure  
The parental population of the model consists of 1 pure mutant bacterium which carries an 
advantageous mutant allele (M) at the locus under selection and N-1 bacteria which represent the 
pure wild-type population, where N is the population size and remains constant. Under the two 
locus model the bacteria have one locus on which selection acts, with alleles M for the mutant 
genotype and W for the wild-type, and one neutral locus with two alleles X and Y. The fitness of W is 
1 and the fitness of the M allele is 1 + s, where s is the selection coefficient. In the initial population, 
which is illustrated schematically in Figure 5.3 (Pre-sweep population), the neutral allele X is 
exclusively associated with the wild-type allele W and allele Y is exclusively associated with the 
advantageous mutant allele M. I refer to the MY bacteria as the pure mutant and the WX bacteria as 
the pure wild-type. Recombination allows four possible combinations of alleles, WX and MY which 
are present at the beginning of the simulation and WY and MX hybrids which are created only 
through recombination.  
The frequency of each bacterial genotype at each generation of the model is parameterised by the 
selection coefficient s and the population recombination rate ρ.  The deterministic model with 
asymmetric recombination is described by the equation groups 5-1 to 5-3. Group 5-1 describes the 
proportion of each genotype at each generation, equation group 5-3 describes the definition of the 
per bacteria recombination rate r used in the deterministic model defined in terms of the population 
recombination rate ρ .  
In group 5-3 the proportion of each genotype in the next generation is determined. Under selection 
the frequency of genotypes that carry the M allele are multiplied by (1+s) and those that carry the W 
allele are multiplied by 1. During the recombination step a bacterium such as WX can be in the 
population already and not recombine, it can recombine with either a W or X allele and so remain 
unchanged in the population or recombine with an allele other than W or X resulting in a different 
bacterial genotype and the amount of WX in the population decreases. WX can increase in the 
population if a bacterium which contains either the W or X allele (i.e. WY or MX) recombines to 
create a WX genotype.  
During a selective sweep, the descendents of the pure mutant MY increase in number until at the 
end of the simulation all bacteria have the M allele, as seen in Figure 5.3 (Post-sweep population). In 
 118 
 
the two locus model there are two possible genotypes of bacteria in the Post-sweep population 
presented in Figure 5.3: MY which is the pure mutant genotype or MX which is a hybrid of the pure 
wild-type (WX) and the pure mutant genotype (MY).  In this model the only way for a wild-type 
neutral allele (allele X in this model) to remain in the population after the sweep has occurred is 
through recombination with the pure mutant genotype, so that it becomes rescued through 
association with the M allele. The wild-type neutral allele X can recombine onto a genome 
containing the advantageous mutant allele M or vice versa. Both result in the X allele being retained 
in the population. 
 
 
Figure 5.3 Two locus model of selective sweep.  
A) Pre-sweep population. Initial population is composed of two genotypes. B) Recombination, recombination can occur 
at rate  between the loci in either direction. C) Selection each bacterium has two loci;, locus one on which selection 
acts with alleles W or M and the second, the neutral locus with alleles X or Y. W has a fitness of 1 and M has a fitness of 
(1+s) where s is the selection coefficient. The fitness of the hybrid type is dependent on the fitness of locus one. D) Post-
sweep population, at the end of the sweep all genomes contain the M allele (red) at locus one.  
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ii. Simulation 
Models were programmed using C++. The population size N was 106. Values for the population 
recombination rate ρ from 1 to 10000 were simulated. Values for the selection coefficient s were 
simulated from 10-3 to 0.9 so that the relative fitness of the mutant allele was varied from 1.001 to 
1.9. 
5.3.2 Results 
i. Impact of recombination on pre-sweep allele prevalence 
Figure 5.4 shows a comparison between the results of the two locus model of a selective sweep with 
symmetric recombination (265) called Sym and the two locus model incorporating asymmetric 
recombination called Asym in Figure 5.4. I present the results of the two models simulated for 
selection coefficients 0.001, 0.01, 0.1 and 0.9. In these simulations the fitness of a bacterium 
carrying the advantageous allele M would be 1.001, 1.01 and so on and the fitness of a bacterium 
carrying the wild-type allele W at that locus would be 1. I also simulated the model for population 
recombination rates from 0.01 to 1000.  
Plotted in Figure 5.4 is the proportion of genomes in the post-sweep population which carry an allele 
from the wild-type population, that is the proportion of the population that are hybrids carrying an 
M and an X allele. The MX genotype is not present in the pre-sweep population and can only be 
created through recombination. As shown in Figure 5.4, the proportion of alleles from the wild-type 
population that are rescued is low for a high selection coefficient and low recombination rate. When 
the population recombination rate is lower than 10 and the selection coefficient greater than 0.001, 
less than 10% of the final population is composed of bacteria that contain an allele from the wild-
type population. As the selection coefficient gets smaller the number of alleles “rescued” through 
recombination from the wild-type population increases. This is because the smaller the selection 
coefficient the greater the amount of time that the WX bacteria remain in the population thus 
increasing the number of recombination events between an X allele and a MY bacteria or an M allele 
and a WX bacteria.  
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Figure 5.4 Comparison between Symmetric and Asymmetric models.  
This plots the relationship between the population recombination rate, selection coefficient and proportion of MX in the 
final population in the two locus model. The log of population recombination rate ρ is plotted against proportion of MX 
in the final population when a sweep has occurred. The results are shown for fitness values of 1+s, where s is  0.001 (red 
lines), 0.01 (black lines), 0.1 (green lines) and 0.9 (blue lines).  The results from the symmetric model are plotted as 
dashed lines, those for the asymmetric model as solid lines. 
 
Figure 5.4 shows a comparison between the results of the two locus model of a selective sweep with 
symmetric recombination (48) and our two locus model incorporating asymmetric recombination.  
As shown in Figure 5.4, when the ρ is lower than 10 and s greater than 0.01, less than 10% of the 
final population is composed of bacteria with genotype MX. As ρ increases the amount of MX in the 
final population increases, and as s increases the amount of MX in the final population decreases. 
This pattern is simulated by both models. 
However though both models follow the same trends in response to changes in the ρ  and s there 
are numerical differences in the two results as demonstrated in Figure 5.4. At higher values of s 
(0.01, 0.1 and 0.9) and with ρ  ≥ 10, the results from the symmetric model predict that the 
proportion of MX remaining in the population will be lower than if the model incorporates 
asymmetric recombination. This is also true for simulations when s = 0.01 and ρ  ≤ 10. 
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The important structural difference between the earlier eukaryotic model and the asymmetric 
model used here is the recombination process. The differences in the mathematical model results 
show the importance of considering the biological differences in the recombination processes when 
studying bacteria. Rather than reciprocal genetic exchange, homologous recombination in bacteria 
involves the introduction of DNA from a donor into a recipient and replacement of a small region of 
the recipient with that from the donor – a process that has been described as localised sex. The 
effect of the difference between asymmetric and symmetric recombination can be most clearly 
illustrated by considering recombination between two bacteria that are identical at one locus. In the 
symmetric model the progeny of a recombination event between a MX and a MY bacteria will be MX 
and MY. Thus the amount of MX and MY will not change in the population with or without a 
recombination event. In an asymmetric recombination event, an allele from the donor bacteria 
replaces the allele at the appropriate locus in the recipient. When MY “donates” M and Y alleles, the 
amount of MX in the population will remain the same if a bacteria receives an M allele but will 
decrease if it receives a Y allele. While the difference in predictions will be small at the two locus 
level, these would increase in importance if many loci were considered. Thus even in a simple two 
locus haploid model bacterial recombination must be considered as a distinct event from that of 
eukaryotic recombination and modelled as such. 
5.4 Conclusion 
I conducted a review of the literature to examine findings from bacterial laboratory populations and 
mathematical models of bacterial and eukaryotic populations on the impact of selective on genetic 
structure.  
The bacterial population studied in the laboratory were laboratory adapted E. coli (233,234,238). 
These bacteria are non-transformable, that is they do not take up DNA from the surrounding 
environment easily. Therefore the assumption that recombination would not occur in these 
populations is reasonable. These populations can be considered to be asexual and that any genetic 
change in these populations would arise from mutation not recombination.  In early studies the 
mutation that conveyed the advantage to a mutant is uncharacterised and its prevalence is tracked 
in the population through the decline of a population which carry a gene that conveys a testable 
phenotype. These studies showed that a genotype which carries an advantageous mutant increased 
in the population and that the population was homogenous at the end of a sweep. These studies 
conform to the asexual model of selection. Later laboratory studies characterised the study 
population using genetic and biochemical tests (245,240,248-251,268,252,269). These studies 
revealed a more complex genetic structure than that predicted by the asexual model. In these 
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populations authors maintained that recombination could not occur and that the bacterial 
population had diversified in the chemostat environment as the ecotype model predicts would occur 
in an environment with multiple niches. 
Laboratory populations of bacteria are very different to those seen in nature. A particular difference 
of interest is the lack of recombination in species of bacteria studied in the laboratory (220). 
Mathematical models provide the ability to examine the impact of particular parameters such as 
recombination or mutation on selection. Mathematical models of bacterial populations were initially 
formulated to simulate selection in a chemostat environment. They simulated an asexual population 
and the results of those models were consistent with the classical asexual predictions of selection 
(255,257,256). Like the classical asexual model they predicted that when an advantageous mutation 
arises on a genome descendents of that genome will sweep to fixation in the population. More 
advanced models of selection included recombination in bacterial populations. These models were 
concerned with examining the impact of selective sweeps on overall genetic diversity and did not 
examine directly whether recombination can retain neutral alleles from the wild-type population 
(257,258).   
The predictions from eukaryotic models are more complex. Depending on parameters used, the 
simulations produced by the models predict that the effect of a sweep on measures of linkage 
disequilibrium in a population is very dependent on the position of the linked neutral allele under 
study. Broadly alleles near to the selected locus may hitchhike with the advantageous mutant to 
fixation but neutral alleles that are further away on the genome behave as though they are unlinked 
to the advantageous allele. Therefore diversity at some point on the genome may be conserved 
(263,267). Bacterial genomes are much smaller and differ structurally from eukaryotic genomes and 
as I outlined in the introduction there are significant structural differences between haploid 
symmetric recombination and bacterial asymmetric recombination (270). These structural 
differences mean that there are differences in the predictions of the two models. Although 
mathematical models incorporate a process like bacterial recombination into the eukaryotic model, 
these models still examine the effect selection in a eukaryotic population. Eukaryotic populations 
have both types of recombination occurring in tandem, whereas in bacterial populations only 
asymmetric recombination occurs at variable rates in different populations. There remains the need 
to use a mathematical model of selection in a bacterial population that can examine the effect of 
recombination on the selective sweep.   
The preliminary predictions of the deterministic model showed that a very small proportion of 
alleles from the wild-type population are rescued through recombination and thus present at the 
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end of the simulation. However, recombination and selection are stochastic processes and, to make 
more robust and insightful predictions, a stochastic model of selection and recombination is needed.  
This approach is developed in the next chapter. 
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6 Can bacterial recombination disrupt the hitch-hiking effect of a 
selective sweep? 
6.1 Introduction  
Surveys of bacterial genetic diversity have revealed many complex and differing patterns and there 
is currently a vigorous debate about how these should be interpreted (271). A paradoxical aspect of 
the genetic structure of bacterial populations is that although bacteria can have very large census 
population sizes, their neutral diversity (the amount of polymorphism found in non-coding regions 
or that results in synonymous substitutions) is much less than would be expected in populations of 
this size at a steady state (272). This dearth of neutral diversity has been used as evidence of the 
impact of selection on bacterial population structure (273). While the reality may reflect the 
interplay of many factors such as ecological differentiation, metapopulation structure, bacterial 
recombination, multi-species competition, repeated population bottlenecks and boom-bust 
dynamics, simple models allow us to focus on identifying the signature and impact of individual 
factors on bacterial populations (271). 
In the previous chapter I reviewed published literature which examined the impact of a selective 
sweep on genetic diversity.  I summarised insights from models, the results of which predict the 
effect of frequent or absent recombination when an advantageous allele and/or genotype sweeps to 
fixation. Under the assumptions of the asexual model, as there is no recombination to separate an 
advantageous mutation from the background on which it arises, the whole genotype will sweep to 
fixation. This results in a population composed of the descendents of the original genotype carrying 
the novel advantageous allele, while all other genetic diversity present in the population before the 
selective sweep will be lost. In contrast, under the assumptions of the sexual model, frequent 
recombination allows the advantageous allele to be transferred to other genomes and alleles at 
neutral loci to be transferred to the sweeping genotype. In this model diversity is only lost over a 
small area of the genotype surrounding the selected locus. 
6.1.1 Selective sweeps as a speciation mechanism: the ecotype model 
Selective sweeps have been proposed by some authors as the key mechanism regulating genetic 
diversity in bacterial populations and providing a mechanism of speciation (274,275). Results from 
the simple asexual model predict that when a novel fitter allele arises at a locus in a bacterial 
population, this allele will increase in frequency and sweep to fixation in the population. In the 
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absence of recombination, one consequence of a selective sweep is the extinction of all genetic 
diversity at all loci other than those within the sweeping genotype. This is referred to as hitch-hiking, 
as neutral alleles which are associated with the novel fitter allele hitch-hike to fixation with it. This 
process has been suggested as a mechanism of adaptation and a driver of population divergence in 
the ‘ecotype model’ (274). An ecotype is defined as a population of bacteria that are ecologically 
similar to each other and where genetic diversity is limited within the ecotype by selective sweep 
events (259). A selective sweep occurs when a mutant arises that is better able to use the resources 
within the ecotype. The offspring of this mutant grow faster and leave more descendents so that the 
population eventually consists only of these offspring. As a result genetic variation that existed 
within other genotypes becomes extinct as they are lost from the population (274). 
In the ecotype model bacterial populations diverge into new species when a mutation creates a new 
phenotype that allows a bacteria and its descendents to live in a new ecological niche. The mutation 
may allow the new phenotype to utilise an environmental resource that the parent bacteria are 
unable to. These bacteria are assumed to be protected from selective sweeps in the parent ecotype 
as this population is ecologically distinct and recombination is assumed to be practically absent 
between niches (258,276). The two populations can then exist independently and behave as distinct 
species even though they may exist in the same physical location. Over time, new, fitter bacteria will 
arise in each population through mutation and sweep to fixation within the separate ecotypes, 
allowing the two populations to further diverge away from each other. In this way distinct 
phenotypic clusters exist independently in ecological niches while potentially sharing a physical 
location and maintaining transient amounts of diversity within a cluster (258). 
Cohan has expanded this basic model to include several scenarios, one of which incorporates the 
migration of strains through human transport thus allowing multiple genotypes within an ecotype 
(albeit transiently). Another suggests that if advantageous mutants arise frequently, frequent 
sweeps would not allow diversity to accumulate at all. Further work examines small populations of 
bacteria where genetic drift is capable of maintaining the same dynamic as selection (274).  
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Figure 6.1 Stable ecotype model. Ecotype formation events are represented by a change in colour.  
Periodic selection events are represented by asterisks. Black lines above the phylogenies represent the sequence 
clusters that should be observed in samples of the present day population. The Stable Ecotype model, in which ecotype 
formation is relatively rare, and periodic selection events frequently purge all diversity from within each ecotype, 
therefore predicts a one-to-one correspondence between sequence clusters and ecotypes. Reproduced from (277). 
6.1.2 Homologous recombination can prevent a hitch-hiking event occurring 
Under the ecotype model recombination is a mechanism which generates novel allelic combinations 
that may establish a novel phenotype.  The Cohen et al. contend that recombination is so infrequent 
in bacterial populations that they essentially evolve as a population of asexual organisms (274). This 
contention has been criticised by other authors who believe that recombination would prevent a 
selective sweep from purging diversity from within an ecotype and would prevent two species 
successfully diverging. If bacterial populations evolve as sexual populations rather than asexual ones 
recombination could re-assort alleles at loci in the genome other than the locus under selection.  
This would result in genetic diversity present in the wild-type population before the selective sweep 
being retained and the hitch-hiking effect of the selective sweep would be prevented (278). 
Recombination between ecotypes and across loci other than those that convey phenotypic 
difference would mean that two ecotypes could be almost identical at all loci other than those under 
selection. Thus recombination could prevent the formation of new distinct species (279).  
6.1.3 Interpreting the outcome of a selective sweep 
As the ultimate aim of any evolutionary model is to produce patterns which are a realistic depiction 
of the outcome of evolutionary processes in nature, the second aim of this chapter is to examine 
which summary statistics provide an accurate description of the process and outcome of selection.  
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One method of describing the genetic diversity in bacterial populations is MLST. This is a method of 
bacterial typing which I described in the first chapter. It is a typing scheme where seven house-
keeping genes are sequenced and each different sequence at a locus is assigned a different allele 
number. The allele numbers at each of the seven loci are used to define the sequence types of each 
bacterial isolate in the population (101,280,281). A diversity index is a mathematical measure of 
diversity in a community. In the context of microbial population genetics and MLST it provides a 
measure of sequence type (ST) diversity.  
Diversity indices provide more information about population composition than ST richness (i.e. the 
number of sequence types present); they also take the relative abundances of different STs into 
account. Consider two communities of 100 bacteria each and composed of 10 different sequence 
types. One community has 10 bacteria of each ST, the other has one bacteria of each of nine STs, 
and 91 bacteria of the tenth ST. Clearly the first population is more diverse, but both populations 
have the same ST richness. By taking relative abundances into account, a diversity index depends not 
only on ST richness but also on the evenness, or equitability, with which bacteria are distributed 
among the different STs.  
Two methods of summarising the diversity in a bacterial population can be used to summarise MLST 
data: allelic distributions (nearest neighbour and mismatch) (106) and Simpson’s D (292). 
i. Allelic distributions 
An allelic distribution is a plot of the distribution of allelic distances between isolates. When using 
the MLST two isolates can have an identical ST, or differ at one to seven loci. That is, a pair of 
bacteria which have the same alleles at five of seven loci are two alleles distance apart. The 
mismatch distribution is the proportion of strains that differ at i=0, 1, 2, 3, 4, 5, 6 or 7 loci. Defined 
analytically this distribution can be expressed for the multi locus case of strains which differ at I k of i 
studied loci when k> 0 by the equation at equilibrium: 
6-1 
  
And when k=0:  
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In equation 6-1 ρ is the population recombination rate and θ is the population mutation rate. This 
measure is described in more detail in (106). 
The nearest neighbour distribution is a description of the distribution of the proportion of pairs of 
isolates whose nearest relative differs at 0, 1, 2, 3, 4, 5, 6 or 7 loci from it. 
ii. Simpson's diversity index (D)  
D is a simple mathematical measure that characterizes species diversity, or in this context ST 
diversity in a population (292). In population genetics D is equivalent to the heterozygosity of a 
sample, in this context it is the probability that two isolates selected at random from the population 
will have different STs.  
Simpson’s D is defined as: 
6-2  
  
The fraction with ST i is defined as: 
6-3 
  
The equation can be derived as follows. The probability that the a single bacterium sampled at 
random will belong to the group is . The probability that two bacteria sampled 
consecutively will belong to that group is . This can then be summed for all the STs (of which there 
are  in number) to give the probability that two bacteria consecutively sampled will be of the same 
ST.  This summation is subtracted from 1 to give the probability that two consecutively sampled 
bacteria will have different STs. 
The relationship between Simpson’s D and the proportion of bacteria that differ at none of seven 
loci, i.e. the first point on the mismatch distribution is described by equation 6-4. 
6-4 
  
Another aspect of observing and interpreting selective sweeps in nature is selecting a suitable 
sample of the population to study. Using a mathematical model I can explore the impact of a 
selective sweep on a population; how long an advantageous allele takes to sweep to fixation, how 
long it remains at fixation and how the population structure is expected to be disturbed by the 
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selective sweep. It also allows me to examine the level of population discrimination at which I would 
need to examine the effect of a sweep.  
6.1.4 Aims 
In this chapter I will to address the first objection to the ecotype model: that asymmetric bacterial 
recombination is frequent enough in bacterial populations to prevent a selective sweep acting to 
remove genetic diversity over the whole genotype within an ecotype. In the previous chapter I 
showed that as bacterial recombination was a distinct process from its eukaryotic counterpart a 
specific model was needed to study this process. To this end I will: 
 Expand the ‘bacterial’ or asymmetric model outlined in Chapter 5 to include stochastic 
processes, 
 Use a stochastic model that allows recombination and mutation to examine the effect of 
selection on overall diversity, 
 Examine the scenario of clonal interference to ascertain whether the addition of this complexity 
prevents the loss of genetic diversity as a result of the sweep. 
I will also examine how different measures of diversity record the impact of a selective sweep. To 
this end I will: 
 Adapt a stochastic eight locus model of bacterial evolution with recombination and mutation to 
incorporate a selective sweep, 
 Examine the values of Simpson’s D and mismatch distribution at different points in the 
simulation. 
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6.2 Stochastic Two Locus Model 
In the previous chapter I used a two locus deterministic model to illustrate the difference between 
bacterial homologous asymmetric recombination and eukaryotic symmetric recombination. The 
results of this model showed that for most of the parameters examined very small proportions of 
the alleles from the wild-type population were present in the final population after the selective 
sweep. The results of the two locus asymmetric deterministic model are illustrated in Figure 6.2. As 
recombination and selection are stochastic processes, I adapted the two locus model to incorporate 
stochastic processes into both the selection of bacterial genotypes at each generation and the 
process of recombination.  
 
Figure 6.2Two Locus Asymmetric deterministic model.  
Proportion of the population of recombinant type MX. The population recombination rate ρ is plotted on the log scale 
against proportion of MX in the final population. The results are shown for selection coefficients s of 0.001 (dotted line), 
0.01 (dashes line) and 0.1 (solid line). 
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6.2.1 Stochastic Model Structure 
The population simulated by the stochastic model is the same as that simulated by the deterministic 
model in Chapter 5. When illustrating this population I considered it as composed of three stages, 
pre-sweep (the start of the simulation), the intermediate phase (illustrated by demonstrating the 
recombination and selection events) and the post-sweep population, when the wild-type is extinct 
and all bacteria carry the advantageous allele, illustrated in Chapter 5, figure 5.1.  
As in Chapter 5, each bacterium has two loci, the locus under selection and a neutral locus. In the 
pre-sweep population there is one bacterium carrying an advantageous allele (M), all other bacteria 
carry the wild-type allele (W) at the selected locus. At the second neutral locus one bacterium 
carries a Y allele while all other bacteria carry an X allele. The X allele represents all other wild-type 
neutral diversity present in the pre-sweep population at this locus rather than one particular allele. 
At the start of the simulation the M allele is exclusively associated with the Y allele and the W allele 
is exclusively associated with the X allele. Throughout this chapter I refer to the WX genotype as the 
wild-type and the MY genotype as the mutant type. Genotypes MX and WY, created through 
homologous recombination between the wild-type and mutant genotype are referred to as hybrid 
genotypes.  
The model is extended from the Wright-Fisher model of allele frequency change, and incorporates 
selection and recombination (282). In the Wright-Fisher model offspring are sampled from the 
parent generation which then dies, so generations are discrete and non-overlapping. The number of 
different types of bacteria at each generation is simulated under a multinomial distribution 
dependant on the frequency of the genotypes (WX, WY, MX or MY) in the population from which the 
next population is drawn. For computational efficiency the multinomial distribution is described as 
using the binomial distribution commands in C++ so that , the number each genotype that appears in 
a sample size N  
  distributed, where the p  is the frequency of the genotype at that timestep.  For each 
subsequent genotype the population is sampled without replacement.  
The first step in each simulation of the model defines the proportions of each allele present in the 
population at time (t)( . The equations describing this step are detailed in 6-5. 
The next step in the programme is the selection event, detailed in equation group 6-6 below. After 
the selection event the population is defined under the multinomial distribution 
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( , his step is detailed in equation group 6-6 and the frequencies of each 
genotype at this point ( . are defined in equation group 6-7. 
6-5 
  
  
  
  
6-6 
  
  
  
  
6-7 
 
  
  
  
6-8 
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Recombination then occurs in the population through a stochastic three-step process. In stage one 
(see equation group 6-9), the probability of an allele’s availability to recombine with a recipient 
genome is simulated under the binomial distribution at rate  (the recombination rate) depending 
on the frequency of the allele in the population. I derived r in terms of the population recombination 
rate so that , where  is the population recombination rate and N is the population size. 
Alleles enter the recipient genome simulated under the multinomial distribution dependent on the 
proportion of free alleles estimated in stage one and the frequency of the relevant genotype in the 
population detailed in equation groups 6-10, 6-11, 6-12 and 6-13. Stage three simulates the 
integration of recombinant alleles through calculating the number of different types now present in 
the population (see equation group 6-14). The new generation (t+1) is then defined as detailed in 
equation group 6-15. 
6-9 
    
  
  
  
6-10 
  
  
  
  
6-11 
  
  
  
  
6-12 
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6-13 
  
  
  
  
6-14 
  
  
  
  
6-15 
  
  
  
  
 
6.2.2  Selection of recombination rates and selection coefficients 
The model was simulated for a range of parameter values. The population size N was 106. Values for 
the population recombination rate ρ were simulated from 1 to 10000 per generation. Values for the 
selection coefficient s were simulated from 10-3 to 0.9 so that the fitness of the M allele was varied 
from 1.001 to 1.9.   
In this analysis I used a wide range of recombination rates. These have been estimated previously 
and are described in detail in (106,283): the authors used the mismatch distribution, maximising the 
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multinomial log likelihood with respect to the values of ρ (and θ the population mutation rate). This 
was fitted to the mismatch distribution calculated from the entire contents of publically available 
MLST datasets for Neisseria meningitidis (http://www.pubmlst.org/neisseria/), Staphylococcus 
aureus (http://www.saureus.mlst.net), S. pneumoniae (http://www.spneumoniae.mlst.net), 
Streptococcus pyogenes (http://www.spyogenes.mlst.net/), and Helicobacter pylori 
(http://www.pubmlst.org/helicobacter/) among others (283). 
 
S. aureus has been shown to be almost clonal with alleles changing by point mutation about sixteen 
times more commonly than by recombination (102), with a population recombination rate of 2.4 
(283). At the other end of the scale, H. pylori is estimated to have a high population recombination 
rate of 73.3 (283).  
In this model I used a wide range of selection coefficient values. Previous laboratory and theoretical 
studies of the distribution of the fitness effects of advantageous mutants have shown that fitness is 
distributed exponentially (284); most advantageous mutations have small relative fitness effects. In 
laboratory studies the relative fitness of detectable advantageous mutations has been shown to 
range between ~1.05 and 1.25 when the ancestral population is well adapted to the laboratory 
environment (284,285). The range of parameters for the fitness effects of mutations are illustrated 
in Figure 6.3. In laboratory studies it is difficult to detect small changes in fitness advantage; 
therefore the lower bound of selection coefficients is higher than that which is likely to occur in 
nature (285). The choice of the lower bound for s was taken from a review of literature of past 
models of selective sweeps (286) and also what was computationally feasible to simulate. When s ≤ 
0.0009 no selective sweeps occurred in 1000 simulations of the model, therefore s = 0.001 is the 
lower bound of the selection coefficient in these simulations. The parameter space studied in the 
model is considered to be a reasonable representation of the possible range of fitness effects in a 
bacterial population. 
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Figure 6.3 Distribution of fitness effects.  
Distribution of fitness effects among 18 advantageous mutants assayed in the permissive environment. Bars indicate the 
observed distribution of fitness effects. The dots indicate expected values given an exponential distribution as calculated 
by the authors. Reproduced from (285). 
6.2.3  Model outputs 
The impact of recombination on diversity is calculated from three outputs in the two locus model. 
The first is the proportion of the post sweep population that is made up of the MX genotype. The 
second is the probability that a genotype carrying an X allele at the neutral locus can sweep to 
fixation, defined as π.  The third is the number of X alleles which become associated with the M 
allele through recombination over the duration of the simulation.  
6.2.4 Results  
i. Proportion of X alleles retained 
Figure 6.4 shows the average value of P(MX) from multiple sweep events that occurred over 1000 
simulations of the model for each value of ρ and s. As can been seen in Figure 6.4 the proportion of 
MX genotypes is small for a high value of s and low value of ρ. For example, when ρ < 10 and s > 
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0.001 less than 10% of the final population is composed of MX genotypes. When ρ is very much 
higher a substantial proportion of X alleles can be rescued, particularly when s is small. Values of ρ = 
1000 are considered implausibly high. At an upper-bound of ρ = 200, which is still well in excess of 
recombination rates that have been measured, the proportion of MX in the final population varies 
from 2% for s = 0.1 to 60% when s = 0.001 .   
 
Figure 6.4 Relationship between recombination rate, selection coefficient and proportion of MX in the final population 
in the two locus stochastic model.  
The population recombination rate ρ is plotted on the log scale against proportion of MX in the final population when a 
sweep has occurred. The results are shown for selection coefficients s of 0.001 (dotted line), 0.01 (dashes line) and 0.1 
(solid line).  The results are presented for an average of 1000 simulations of the model. 
 
ii. Impact of recombination on the hitchhiking event 
When a selective sweep occurs in a clonal population the advantageous allele sweeps to fixation 
along with the rest of the genotype on which the advantageous allele arose. At the end of the sweep 
all alleles in the population will be alleles or descendents of alleles present in the original bacterium 
carrying the advantageous allele. In a recombining population (even at rates seen in bacterial 
populations), Doolittle and others predict that when the mutant allele comes to fixation, alleles at 
other loci will often be those rescued from the wild-type bacteria in the pre-sweep population 
(287,279).  
To assess the probability of this prediction I created a metric π, which is the proportion of selective 
sweeps that result in the fixation of an X allele at the neutral locus. To put this in terms of the 
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components of the model, if in 5 of 100 sweeps, P(MX)=1 at the last generation of the simulation, 
then π = 5/100.  
The lower bound of π was set to 0.001 when fixation of an X allele had failed to occur within 1000 
sweep events. Below this boundary the fixation probability was considered to be too low to be 
computationally feasible to measure. In my simulations the fixation of the X allele did not occur in 
1000 selective sweeps when ρ ≤ 100, even when s was at the lower bound of 0.001, as shown in 
Table 6.1.  
A ρ of 100 is a very high population recombination rate; for example ρ of 73.4 has been estimated 
from populations of H. pylori (283). The result of these simulations demonstrated that the complete 
disruption of the purging effect of the selective sweep is an extremely rare event in populations with 
low, intermediate or high population recombination rates. Other than populations such as H. pylori 
with very high recombination rates, a selective sweep at a selected locus will result in the loss of 
alleles that were associated with the wild-type population at other loci.
 
Table 6.1 Probability of fixation of neutral allele in 1000 selective sweeps as a function of recombination and selection. 
ρ s 
 0.001 0.01 0.1 
10 < 0.0001 < 0.0001 < 0.0001 
100 < 0.0001 < 0.0001 < 0.0001 
1000 0.20 0.01 < 0.0001 
 
iii. Impact of recombination over time 
In the analysis of the model simulations I have shown that small but detectable amounts of the X 
allele (which in the wild  population was exclusively associated with the wild-type genotype WX) 
remain in the population at relatively high recombination rates when the selection coefficient is very 
small (s ≤0.001). However, I have also shown that even at high recombination rates when ρ ≥ 100, 
the probability of the X allele becoming fixed in the population (to the exclusion of the Y allele) is 
very rare. Thus, when the X allele is maintained in the population it exists with the Y allele in the 
population also.  
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In order to examine further the relationship between ρ, s and the impact of the selective sweep on 
descent and why so few hybrids are observed in populations that recombine at high rates, I plotted 
the creation of new hybrids against time along with the prevalence of the wild-type population. 
Figure 6.5 shows the number of X alleles incorporated into a genotype carrying the advantageous 
mutant allele over time. In this simulation the total population size is 106 and ρ is 100. The number 
of X alleles incorporated reaches a maximum when the WX and MY genotypes are at intermediate 
levels. The number of generations until the extinction of the WX genotype increases as the selective 
advantage of the selected mutant allele decreases. The longer bacteria with a WX genotype are 
present at intermediate levels in the population, the more likely a recombination event will occur 
between the WX genotype and the MY genotype. At the start of the simulation the creation of the 
hybrid is unlikely (unless recombination is at a very high rate) as the MY genotype is extremely rare. 
At the end of the simulation the opposite is true: the WX genotype is extremely rare so 
recombination with the MY genotype is an extremely rare event.  
The amount of X alleles in the final population is dependent on the amount of time the wild-type 
genotype and mutant genotype are at intermediate values, as well as the recombination rate. This 
period of time is dependent on how fast the sweep is, the speed of which is dependent on the 
relative fitness of the advantageous allele, which in turn is determined by the selection coefficient. 
As the value of s decreases, the amount of time the WX genotype remains in the population 
increases and the amount of the X alleles that remain in the population increases.  
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Figure 6.5 Impact of recombination over time.  
A) Number of pre-sweep X alleles from the wild-type WX genotype rescued by becoming associated with the M through 
recombination over time. B) Proportion of the wild-type genotype, WX, in the population over time. The results are 
shown for selection coefficients s of 0.1 (grey), 0.01 (blue), 0.001 (red).  ρ = 100 and N=106.  
 
As a result, the lower the value of s the greater the amount of wild-type alleles present at neutral 
loci in the population. I examined the proportion of MX genotypes in the final population for very 
low selection coefficients and how probable a selective sweep was for a given selection coefficient.  
To do this I used an estimation of the fixation probability of an allele taken from the published 
literature on nearly neutral theory, which is an extension of the neutral theory. Under the neutral 
theory a neutral allele has a 1/N probability of becoming fixed in the population. The nearly neutral 
theory expanded the neutral theory in response to the observation that the fitness of a mutation is 
not neutral or non-neutral but may be a range of values (288-290). As the selection coefficient 
approaches zero, the relative fitness of the mutant allele approaches neutrality. The nearly neutral 
theory states that the effect of a selection coefficient can be considered neutral when sNe > 1 where 
Ne is the effective population size. The probability of an allele with a selection coefficient s becoming 
fixed in the population is shown by equation 6-16 where N is the population size, s is the selection 
coefficient and p is the initial frequency of the mutant. 
6-16 
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Figure 6.6 Relationship between the fixation probability of the M allele and P(MX), the proportion of MX in the post-
sweep population (Y axis).  
The fixation probability is calculated from the equation derived by Ohta et al. 
Ns
Nsp
e
e
u
2
2
1
1
 (288), where N = 106 is 
the population size, s is the selection coefficient and p is the initial frequency of the mutant.  
 
In Figure 6.6, when u is 2x10-5, the selection coefficient s is 10-5 and when a sweep occurs in the 
population, 100% of the population is composed of MX genotypes. However, with these parameter 
values only one selective sweep occurred out of 5000 simulations of the stochastic model. With a 
selection coefficient of 10-6 no sweeps occur out of 5000 simulations. Thus, although a selection 
coefficient may be considered non-neutral, a sweep may in fact be very rare, so rare that it makes it 
computationally unfeasible to estimate. 
P
(M
X
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6.3 Eight Locus Model of a Selective Sweep in a Mutating and Recombining 
Population 
In the models described in Chapter 5 and section 6.2, I examined whether recombination can disrupt 
the hitch-hiking effect of a selective sweep. I showed that the majority of genetic diversity present in 
wild-type genotypes in the pre-sweep population is lost as the result of a selective sweep. This 
analysis was only concerned with the fate of the neutral wild-type alleles in the population. The 
question of interest was which genotype in the pre-sweep population neutral alleles in the post-
sweep population were related to: the wild-type genome or the genotype carrying the advantageous 
allele. As the wild-type alleles could only be ‘saved’ through recombination the effect of mutation 
was not considered in the model.  
At the beginning of this chapter I outlined that the ultimate aim of any model is to provide outputs 
which can inform the analysis of natural populations of bacteria. To understand the impact of a 
selective sweep on a natural population of bacteria I sought to use a more realistic model that 
incorporated mutation. In addition I aimed to format the model so that the results of simulations 
could inform analysis of datasets collected from natural bacterial populations. These populations 
have commonly been typed using MLST, and so any output from the model should be compatible 
with this format. To fulfil this aim I used a model that incorporates mutation and recombination at 
multiple loci. 
6.3.1 Model structure 
The model builds on earlier work which allowed simulations of bacterial populations that can be 
compared to experimental data derived using MLST (106,283). This original model was an extension 
of the neutral infinite alleles model (291) describing neutral variation at seven loci evolving by 
mutation and recombination. A simple modification of this is a parsimonious model for describing 
population genetic variation in S. pneumoniae (106). It is parameterised by population mutation and 
recombination rates, denoted θ and ρ respectively, and by population size N. , with m the 
mutation rate and with  r the recombination rate.  
The model illustrated in Figure 6.7 considers N individuals with recombination and mutation 
occurring at seven neutral loci but includes an eighth locus on which selection acts. The model is 
parameterised by rates θ and ρ, as above, together with the fitness advantage of the advantageous 
mutant. The initial population consists of a single genotype. At each generation of the model, 
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genotypes are selected at random from the previous generation, then these genotypes can mutate, 
recombine or both events can occur. At each generation recombination can also occur at the eighth 
loci. The probability of recombination occurring at each generation to each individual genotype is 
simulated through random number generation with probability of r the recombination rate. The 
donor allele is randomly chosen from other genotypes in the population and recombination always 
changes a whole locus. Mutation can occur at rate m throughout the simulation at the seven neutral 
loci and always results in a novel allele being generated. The population diversifies through mutation 
and recombination until it is at an equilibrium level of diversity.  
When the population is at equilibrium one genotype is selected at random and a mutation occurs at 
the eighth locus generating the advantageous allele. This allele conveys a fitness of 1+s to any 
genotype in which it occurs. If the advantageous allele is lost through recombination then the fitness 
advantage is lost. If the advantageous allele is acquired through recombination then the genotype 
gains the associated fitness advantage.  
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Figure 6.7 Eight locus individual model of selection. This illustration shows the model for a population of five individuals.  
The bacterial strain at each generation (time interval t) is defined by seven neutral loci and one locus which is under selection. At each generation every individual can infect another. 
Mutation (red line) and recombination (green line) can occur at each transmission step. Mutation occurs at rate m and recombination occurs at rate r. Recombination and mutation can 
affect more than one allele in a single step. Each mutation creates a new allele. A recombination event results in an individual bacterium inheriting an allele from a random donor. Once 
dynamic equilibrium has been achieved a mutation at the eighth locus is assigned the fitness 1+s, this mutation is shown here at 1*. Any genotype that carries this mutation has the 
fitness 1+s. Illustration adapted from (106). 
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iv. Model outputs 
The overall diversity of the simulated population is measured by Simpson’s D, which is a measure of 
bacterial strain (genotypic) diversity in a population (292). By taking strain relative abundance into 
account it is possible to measure not only the strain richness but also the distribution of those strains 
in the population. Simpson’s D is defined as in equations 6-2 and 6-3. 
This model is a multilocus simulation incorporating recombination and mutation. Simpson’s D 
measures overall diversity, which is the rate at which new strains are generated either by 
recombination or mutation. Even when a measure of strain diversity is identical for two populations, 
if the rate of recombination relative to mutation differs in the two populations then the population 
structure of those populations could differ. This is measured using the allelic mismatch distribution.  
v. Parameter selection 
The recombination rate affects the diversity of the population, even if selection is not present. 
Hanage et al. explored the effect of recombination on the population structure in a population 
evolving under the neutral model (283), at a fixed heterozygosity of D=0.88. Using the allelic 
mismatch distribution, the authors showed that increasing r/m, while keeping the rate at which new 
strains are generated constant, impacts the population structure, even though the diversity of 
strains in the population may be constant, illustrated in Figure 6.8. How those strains are related i.e. 
how different they are from each other can vary markedly due to recombination.   
 
Figure 6.8  Increasing recombination in a population with constant homozygosity.  
The allelic mismatch distributions  are shown as solid bars. Three combinations of θ and ρ are shown along an 
isocline of D = 0.88: a clonal population where θ=7 and ρ=0, a population with intermediate levels of recombination 
(ρ/θ=0.5, θ=4.75, ρ=2.38), and a population with high levels of recombination (ρ/θ=5, θ=1.69, ρ=8.45). These simulations 
had a population size of 2000. Reproduced from (283). 
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In order to examine the impact of increasing the ratio of recombination to mutation during a sweep 
the parameters of the population recombination rate and mutation rate were set so that D remains 
constant under neutrality, as described previously (283). From Figure 6.9 I selected an isocline of 
diversity where Simpson’s D = 0.88, which dictated the recombination and mutation values which 
allowed this measure of diversity to be constant under neutrality. 
 
In the clonal simulation ρ=0 and θ=7, in the intermediate simulation ρ=2.38 and θ=4.75 (ρ/θ = 0.5) 
and in the high recombination simulation ρ=8.45 and θ=1.69 (ρ/θ = 5). In all simulations N=2000 and 
the selection coefficient is 0.9, as I sought to examine multiple sweeps (a high selection coefficient 
was necessary to allow multiple sweeps to be computationally practical). The simulations were run 
for 1000 generations, until the population reached a dynamic equilibrium and Simpson’s D = 0.88. 
Once dynamic equilibrium was achieved, a mutation at the eighth locus was assigned the fitness 1+s. 
The model was simulated for another 1000 generations until the population has returned to 
equilibrium, which was measured by the value of D returning to 0.88. 
 
Figure 6.9 Effect of mutation and recombination on strain diversity.  
The predicted strain diversity within the underlying neutral population, measured by the homozygosity  source, is 
plotted as a function of the population mutation rate θ and recombination rate ρ (lower values of 1-D indicate more 
diversity). The line ρ/θ=1 is shown. The positions of Streptococcus pneumoniae (S.pn), Neisseria meningitidis (N.m) 
Staphylococcus aureus (S.a), Helicobacter pylori (H.p), Streptococcus pyogenes (S.py), Burkholderia pesudomallei (B.p) 
and Bacillus cereus (B.c) based on parameters estimated from all data for those species in the corresponding MLST 
databases, are shown. Reproduced from (283). 
6.3.2     Results  
The results of simulations under clonal (A), medium recombination (B) and high recombination (C) 
parameter sets are shown in Figure 6.10. Each graph shows D measured at each generation for five 
selective sweeps, each with a baseline measure of D of 0.88. In each simulation the advantageous 
allele, which has a relative fitness of 1.9, is introduced into the population after 1000 generations.  
1
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I sought to examine whether changing the ratio of recombination to mutation affected the depth 
and the length of the sweep. I therefore simulated within a parameter space which has a consistent 
measure of D under neutrality for differing ratios of mutation to recombination. Diversity is restored 
in the population through the generation of novel alleles by mutation and the re-assortment of 
these novel alleles through recombination. In Figure 6.10, in each simulation the genotype carrying 
the advantageous mutant sweeps to fixation in the population over a small number of generations, 
rapidly decreasing the value of D. It is evident that the genomic diversity in the population is severely 
reduced for a short period of time as a result of the selective sweep. 
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Figure 6.10 Strain diversity over time.  
A measure of heterozygosity D is plotted over time for clonal (A), intermediate (B) and high (C) recombination to 
mutation ratios. Each graph shows the results of 5 selective sweeps. The parameters for ρ and θ are taken from an 
isocline of D=0.88. In A ρ=0 and θ=7, (ρ/θ = 0) in B ρ=2.38 and θ=4.75 (ρ/θ = 0.5) and C ρ=8.45 and θ=1.69 (ρ/θ = 5). In all 
simulations N=2000.  
 
 
 
A 
B 
C 
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In results from clonal simulations shown in Figure 6.10(A), the selective sweep peaks at a lower 
average value of D than the simulations where ρ/θ = 0.5 or ρ/θ = 5. In simulations where ρ/θ = 5 the 
population takes longer to return to dynamic equilibrium than in simulations where ρ/θ = 0.5 or 
where ρ = 0.  
This apparent effect of recombination is due to the parameterisation of the model. The impact of 
maintaining constant D is that as the recombination rate increases, the mutation rate must 
decrease. Thus, at high recombination rates shown in Figure 6.10(C) the mutation rate is low and 
consequently the population takes longer to return to D = 0.88 than the clonal simulation, as novel 
alleles are generated at a much slower rate. Conversely in a clonal population the mutation rate is 
high therefore mutations remove the advantageous mutation and decrease the impact of the 
selective sweep. Thus, increasing the rate of recombination relative to mutation does not have any 
discernable impact on the population if changes in the population are measured by Simpson’s D.  
A simple diversity measure, such as D, does not reveal the full impact of recombination on a 
selective sweep, although it provides an excellent measure of the impact of the selective sweep on 
overall diversity. I therefore looked at the mismatch distribution to observe the effect of a sweep on 
population structure.  
In the results from a simulation of a clonal population, shown in Figure 6.11(A) when the simulation 
is at equilibrium the proportion of isolates that differ at 0, 1, 2, 3, 4, 5, 6 and 7 loci increase 
monotonically. The proportion of isolates that differ at all loci will increase as more loci are 
examined, as under clonality the only way two bacteria can share an allele is through descent. As the 
simulation continues, each clonal lineage accumulates novel alleles which are only found in its 
descendents. When selection occurs (shows as black bars), the standing diversity is decreased in the 
population within 25 generations. At the point of lowest diversity in the population 66% of the 
population are identical at all loci, while 32% are identical at all but one locus. In these simulations 
the population is reduced to one clonal lineage with related single locus variants. At 1025 
generations there were 125 strains in a population of 2000 bacteria and when equilibrium was re-
established the number of strains in the population was 241 and 61% of those strains were 
discordant over 7 loci.  
When a population has a medium recombination to mutation ratio (ρ/θ = 0.5), at equilibrium the 
proportion of bacteria that are identical at all loci is slightly less than a population with no 
recombination. However, there is a difference in the proportion of bacteria that differ at five or 
more loci. Compared to the clonal population, (shown in Figure 6.11(B)) fewer isolates differ at five, 
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six and seven loci at equilibrium. At the peak of the selective sweep, 40% of the population is alike at 
all loci while 32% of the population differs at more than six loci. Unlike the clonal population the 
proportion of isolates that differed at six loci is the same at the peak of the selective sweep and 
when the population is at equilibrium. At the peak of the selective sweep the population is reduced 
to two clonal lineages: the bacteria carrying the advantageous mutant and its single locus variants 
(60% of the population) and a group of bacteria (35%) that differ at six loci. Again, as seen in the 
clonal model, this is resolved to neutral expectation by 2000 generations.  
In the population that has a high ratio of recombination to mutation when the population is at 
equilibrium most bacteria are identical at three loci. This is due to the fact that in order to maintain 
constant homozygosity the mutation rate is decreased as the recombination rate increases, 
therefore the number of novel alleles and strains generated is very low. At the peak of the selective 
sweep most bacteria (80%) are alike at all loci, the highest level of homozygosity in the three 
parameter spaces. 
 
 152 
 
 
 
 
 
Figure 6.11 Mismatch distribution results from eight locus model.  
The proportion of bacteria that are discordant at 0, 1...7 loci in clonal (A), intermediate (B) and high (C) recombination to 
mutation ratios. The parameters for ρ and θ are taken from an isocline of D=0.88. In (A) ρ=0 and θ=7, in (B) ρ=2.38 and 
θ=4.75 and (C) ρ=8.45 and θ=1.69. In all simulations N=2000. The white column is the allelic distribution when D is at the 
minimum value, the black column is from the population when D has returned to 0.88 
A 
B 
C 
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6.4 Clonal interference 
Having considered the simplest model of a selective sweep, a two locus model with a single 
advantageous mutant, and a multilocus model of a selective sweep, I sought to consider a more 
complex evolutionary scenario. I sought to examine whether a more complex model allowed more 
of the neutral wild-type alleles to be ‘rescued’ from the pre-sweep population.  
In the conventional model of asexual evolution advantageous mutations rarely arise in the 
population. When they do, the genotype on which they arose expands clonally through the 
population until it is fixed in the population, purging the population of genetic diversity. This is the 
strong selection with weak mutation model of asexual evolution and the scenario I modelled in the 
previous three models studied (286,293,294). When a population is large and has a high mutation 
rate, advantageous mutations may be common enough that they occur at the same time in the 
population. In an asexual population, the absence of recombination results in competition between 
the clones that carry the different advantageous mutations. This phenomenon is known as clonal 
interference (295). Theoretical models of clonal interference lead to increased fitness effects and 
longer fixation times of the winning advantageous mutation (296,297,295). Evidence for the 
occurrence of clonal interference has been inferred from laboratory studies of bacterial populations 
(239,298-300). Previous studies have examined the fate of the advantageous mutation, but did not 
address the effect of the clonal interference on genotype wide diversity. In order to examine the 
effect of two competing advantageous mutations on the standing diversity during a sweep I 
expanded the original selective sweep model.  
6.4.1 Model structure 
I extended the two locus selective sweep model to include a second advantageous allele. These two 
alleles are at the same locus: allele Ma is one advantageous allele and Mb is the competing 
advantageous allele. As in the original model, W is the wild-type allele at the same locus. The three 
neutral alleles at the second locus are X, Y and Z. The fitness of W is 1, the fitness of Ma is 1 + sa and 
the fitness of Mb is 1+sb, where sa and sb are the selection coefficients of the advantageous and 
interfering mutations respectively and sa > sb. At the beginning of the simulation (pre-sweep 
population) there is one bacterium carrying the Ma and Y alleles (genotype MaY) and one bacterium 
carrying the Mb and Z alleles (genotype MbZ). The remainder of the population is the genotype WX. 
As shown in Figure 6.12, in the pre-sweep population the X allele is exclusively associated with the W 
allele (genotype WX), the Y allele is exclusively associated with Ma, and the Z allele is exclusively 
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associated with Mb. Recombination allows nine possible combinations of alleles, WX, WY, WZ, MaX, 
MaY, MaZ, MbX, MbY, MbZ.  
The model is extended from the Wright-Fisher model of allele frequency change, and incorporates 
selection and recombination (282). The number of different types of bacteria at each generation is 
simulated under a multinomial distribution dependant on the frequency of the genotypes (WX, WY, 
WZ, MaX, MaY, MaZ, MbX, MbY and MbZ) in the population from which the next population is 
drawn. 
The first step in each simulation of the model defines the proportions of each allele present in the 
population at time (t). The equations describing this step are detailed in equation group 6-17. The 
next step in the programme is the selection event, detailed in equation group 6-18. When selection 
acts on the population, those bacteria that carry the Ma allele are multiplied by (1+sa) and those 
that carry the Mb allele are multiplied by (1+sb). Those bacteria that do not carry a advantageous 
Ma or Mb allele are multiplied by 1. After the selection event the population is defined under the 
multinomial distribution. This step is detailed in equation group 6-19 and the frequencies of each 
genotype at this point are defined in equation group 6-20. 
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Figure 6.12 Structure of clonal interference extension.  
The initial pre-sweep population is composed of three genotypes, pure wild-type WX (blue), pure mutant type MaY (red) and pure interfering type MbZ (purple). Recombination can occur 
at rate between the loci in either direction. Selection increases the proportion of bacteria with the Ma or Mb beneficial mutations according to their selection coefficients, sa and sb). 
The fitness of hybrid genotypes are dependent on the allele at the selection locus. In the final population post-sweep population all genotypes contain the Ma or Mb allele (red or purple) 
at the selection locus and the rescue of pre-sweep X alleles (blue) at the neutral locus is measured by the proportion of the hybrid genotypes MbX and MaX.
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Recombination then occurs in the population through a stochastic three-step process. In stage one 
(see equation group 6-21), the probability of an allele’s availability to recombine with a recipient 
genotype is simulated under the binomial distribution at rate  (the recombination rate) depending 
on the frequency of the allele in the population. r is derived in terms of the population 
recombination rate so that  where the population recombination rate and N is the 
population size. Alleles enter the recipient genotype simulated under the multinomial distribution, 
which is dependent on the proportion of free alleles (estimated in stage one) and the frequency of 
the relevant genotype in the population. This process is detailed in equation groups 6-22 to 6-25. 
Stage three simulates the integration of recombinant alleles, calculating of the number of different 
genotypes now present in the population; presented in equation group 6-26. The new generation 
(t+1) is then defined as detailed in equation group 6-29. 
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i. Parameter selection 
I ran simulations varying the ratio between the sa and sb selection coefficients by increasing the 
value of sb while keeping sa constant. This varies the interaction between the Ma mutant and the 
interfering Mb mutant. The simulation was stopped at 10,000 generations, when the WX type had 
become extinct in all simulations. The population size N was 106. Values for the rate of 
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recombination ρ from 1 to 10000 were simulated. Values for the selection coefficient sa and sb were 
simulated from 10-3 to 0.25 (subject to the constraint that sa > sb). 
6.4.2 Results  
The results of a two locus model of clonal interference are shown in Figure 6.13. In this model a 
selective sweep is defined as occurring when the WX genotype is extinct in the population. At this 
point all the isolates in the population will contain either the Ma allele or the Mb allele. This study is 
concerned with the occurrence of polymorphism at the neutral locus and more specifically, the 
retention of neutral X alleles from the pre-sweep population, which can be incorporated into the 
final population through the formation of the MbX hybrid or the MaX hybrid. Once the WX genotype 
is extinct in the population no more X alleles can be rescued through recombination. Therefore the 
fate of the MbZ and MaY genotypes are not considered here.  
 
Figure 6.13 Number of WX, MaY and MbZ in the population over time. .  
The results are shown for selection coefficients sa of 0.1 and sb of 0.005. In these simulations ρ = 10, N=106 and the 
results are presented for an average of 1000 simulations of the model. 
 
As Figure 6.13 shows, the WX genotype is extinct in the population by 1500 generations and the MaY 
genotype makes up the majority of the population. In the previous section of this thesis I showed 
that an important factor in the conservation of wild-type neutral alleles from the pre-sweep 
population (X alleles) was the length of time the WX genotype remained in the population. I 
therefore examined whether the clonal interference increased the time to extinction of the WX 
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genotype. Figure 6.14(A) shows the result from two sets of simulations of the clonal interference 
model and a comparable set of simulations from the single advantageous allele model.  
I then investigated how many alleles descended from the wild-type genotype in the pre-sweep 
population are retained in the population. As in the previous models an X allele is representative of 
any allele from a wild-type genotype in the pre-sweep population. In these simulations the X allele 
from a wild-type genotype can be retained in the post-sweep population by recombining with either 
advantageous mutant. The number of these bacteria which carries both an advantageous allele Ma 
and Mb and the X allele is shown in Figure 6.14(B).  Figure 6.14(A) shows the number of wild-type 
bacteria (WX type) in a population of 106 bacteria over 10,000 generations. Compared to a simple 
model with one advantageous allele (shown as a solid line), clonal interference has some effect on 
the length of time the wild-type genotype, WX, remains in the population.  In the original model the 
WX type is completely extinct by 200 generations, in the clonal interference model with sb = 0.01 
(shown as a dotted line) and sb = 0.005 (shown as a dashed line) extinction occurs at 400 and 1400 
generations. In the original model WX falls below 10,000 bacteria at 188 generations, and in the 
clonal interference model at 420 generations with sb = 0.01. When ρ = 100, the clonal interference 
allows 700 more bacteria with the X allele to be retained in the population. In the context of the 
population as a whole (106) this is a very small proportional increase as shown in Figure 6.14 (B).  
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Figure 6.14 Dynamics of clonal interference over time.  
A) Total number of pure wild-type plotted and B) The number of new hybrids MaX and MbX plotted against time. The 
results are shown for selection coefficients sa of 0.1 and sb of 0.005 (dotted line) and sa of 0.1 and sb of 0.01 (dashed 
line), the solid line shows the result from the single mutant model when s=0.1, ρ = 10. 
 
The simulations of the clonal interference extension to the model showed that advantageous 
mutations remain associated with the genetic background in which they originally occurred, with the 
exception of a small number of hybrids. The genetic diversity that had arisen before the occurrence 
of the two advantageous mutations is lost, therefore added complexity does not prevent a selective 
sweep reducing neutral diversity in the population.  
6.5 Discussion and conclusion 
In this section I will examine some key insights from the mathematical models presented in this 
chapter, and interpret these with reference to appropriate previous studies in published literature.  
The occurrence of homologous recombination and the important role that it plays in shaping the 
genetic structure of bacterial populations is clear.  However, the impact of recombination on 
different evolutionary processes is a source of study and debate (301). Using simple models I 
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investigated the impact of bacterial homologous recombination on a selective sweep which in the 
ecotype model provides a mechanism of speciation (259). The ecotype model groups bacteria into 
ecologically constrained monophyletic clusters. Selective sweeps allow the bacteria to adapt to their 
environment and restrict genetic diversity in the ecotype so that the ecotype remains a closely 
related cluster of bacteria (258,259,274). One of the objections to this model is that the ubiquity of 
homologous recombination threatens the formation of closely related genetic groups. Some 
investigators have maintained that selective sweeps are unable to occur in bacterial populations as 
homologous recombination would disrupt the process. They have stated that homologous 
recombination could re-assort the genotype faster than a selective sweep could be completed and 
so diversity would not be purged except at loci under selection (302,278). I addressed this issue by 
introducing a model of selective sweeps incorporating bacterial homologous recombination which is 
suitable to analyse the impact of varying rates of localised recombination on a selective sweep. 
Using the stochastic two locus model I tracked the recombination events which retained neutral pre-
sweep alleles. This showed that the speed of extinction of the wild-type population impacts on the 
amount of wild-type alleles retained, such that the latter was highest when the selection coefficient 
of the beneficial allele was small. This process was shown to be most important again in the simple 
model of clonal interference. In the simple two-locus model the proportion of wild-type alleles at the 
neutral locus was low when population recombination rates were <10 for selection coefficients for 
the beneficial allele at the selection locus of 0.01 or greater.  Higher proportions could be rescued 
when recombination rates were much higher and this leads to a consideration of recombination 
rates in natural populations of bacteria.  
i. Asymmetric bacterial recombination is not frequent enough in natural bacterial populations to 
prevent a selective sweep acting to remove genetic diversity over the whole genotype within 
an ecotype 
Throughout this work I have used values of population recombination rates that were estimated 
from population genetic models which estimate the frequency of recombination relative to mutation 
(25, 15). In the first instance I considered the absolute population recombination rate rather than 
the ratio to mutation; these have been estimated as varying between 0.7, for Bacillus cereus, to 73.3 
for H. pylori. These estimates are in agreement with empirical evidence (303) and certainly suggest 
that bacterial populations with population recombination rates above 50 are an exception (25, 15).  
When examining the eight loci model I parameterised the population in terms of the ratio of 
recombination to mutation. I characterised a population with ρ/θ =0.5 and 5 as being intermediately 
and highly recombining respectively. In terms of natural populations of bacteria, S. pneumonia has 
been estimated as having ρ/θ = 4 , N. meningitis  ρ/θ = 9 and S. aureus   ρ/θ = 0.5.  These estimates 
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are taken from previous analysis of bacterial populations which have been demonstrated as being 
consistent with empirical evidence (25, 15). Another method of estimation of the ratio of 
recombination to mutation has been developed which has estimated much higher ratios of 
recombination to mutation from natural populations of bacteria. The results of this analysis reported 
more extreme ratios at both the recombining and clonal end of the spectrum. The authors 
computed a value called r/m, which is the ratio of rates at which nucleotides become substituted as 
a result of recombination and mutation. If r/m = 10, then recombination introduces 10 times more 
nucleotide substitutions than point mutations during the evolution of the population this is 
consistent with a value of ρ/θ  = 2 if each recombination event introduces five substitutions on 
average (304). The authors reported a range of r/m, from 63.3 to 0.02. Unfortunately the authors do 
not estimate absolute mutation or recombination rates and so it is difficult to interpret the results of 
the two locus model in light of these parameters. Interpreting the result of the eight locus model in 
light of these parameters, only four bacteria had an r/m above 25 (comparable to ρ/θ = 5) (304). 
Thus the results of the model can be considered to hold for the majority of bacterial populations 
whose recombination rates have been estimated. 
ii. The impact of a selective sweep is highly dependent on the selection coefficient 
Although I have shown that homologous recombination cannot prevent the occurrence of a selective 
sweep in a bacterial population, the effect is highly dependent on the speed of the sweep. The speed 
of the sweep is in turn dependent on the relative fitness of the advantageous mutant allele. It 
remains unclear how common fast selective sweeps are in natural populations of bacteria and how 
useful the ecotype model is in describing the way in which most bacterial populations evolve. The 
range of fitness in laboratory populations of bacteria has been shown to be exponential in a well 
adapted population (284). Recent research has shown that this distribution is not an adequate 
description in populations under environmental stress when mutants of greater relative fitness are 
more common (305). This could indicate that a fast selective sweep will be more common in 
unstable environments.  
iii. A monophyletic population is the predicted outcome of a selective sweep 
These findings leads us to agree with one premise of the ecotype model, namely that a selective 
sweep will result in a monophyletic population. So within populations, or putative ecotypes, that are 
shaped by repeated selective sweeps, I would expect neutral variation and phenotypic 
characteristics to be aligned. A test of the ecotype model in various contexts is the extent to which 
such monophyletic associations are found in natural populations of bacteria. Although there has 
been substantial study of periodic selection in laboratory populations, there has been comparatively 
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little study of the relevance of this phenomenon in naturally occurring populations of bacteria. The 
study by Guttman and Dykuizen, 1994 examined the gapA gene (see the glossary in Appendix A for a 
brief explanation of gene names) in E. coli using nucleotide data. It found that the sequences of the 
gene were unusually alike. However other genes also sequenced in the study maintained diversity. 
The interpretation by the authors of the study is that a selective sweep occurred through the E. coli 
population at the gapA locus and recombination over the rest of the genome maintained diversity 
(306). This interpretation of the work has been questioned on the grounds that recombination is not 
sufficiently common in E. coli populations to maintain diversity during a selective sweep. Other 
researchers have interpreted the results of this study as showing distinct clusters of E. coli ecotypes 
in which separate periodic selection events of a universally advantageous allele have occurred (274). 
The advantageous mutant that is advantageous in all ecotypes had been passed from ecotype to 
ecotype by recombination. Of course, this interpretation can only be validated if corresponding 
ecotypes could be identified in the E. coli population, and this has not been done. In either case, the 
study only sequenced twelve isolates of E. coli, one of which was the laboratory strain K12. The small 
amount of isolates compared could leave the study vulnerable to sampling bias and a laboratory 
strain of E. coli is not representative of the evolution of a strain from a natural population of 
bacteria. A second study by Wagner and Riley identified low synonymous site variation at the lacY 
locus in E. coli. However, even if recombination could rescue diversity over the whole genome, it 
would be expected that recombination is extremely rare between neighbouring sequences. In the 
Wagner and Riley study the neighbouring phoA gene sequence was not found to share the same 
level of sequence diversity as the lacY locus (see the glossary in Appendix A for a brief explanation of 
gene cluster names) (307). If a selective sweep had acted on lacY I would expect low synonymous 
site variation at neighbouring genes such as phoA, as it is unlikely that close neighbours on the 
genome will be separated by recombination over the time it would take for a sweep to come to 
fixation.  
In a review, Cohan describes a community phylogeny model constructed to test the ecotypes model 
(259). The community phylogeny model attempts to identify sequence clusters in natural 
populations which correspond to different ecotypes. This was applied to bacterial communities in 
the Negev Desert and identified a putative ecotype of Bacillus licheniformis specialised to the higher 
exposure to sunlight of the south facing slope of the canyon (259). The identification of clusters does 
not provide information about how those clusters developed and the selection processes involved 
and so does not necessarily provide evidence for selective sweeps in natural populations.    
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iv. A longitudinal sample of a bacterial population is needed to successfully examine the impact of 
a selective sweep 
A more general issue raised by the results of this chapter is what metrics are appropriate for 
analysing the impact of selection on a bacterial population. Measures of allelic diversity such as 
Simpson’s D and other measures of homozygosity are very useful in describing the overall reduction 
in genetic diversity in the population. What they cannot measure is the more subtle changes in the 
genealogy of the population, as the impact of the sweep on the amount of genetic difference in the 
population can be undone in a relatively short amount of time through mutation. A more lasting 
impact of that sweep is the change in the genealogy of the population. Using measures which 
quantify the proportion of wild-type genes remaining in the population and the probability of 
fixation of a wild-type gene, the ancestry of a post-sweep population can be traced to the first 
bacteria carrying the advantageous mutant. The impact of homologous recombination on the 
population is most keenly felt on the genealogy of the population (at the end of the sweep most 
bacteria are descended from the first bacteria carrying the advantageous mutant) rather than the 
genetic diversity which may be relatively quickly restored through mutation. Thus any study of 
selective sweeps in bacterial populations should be carried out using metrics which quantify both 
difference and descent as used in this study. These results also highlight the importance of using 
good longitudinal data to properly show selective sweeps in natural bacterial populations, rather 
than sampling a snapshot in time. 
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7 Impact of pneumococcal carriage vaccination on the population 
structure of Streptococcus pneumoniae 
7.1 Introduction 
The previous two chapters examined a simple selective sweep where a bacterium developed an 
advantageous mutation and consequently increased in number in a population. As I reviewed in 
Chapter Five this is the form of bacterial selection that has been most commonly studied using 
population genetic theory and in the laboratory. To use population genetic theory to understand the 
impact of human interventions in bacterial populations it is necessary to examine more complex 
selective scenarios. In 2000 the PCV7 vaccine was introduced in the United States, which placed a 
strong selective pressure on serotypes which the vaccine targeted, as I will review below. This 
chapter presents analysis of the impact of the PCV7 vaccination programme on genetic diversity 
(characterised using MLST) in the pneumococcal population.  
i. Vaccination with PCV7 has resulted in serotype replacement in carriage 
The introduction of the PCV7 vaccine has resulted in a reduction of IPD caused by the seven 
serotypes targeted by the vaccine (308). However, in the years following the introduction of the 
vaccine there has been an increase in IPD caused by serotypes not targeted by the vaccine, most 
notably serotype 19A (56). There has been concern that over time this serotype replacement will 
continue and erode the benefits of vaccination. In response to this Hanage et al. (309) examined a 
longitudinal carriage sample to examine whether the increase in serotypes not targeted by the 
vaccine could be expected to continue, or whether the frequency of serotypes has reached a new 
equilibrium and so future changes in serotype frequency will be small (309). Using population 
genetic techniques, the authors examined whether the impact of selection pressure from 
vaccination could be detected and whether the pneumococcal population returned to a dynamic 
equilibrium during the period studied. They compared the serotype diversity in samples collected 
from a longitudinally sampled vaccinated community with three communities sampled prior to the 
introduction of vaccination.  The authors showed that there was a statistically significant increase in 
serotype diversity in the vaccinated communities compared to un-vaccinated communities indicating 
the selective pressure of vaccination. This is illustrated in Figure 7.1 which shows the relative 
proportions of serotype plotted by rank frequency.  The sample collected in 2007 showed no 
significant difference in serotype diversity from the pre-vaccination population (309).  
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Figure 7.1 Rank frequency distributions of serotypes in the samples collected in Massachusetts during 1998-9 (A), 2001 
(B), 2004 (C) and 2007 (D).  
The median values obtained from 1000 samples of the same size drawn from the combined pre-vaccine distribution are 
shown as a solid line with dashed lines either side representing the 5th and 95th percentiles. Larger numbers of 
serotypes in the later samples reflect larger sample size. Figure reproduced from (309). 
 
In the study conducted by Hanage et al., the authors considered that selective pressure of the 
vaccine will only impact on the specially targeted serotypes included in the vaccine. Before the 
introduction of the PCV7 vaccination, vaccination was thought to be protective against colonisation 
A 
B 
C 
D 
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by serotypes 6A, 9A, 9L, 9N, 19A, 23A and 23B, due to cross-reactive protection (48). These were 
referred to as PCV7 cross reactive serotypes. However, the response to vaccination in the prevalence 
of these serotypes has not been uniform. 6A, 9A and 9N have reduced in prevalence in carriage 
studies. Conversely 19A, 23A and 23B have increased in prevalence in carriage studies (5). Thus, a 
serotype’s putative cross reactivity in vitro has not been shown to be a useful predictor of their 
behaviour in PCV7 vaccinated communities. This is in contrast to those serotypes included in the 
PCV7 vaccination which have shown consistent reduction in incidence in response to vaccination (6). 
ii. Vaccination pressure may result in sequence type replacement, though the extent may depend 
on the impact of capsular switching 
As discussed in Chapter 1, the variation between strains in a pneumococcal population can be 
indexed by identifying antigenic (serotype) variation or genetic variation that is not under known 
selective pressure. As vaccination targets certain serotypes, the indexing of antigenic variation is an 
essential part of understanding the impact of the vaccination campaign. However, the identification 
of capsular switching and the transfer of antibiotic resistant genes (described in Chapter 1) shows 
that important clinical characteristics, such as antibiotic resistance, may be associated with 
particular genotypes rather than a serotypes and highlight the importance of identifying and 
understanding changes in genetic variation within a serotype.  
As the current pneumococcal vaccines target the serotype, the wider genome is not under selective 
pressure from the vaccine. The ST genes do not include the capsular polysaccharide genes and 
therefore are a measure of genetic diversity in parts of the genome not under direct selective 
pressure from vaccination. However, a simple model of selection would predict that STs associated 
with the vaccine serotypes would decline in frequency in the population in response the selective 
pressure of the vaccine. As serotypes not targeted by the vaccine increase in frequency in the 
population, STs associated with these serotypes would also increase in frequency in the population. 
It is therefore of interest whether strain structure changes in response to vaccination as expected, or 
whether certain STs are more ‘successful’ than others and expand in the population more than 
expected. 
Although there is a strong association between specific serotypes and associated STs, capsular 
switching has been documented in pneumococcal populations (51), as described in Chapter 1. 
Therefore STs that were associated with vaccine serotypes may remain in a pneumococcal 
population under selective pressure from vaccination, though now associated with a non-vaccine 
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serotype. Thus, although serotype replacement may occur in the pneumococcal population, the 
extent of associated ST replacement is dependent on the impact of capsular switching. 
7.1.1 Aims 
In an extension of the analysis carried out by Hanage et al. (309) I will examine the impact of PCV7 
vaccination on genetic variation and population structure of strains in pneumococcal carriage. To 
this end I will analyse samples of carried pneumococci from Massachusetts, the UK and Finland to: 
 Examine whether vaccination results in ST replacement,  
 Analyse the impact of vaccination on ST frequency and diversity, 
 Identify the impact of capsular switching if it is present.  
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7.2 Methods 
7.2.1 Data-sets  
i. Un-vaccinated communities 
I used three data-sets collected from un-vaccinated communities. As an indicator of baseline ST 
distribution in Massachusetts I analysed a sample of 71 carried isolates from children aged between 
three months and six years of age. The samples were collected between 1998 and 1999 and all 
children in the sample had attended a family practice suffering from acute otitis media (AOM) (46). 
These isolates were assumed to be broadly representative of the distribution STs in nasopharyngeal 
carriage in the community during this period.   
As there may be small differences in the ability of carried serotypes to cause AOM (310), I also 
analysed two samples from un-vaccinated communities outside Massachusetts. I analysed a sample 
of carried isolates from healthy children less than two years of age in Oxford, UK (311) and Tampere, 
Finland (310).  
Isolates in the UK data-set had been obtained from a longitudinal pneumococcal carriage study 
performed by the Oxford vaccine group (University of Oxford) during 1999-2001. Children were 
enrolled in this study at birth and lived in the city of Oxford and surrounding area. Samples of 
nasopharangeal flora were obtained from 100 children sampled repeatedly over two years. 264 
isolates obtained and characterised by MLST were used in this data-set (311).  
The Finnish data-set was collected from a survey of 329 children from Tampere, Finland. The 
children were monitored from 2 to 24 months of age as part of a study into acute otitis media 
(FinOM) (312). S. pneumoniae were isolated from nasopharyngeal samples from healthy children in 
the FinOM cohort study between 1994 and 1997 (310). 
All three data-sets have been modified by the authors of the published studies so that each isolate 
was from one episode of carriage per child. Where more than one isolate with the same ST and 
serotype was collected from the same child this was excluded from the data-set. The size of the 
data-sets used in the analysis are MA 1998-8 N=71, Finland N=216 and UK N=228.  
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Table 7.1 Original data-set composition of un-vaccinated communities 
 UK (311) Finland (310) MA 1998-9 (46) 
Location of study Oxford, UK Tampere, Finland Massachusetts, USA 
Number of isolates 264 217 90 
Age of children  0-24 months 2-24 months Under 7 years 
Type of study Birth cohort Birth cohort Antibiotic resistance survey 
 
ii. Longitudinal sampling in vaccinated communities 
Samples were collected from children under seven years of age in 2001, 2004, 2007 and 2009 from 
children attending family practices in eight Massachusetts communities. In 2001 and 2004, 16 
communities were sampled; the eight additional communities sampled during these years were 
excluded from this analysis for consistency. Details of the collection of samples from these 
communities in 2001, 2004 and 2007 is described in detail in (48,47,313,50). Samples were collected 
in 2009 following a method consistent with previous years described in references (48,47,313,50).  
I will briefly summarise the process of data collection. The communities used in the studies were 
selected on the basis of geographic separation, evidence that few children crossed community 
boundaries to seek paediatric care, and diversity of size and demographic characteristics using 
available US census data (48). In all data-sets isolates were collected from young children under 
seven years of age. This age group was chosen to include the period of highest risk of pneumococcal 
carriage and to be large enough to collect the required sample size. Children were eligible for 
inclusion if they were younger than 7 years, resided in a study community, and presented for either 
a routine well-child or “sick visit” at a participating practice. Parental consent and nasopharyngeal 
swabs were obtained by either trained study personnel or trained office practice nurses. PCV7 
vaccination history was recorded from the medical record (30). 
Specimens were collected from children using a calgiswab which was inserted into the back of the 
nose of the child. The sample was placed into transport medium and transported for analysis at the 
Children’s Hospital in Boston (30). S. pneumoniae colonies were identified from nasopharyngeal 
samples through growth on specific media. Serotype was determined for a single colony from a pure 
culture of each isolate by the quellung reaction, using serotype-specific pneumococcal antisera (30).  
The assignment of STs to isolates in the data-sets used in this analysis has previously been described 
in detail (313). In summary, the ST of each isolate was determined by MLST as previously described 
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(314). For each of the seven housekeeping genes (loci); aroE, gdh, gki, recP, spi, xpt and ddl, 
nucleotide sequences were obtained on both DNA strands. Alleles and ST assignments were made 
using the MLST website (www.spneumoniae.mlst.net). A summary of the data-sets is presented in 
Table 7.2. 
7.2.2 Analysis 
i. Estimation of ST diversity 
The diversity of each data-set was assessed using Simpson’s index of diversity D (292). This has been 
used previously to describe changes in serotype diversity in the samples described in this chapter 
Here I use it to examine ST diversity and so Simpson’s D is the probability that two isolates chosen at 
random will have a different ST. The standard calculation of Simpson’s D includes self pairs if 
calculated in a finite population, which in a small population may reduces the usefulness of the 
measure. Simpson’s D corrected for a finite population size is defined as: 
7-1  
  
The fraction with ST i is defined as: 
7-2 
  
In these calculations m is the total number of STs and N is the total sample size. The variance and 
95% confidence interval were calculated as previously (for an infinite population due to 
computational necessity) (315). The values of D will be distributed around the true diversity with the 
variance  defined as: 
7-3 
  
An estimate of the standard deviation of the true diversity of a population is given by  and 
the approximate 95% confidence intervals estimated as: 
7-4 
 (315). 
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To estimate whether the values of D were significantly different between the data-sets I calculated a 
P value using a two tailed Welch’s t-test.  
To further explore the impact of vaccination I calculated the rank frequency distribution of STs for 
each sample. The frequency of each ST is described by equation 7-2. Having calculated the 
distribution of frequency of STs denoted by   I ranked the frequencies 
from largest (rank 1) to smallest (rank m), where m is the total number of STs in the sample.  
To compare a range of rank frequency distributions to the vaccine era samples, I simulated 1000 
Monte Carlo replicates drawn from the empirically observed rank-frequency distribution of the non-
vaccine sample MA 1998-1999. This analysis was carried out using the R statistical package. 
ii. Analysing changes in STs using eBurst 
To examine the longitudinal trends in STs and their association with serotypes in a community I 
analysed data-sets collected in 2001, 2004, 2007 and 2009 using eBurstV3 software (316). This 
software analyses the allelic profiles in a data-set and groups isolates into eBurst groups.  eBURST 
groups are considered to approximately define clonal complexes, STs that share sufficient similarity 
that they are considered to descend from a recent common ancestor. In this analysis an ST was 
assigned to a clonal complex when identical at ≥6 loci to at least one other ST in the group. Details of 
the number, size and makeup of clonal complexes for each data-set was generated. A population 
snapshot (a diagram displaying all clonal complexes and singletons in the sample) was also 
generated for each data-set.  
I then divided the sample into vaccine and non-vaccine serotypes. The allelic profiles of the vaccine 
associated sub-set were compared to the allelic profiles of the non-vaccine associated sub-set using 
the eBurst comparison tool. I generated a population snapshot which compared the STs found 
associated with vaccine serotypes with those STs found associated with non-vaccine serotypes. 
7.3 Results 
7.3.1 ST diversity  
i. ST diversity in un-vaccinated communities 
To analyse ST diversity in carriage prior to vaccination, I examined independent samples from similar 
age groups in three un-vaccinated communities, presented in Table 7.1. Displayed in Table 7.2  
estimates of Simpson’s D calculated from the three data-sets. The sample collected in Massachusetts 
prior to vaccination has a smaller measure of Simpson’s D (lower diversity) than the samples 
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collected in Finland and UK. The differences between Simpson’s D are quite substantial between 
values close to 1 (the absolute maximum), however, there is no statistically significant difference 
between these values of Simpson’s D.  
Figure 7.2(A-C) shows the rank frequency of the STs plotted for each sample collected in un-
vaccinated communities. For the Tampere (B) and UK (C) samples, the MA 1998-1999 distribution is 
shown for comparison and the 95% intervals of 1000 samples drawn from the empirically observed 
MA 1998-1999 rank frequency distribution are also shown. 
The Massachusetts data-set sampled prior to vaccination (MA 1998-9) is the least diverse of the 
three populations. In this data-set the most common and second most common STs makes up 18% 
of the population. In the UK and Finland data-set the two most common STs make up 12% and 11% 
of the population respectively.   
Table 7.2 Sample characteristics  of vaccinated and unvaccinated communities 
Sample Sample Size Number of STs D (95% CI) 
MA 1998-9 71 43 0.97 (0.96, 0.98) 
Finland 216 91 0.98 (0.98, 0.99) 
UK 228 100 0.98 (0.97, 0.98) 
MA 2001 126 61 0.97 (0.96-0.99) 
MA 2004 222 85 0.96 (0.95-0.98) 
MA 2007 291 86 0.96 (0.95-0.97) 
MA 2009 293 94 0.97 (0.97-0.98) 
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Figure 7.2 Frequencies of individual sequence types (STs) in data-sets sampled from unvaccinated communities arranged 
by rank.   
(A) MA 1998-1999, (B) Finland and (C) UK. In graphs (B) and (C) the rank frequency distribution in the baseline     un-
vaccinated community MA1998-9 is plotted as a blue dashed line. The 2.5th and 97.5th percentile values for each point 
obtained from 1000 samples of the sample size drawn from the baseline unvaccinated community (MA 1998-1999) are 
shown as a blue shaded section in graphs (B) and (C). 
 
 
A 
B 
C 
Rank of Sequence Type 
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ii. Comparison of ST diversity in un-vaccinated and vaccinated communities 
The values for Simpson’s D were calculated for each sample. The lowest value of D was 0.96 and 
estimated from MA 2004, 0.96 (95% CI 0.95-0.98) and MA 2007, 0.96 (95% CI 0.95-0.97). The value 
of D in the pre-vaccine population in Massachusetts (MA 1998-9) was 0.97 (95% CI 0.95, 0.99) and by 
2009 the estimate of D had returned to this level. However, none of these changes in value were 
statistically significant at the 5% level. 
Figure 7.3 (A-D)  shows the rank frequency distribution is for the post-vaccination samples and the 
MA 1998-9 sample, which is plotted as a blue broken line for the purposes of comparison in each 
graph. The MA 1998-1999 sample was chosen as the baseline population.  For each sample the 5% 
and 95% percentile values of 1000 samples drawn from the empirically observed MA 1998-1999 rank 
frequency distribution are also shown. 
In the samples collected immediately after the implementation of vaccination (MA 2001) ST diversity 
decreased in the population compared to the sample collected prior to vaccination. The peak 
homozygosity of the population was reached in 2004 and 2007 when the most common ST made up 
14% of the population. In the samples collected in 2009 the ST diversity is increased and by 2009 the 
most common ST made up 8% of the population. This sample was not significantly different to the 
baseline estimate taken from the MA 1998-9 population when the most common ST made up 9% of 
the population.   
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Figure 7.3 Rank-frequency distributions of individual sequence types (STs) in data-sets sampled from vaccinated 
communities MA 2001 (A), MA 2004, (B), MA 2007 (C) and MA 2009 (D).  
The rank frequency distribution in the baseline un-vaccinated community MA1998-9 is plotted as a blue dashed line in 
each. The 2.5th and 97.5th percentile values for each point obtained from 1000 samples of the sample size drawn from 
the baseline unvaccinated community (MA 1998-1999) are shown as a blue shaded section in each graph.  
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7.3.2 Changes in STs after the introduction of vaccination 
i. eBurst analysis 
In order to examine the effect of vaccination on the diversity of STs in the population, I first 
established which STs were associated with serotypes included in the vaccine. At the time of writing 
the full information on the serotype of each isolate in the data-set collected in Massachusetts in 
1998 was not available. Therefore for this analysis I used 2001 as my baseline population.  
For 2001, 2004, 2007 and 2009 I compared isolates with a PCV7  vaccine serotype (4, 9V, 14, 19F, 
23F, 18C, 6B) and isolates with other serotypes using an eBURST comparative population snapshot. 
In this eBurst population snapshot each ST is represented by a yellow circle. The size of the circle is 
the relative frequency of the ST in the sample. The larger the circle the greater the number of STs. 
When an ST differs at one locus from another ST it is referred to as a single locus variant (SLV) and a 
black line is drawn between the two STs. In a clonal complex the probable ancestor of the clonal 
complex is assumed to be the isolate with the greatest number of SLVs and is coloured blue. In these 
comparative population snapshots, an ST number with a number labelled in green is  only associated 
with vaccine type (VT) serotypes, those in black with non-vaccine type (NVT) serotypes, and those in 
pink were found with both VT and NVT serotypes.  
Figure 7.4 shows the population snapshot for the sample collected in 2001. In this sample only two 
STs are associated with both a VT and NVT serotype (ST 439 and ST 199). All other STs are associated 
with either a VT or NVT serotype.   
Figure 7.5 shows analysis of the 2004 population. There has been an increase in STs that were not 
associated with NVT serotypes in the 2001 sample. Of particular note are STs 62 and 558 which have 
increased in frequency in the population. In Figure 7.4 and Figure 7.5 these STs are circled in red.  
STs 199 and 439, which had previously been associated with both serotype groups, are now 
associated solely with NVT serotypes. ST 320, previously associated with only VT serotypes, is now 
only associated with NVT serotypes.  The population snapshot from 2007 (Figure 7.6)  shows that STs 
associated with NVT serotypes expand in the population but, other than STs 199 and 439, do not 
form clonal complexes.  By 2009 (Figure 7.7) STs 62, 439 and 38 have formed clonal complexes.
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Figure 7.4  Population snapshot of sequence types in 2001.   
The green labelled sequence types are associated with PCV7 serotypes. The black labelled sequence types are associated with non vaccine serotypes. STs 
199 and 439 are found associated with both serotype groups and coloured in pink. STs 558 and 62 referred to in the text are circled in red.    
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Figure 7.5 Population snapshot of sequence types in 2004.   
The green labelled sequence types are associated with PCV7 serotypes. The black labelled sequence types are associated with non vaccine serotypes. STs 448, 667 and 690 are found 
associated with both serotype groups and coloured in pink. STs 558 and 62 referred to in the text are circled in red.                    
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Figure 7.6 Population snapshot of sequence types in 2007.  
 The green labelled sequence types are associated with PCV7 serotypes. The black labelled sequence types are associated with non vaccine serotypes. STs 138, 23 and 42 are found 
associated with both serotype groups and coloured in pink. STs 558 and 62 referred to in the text are circled in red.        
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Figure 7.7 Population snapshot of sequence types in 2009.   
The green labelled sequence types are associated with PCV7 serotypes. The black labelled sequence types are associated with non vaccine serotypes. STs 1390 and 36 are found 
associated with both serotype groups and coloured in pink. STs 558 and 62 referred to in the text are circled in red.     
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ii. Impact of serotype replacement on ST frequency 
Analysis of the longitudinal samples of vaccinated communities using eBurst demonstrated that the 
ST composition changed over time. There was a notable increase in those STs associated with NVT 
serotypes and a decrease in STs associated with VT serotypes. However some STs which had been 
associated with VT serotypes remained in the population. Table 7.3 examines the fate of STs 
associated with VT serotypes in more detail. In 2001 30% of STs in the population were associated 
only with a VT serotype. These STs are labelled with a green ST number in Figure 7.4. Only 5% of that 
30% is still present in 2007. Three STs were associated only with VT serotypes in 2001 and survived 
into 2007: STs 138, 320 and 36 (shown in Table 7.4). The rise in these STs to make up 14% of the STs 
in the 2009 population is a result of the expansion of ST 320. By this time ST 320 is associated with a 
NVT serotype 19A.  
 
Table 7.3 Frequency of STs associated with VT and NVT serotypes in 2001 and change in frequency in later years 
 VT associated in 2001
a, b
 NVT associated in 2001 Shared associated in 2001
c
 
2001 0.30 0.56 0.14 
2004 0.07 0.77 0.16 
2007 0.05 0.79 0.15 
2009 0.14 0.88 0.12 
a) STs associated only with 4, 9V, 14, 19F, 23F, 18C, 6B serotypes in 2001 
b) In 2004, 2007 and 2009 this is the proportion of STs which had been associated with a VT in 2001 (may now 
be associated with a NVT) 
c) Sequence types associated with vaccine serotypes and one other non-vaccine serotype in 2001 
 
Table 7.4 Capsular Switching  
ST 2001 2004 2007 2009 
138 6B 6B 6C & 6B 6C &6A 
320 19F 19A 19A 19A 
36 23F 23F 19A & 23B 23B & 14 
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7.4 Discussion 
i. Impact of selection on genetic diversity 
I found that I could detect the impact of selection, due to vaccination, on the population structure of 
carried pneumococci by comparing three longitudinal MLST samples collected from vaccinated 
communities with samples collected in communities prior to vaccination. There were notable 
changes in the distribution of STs in vaccinated communities when analysed using the rank 
frequency distribution. However unlike analysis of serotype diversity published previously, changes 
in the estimated value of Simpson’s D were not statistically significant, results are presented  in 
Table 7.2 .  
The rank frequency distribution of STs in the longitudinal samples from 2001, 2004, 2007 and 2009 
document changes in the population structure in response to conjugate vaccination. Between 2001 
and 2004 the population is less diverse, while this trend is reversed between 2004, 2007 and 2009. 
This is comparable with previous research into the effect of vaccination on serotype diversity (317) 
and consistent with vaccination rates in the population. Vaccine coverage in the Massachusetts area 
has been documented as low during 2001 and 2002. In the 2001 data-set 36% of children aged 19-35 
months had received three doses of vaccine (10). When the sample was collected from this age 
group in 2004 90% coverage by vaccination had been achieved (48). It is a reasonable assumption 
that the decrease in diversity seen in 2004 reflects the rapid expansion of a few STs associated with 
non-vaccine serotypes. 
ii. By 2009 genetic diversity has returned to pre-vaccination levels 
By 2009 the distribution of STs in the population has regained the shape characteristic of an un-
vaccinated population. It is reasonable to assume that between 2004 and 2009 previously rare STs 
become frequent in the population and novel SLVs of these STs are generated through mutation and 
recombination, increasing ST diversity.  This assumption will be examined in more detail in the 
following sections. In a recently published study Hanage et al. suggested that the changes in 
serotype diversity seen in 2004 reflect the point at which the pneumococcal population was in the 
process of responding to selective pressure imposed by the pneumococcal vaccine (3). In their 
analysis they showed that by 2007 the serotype distribution had returned to the shape and diversity 
seen in un-vaccinated communities, though the serotype composition was now very different (3).  
The authors predicted that no further expansion of non-vaccine serotypes would be expected. The 
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results from the 2009 sample certainly suggest that the authors were correct in their prediction and 
the pneumococcal population in Massachusetts has reached a post-vaccination dynamic equilibrium.   
iii. Changes in ST  frequency in response to vaccination 
In the sample collected in 2001, the majority of STs are associated solely with either a VT or NVT 
serotype, though each serotype can have more than one ST associated with it. Through 2004, 2007 
and 2009 the frequency of STs associated with VT serotypes declines as the frequency of VT 
serotypes decline, which is consistent with studies that have documented the impact of serotype 
replacement in this community. In 2004, 2007 and 2009 STs which had been seen at low frequency 
in the sample collected in 2001 and associated with NVT serotypes increase in frequency in the 
population, to the exclusion of STs associated with NVTs. By 2007 only 5% of STs associated with VT 
serotypes in 2001 were still present in the population, in contrast 80% of the STs associated with 
NVT serotypes in 2001 were still present in the population. Thus, serotype replacement was 
accompanied by a noticeable ST replacement, though some STs common to both VT and NVT 
serotypes (e.g. ST 199 and ST 439) persist at high frequency in all samples.  
iv. Impact of capsular switching 
A small percentage of STs that were associated only with VT serotypes in 2001 were still present in 
the population in 2007. In 2007 these STs were no longer associated with VT serotypes. STs 138, 320 
and 36 are associated with a NVT serotype in 2007. In 2009 ST 36 is also found associated with VT 
serotype 14, which it had not been associated with previously. In the case of each of these STs the 
apparent novel combination could have arisen through recombination (capsular switching) in the 
recent past or this combination of ST and serotypes could have been present in pneumococcal 
populations previously. As there is no record of the ST serotype combination in the global MLST 
database (http://spneumoniae.mlst.net) prior to 2000, it is reasonable to assume that these 
combinations of ST and serotype have arisen post-vaccination, as has been documented previously 
(18). Therefore, due to the role of capsular switching, ST replacement was not as comprehensive as 
serotype replacement in the pneumococcal population.  
ST 320 is of particular public health interest as this ST is associated with multi-drug resistance. ST 320 
was associated with serotype 23F (a VT) in 2001 and is associated with 19A (a NVT) in 2004, 2007 
and 2009. Indeed, between 2007 and 2009 it increases in frequency in the population, while the 
prevalence of 19A remains relatively constant in those two years. This suggests that although the 
frequency of serotypes may now be at a stable equilibrium, changes in the constituent STs of each 
serotype may still occur.  
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v. Limitations of analysis 
There are a number of limitations in this analysis. The sample size is variable across data-sets and the 
sample size of the 2001 and 2004 data-set is not very large. This is due to the exclusion of data 
collected in eight additional communities that were not sampled in 2007. In addition, the sample 
from an un-vaccinated community in Massachusetts was collected from nasopharyngeal carriage in 
children with AOM. The serotypes and thus sequence types which cause AOM may not be 
representative of those found in carriage. The differences between serotypes causing AOM and 
those found in carriage are expected to be minor (as indicated by analysis presented by Hanage et al. 
(6)). This data-set is only an approximate representation of the pneumococcal population in 
Massachusetts prior to vaccination and so direct comparison of ST identity with samples from 2001, 
2004, 2007 and 2009 is not appropriate. 
In the first instance change in ST diversity was assessed using estimates of Simpson’s D. This 
measure did not find any significant change in the diversity in the populations over time. The lack of 
significant change could be due to the small size of the samples, or the measure may not be suitable 
to assess ST diversity from these data-sets.  
The simple selective sweep model with levels of recombination seen previously in pneumococcal 
populations predicts that only a small proportion of STs in the post-vaccination population would 
have originally been exclusively associated with vaccine serotypes. In general we would expect that 
serotype replacement should result in associated ST replacement. Table 7.3 shows that this 
expectation is broadly validated. In 2001 30% of STs were exclusively associated with vaccine 
serotypes. In 2007 this had dropped to 5%. Shown in Table 7.4, the STs that survived did so as a 
result of serotype switching. STs 138, 320 and 36 recombined with a non-vaccine serotype which 
they are now associated with, allowing them to persist in the population. This phenomenon is 
known as capsular switching and has been documented previously (317).  
The STs which switch capsules are more likely to come from serotypes that persist for longer at 
intermediate levels in the population. This expectation is explained in Chapter 5 of the thesis where 
Figure 5.2 illustrates that recombination events are more likely to occur when the wild-type and 
mutant type genomes are at intermediate levels. This is validated in the pneumococcal population. 
The STs which recombined with a non-vaccine serotype were previously associated with the most 
common vaccine serotypes; 19F, 6B and 23F which were also serotypes that persisted in the 
population (46,47).  
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The selective sweep model and this analysis assumed that STs are selectively neutral: no one ST is 
more likely to persist in the population than others and the STs that persist through recombination 
do so through chance only. Other authors have postulated that some STs are selectively 
advantageous due to multiple antibiotic resistant genes or other unknown characteristics associated 
with the ST (41,51), if STs were not selectively neutral then a larger proportion would survive than 
predicted by the simple sweep model. This analysis found that 5% of STs persisted in the population 
that were previously exclusively associated with PCV7 serotypes.  This is within the maximum 
prediction of the simple selective model which assumes that all STs are neutral. However given that 
capsular switching is likely to be less common than rates of recombination simulated in the simple 
selective sweep model and that the subsequent increase in STs (particularly ST 138) previously 
associated with PCV7 serotypes, the results of this model do not fully conform to the neutral 
expectations. 
7.5 Conclusion 
I have used a number of simple population genetic tests and frequency distributions to detect the 
impact of vaccination on a carried population of pneumococci. I demonstrated that the ST diversity 
in carried pneumococci decreased after vaccination and by 2004 changes in population structure are 
evident. However, by 2009 the distribution of ST frequencies is very similar to that seen in an un-
vaccinated population. I have also demonstrated that ST replacement occurred over this time, 
although ST replacement was not complete due to the impact of capsular switching.  
 195 
 
 
8 Discussion 
Discussions of detailed findings are included in the relevant chapters. This chapter provides an 
overall summary of key findings from each chapter, describes the implications of these findings for 
pneumococcal treatment and prevention and identifies research which follows from this thesis.  
8.1 Summary of findings  
The first chapter introduced S. pneumoniae as a pathogen and a commensal of the upper respiratory 
tract, described its transmission and life cycle and outlined where the greatest burden of morbidity 
and mortality lay. It also outlined that due to enhanced surveillance of pneumococcal invasive 
disease and studies of pneumococcal carriage there was now an unprecedented wealth of data 
describing the serotype distribution, antibiotic resistance prevalence and population structure of S. 
pneumoniae. It outlined that there remained challenges to understand this population structure and 
showed that previous research into multi-strain systems did not adequately address the research 
questions outlined in the aims of this thesis. 
In Chapter 2 I performed a meta-analysis to examine the impact of antibiotic non-susceptibility on 
the risk of mortality. In contrast to previous reviews on this subject, I examined the impact of 
antibiotic non-susceptibility in pneumococcal pneumonia, bacteraemia and meningitis. I showed 
that PNSP pneumococcal pneumonia or bacteraemia infections did not have an increased mortality 
associated with penicillin treatment. However, a meningitis infection with a PNSP pneumococci 
increased the risk of mortality two fold, when these patients were treated with penicillin.  I 
concluded that penicillin could still be used to successfully treat many non-meningeal pneumococcal 
infections. These results concur with the recent revision of appropriate Penicillin MICs for the 
treatment of pneumonia and bacteraemia (65) and medical opinion that penicillin levels in the blood 
and lungs are sufficient to kill PNSP pneumococci but that the blood-brain barrier results in much 
lower levels in the CSF and penicillin cannot reliably be used to treat non-susceptible pneumococcal 
CSF  infections  (111,113).  
Chapter 2 demonstrated the impact of the loss of effective treatment due to the increase in 
antibiotic resistance. In Chapter 3 I examined why some serotypes of the pneumococcus are more 
likely to carry resistance than others. Using a mathematical model I generated the hypothesis that 
serotypes with a long duration of carriage are more likely to have a high prevalence of antibiotic 
resistance than those with a short duration of carriage. In Chapter 4 I tested this hypothesis by 
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analysing the prevalence of penicillin resistant isolates of S. pneumoniae collected as part of invasive 
disease surveillance. Using maximum likelihood estimation, I showed that in children less than two 
years of age, penicillin resistance only occurred in serotypes which had duration of carriage of 
nineteen days or more.  
In Chapters 3 and 4 I considered the circumstances under which antibiotic resistance carries a 
selective advantage in a pneumococcal serotype. In Chapters 5 and 6 I considered the effect that the 
spread of an advantageous gene has on the genetic diversity in a generic in silico bacterial 
population. Specifically, I considered whether asymmetric recombination typical of recombination 
can prevent the loss of diversity over the whole genome.  
In Chapter 5 I reviewed the literature in this area, and compared the results of models of selection 
incorporating asymmetric and symmetric recombination. From the results of this analysis, I showed 
that a mathematical model incorporating asymmetric recombination should be used to examine the 
impact of selection on a bacterial population. In Chapter 6, I developed a stochastic two locus model 
and a multi loci model of bacterial evolution which examined whether recombination can rescue 
genetic diversity associated with the ‘wild-type’ phenotype present in the population before the 
selective sweep. I explored a range of parameters and when I parameterised the model using 
recombination rates estimated from natural populations of bacteria, the loss of genetic diversity was 
a consequence of a selective sweep. Diversity at loci that are not under selection is lost due to the 
hitch-hiking effect of a selective sweep, when neutral loci associated with the locus under selection 
sweep with the advantageous allele to fixation in the population.  
In Chapter 7, I examined the impact of selective pressure from the conjugate vaccines on genetic 
diversity in a pneumococcal population.  I analyse a longitudinally sampled MLST dataset of carried 
isolates. These isolates were collected in 2001, 2004, 2007 and 2009 from healthy children, and 
using the rank frequency distribution successfully detected the impact of selection by the conjugate 
vaccination. I show that in the period immediately following the introduction of vaccination 
sequence type diversity decreases. However, by 2009 sequence type diversity has returned to pre-
vaccination levels. Although I showed that most sequence types associated with vaccine serotypes 
are absent from the population by 2007, I also demonstrated that a number of STs previously 
associated only with vaccine serotypes remain in the population, though now associated with a non-
vaccine serotype.  
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8.2 Implications for disease prevention and suggestions for future work 
One important aim of research into the evolution of S. pneumoniae and other bacterial pathogens is 
to inform treatment and prevention of disease. While I introduced and concluded each chapter by 
contextualising it in current trends in treatment and prevention where appropriate, in this section I 
will interpret broader conclusions from the thesis in the context of treatment and prevention. 
Proponents of pneumococcal conjugate vaccination have suggested that in addition to reducing 
morbidity and mortality due to pneumococcal invasive disease, serotype specific vaccination could 
reduce the prevalence of antibiotic resistance (318,319). They argued that as drug resistance and 
multi-drug resistant strains are strongly associated with certain serotypes, particularly those covered 
by the conjugate vaccine, targeting these serotypes could reduce the incidence of antibiotic 
resistance (1,2). In Chapters 3 and 4 of this thesis I examined why certain serotypes were associated 
with antibiotic resistance but other serotypes were not and in Chapter 7 I examined the impact of 
vaccination on genetic diversity in a sample of carried pneumococci from a population of children. 
Given the conclusions of this research, I will discuss whether a decrease in the prevalence of 
antibiotic resistance is a logical outcome of serotype specific vaccination. 
As I discussed in Chapter 7, the results from a study of longitudinally sampled, carried pneumococci, 
showed that the prevalence of total carriage did not decrease after vaccination was introduced (47). 
However, in the wake of vaccination, the prevalence of vaccine serotypes declined, while the 
prevalence of non-vaccine serotypes increased in carriage (47,309). This phenomenon (serotype 
replacement) has also been documented in surveillance of invasive disease (49,41). Even though the 
proportion of cases caused by non-vaccine serotypes has increased in those regions that have 
introduced vaccination, the clinical impact of this proportional increase is less clear (and beyond the 
scope of this research) (41). Thus, vaccination could only decrease antibiotic resistance if the 
replacing serotypes were less likely to carry antibiotic resistance. In Chapter 4 I showed that 
serotypes with a short duration of carriage were less likely to carry antibiotic resistance. I 
demonstrated that this relationship was preserved after the introduction of vaccination and there 
was no change in the prevalence of resistance in the sample of pneumococcal isolates from IPD.  
This outcome is expected as some serotypes that replaced vaccine serotypes in carriage and disease 
such as 19A have a long duration of carriage and as predicted by the results from Chapters 3 and 4, 
have a high prevalence of antibiotic resistance. Therefore, the introduction of vaccination will not 
necessarily reduce the prevalence of antibiotic resistance in carriage or disease if the replacing 
serotypes have long durations of carriage. However, if replacing serotypes are less likely to cause 
invasive disease, then the incidence of antibiotic resistant IPD could decline. The impact could be 
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particularly important in serotypes that are associated with meningitis (37), where penicillin 
resistance is clinically costly (as I outlined in Chapter 2). Thus, the impact of vaccination on antibiotic 
resistance is a topic deserving further study. 
Antibiotic resistance remains present in the pneumococcal population and as I showed in Chapter 1 
negatively impacts on our ability to treat meningitis. Therefore interventions to reduce the 
prevalence of antibiotic resistance in the community, such as restricting the use of antibiotics in the 
community, must still be pursued. The goals of such interventions are to prevent an increase in the 
prevalence of antibiotic resistance, prevent new resistant strains emerging and ultimately reducing 
the prevalence of antibiotic resistant strains (73,321,205,322). The logic of such interventions is that 
by removing selective pressure from antibiotic consumption, there is no selective advantage to 
resistant strains. If the resistant strain carries a fitness disadvantage, then, if selective pressure is 
removed from the population, the prevalence of resistant strains could fall. Therefore as the cost of 
resistance will determine the rate of decline in the prevalence of antibiotic resistant strains, 
estimating the fitness cost of resistance is an important part of addressing the possible impact of 
public health interventions to restrict antibiotic use.  
Analysing the results from the mathematical model presented in Chapter 3, I showed that there was 
a consistent association between the prevalence of resistance, antibiotic use in the community and 
the threshold duration of carriage above which antibiotic resistant strains are maintained in the 
population. In Chapter 4 I began to develop and refine this method, through more sophisticated 
simulations and estimated an approximate fitness cost of antibiotic resistance. However, more 
sophisticated analysis and simulations are needed to refine these estimates. In addition analysing 
antibiotic resistance prevalence data from different settings with very low and high antibiotic use 
(such as Finland and Spain) would allow us to develop a more robust estimation of the cost of 
resistance. 
In Chapters 5 and 6 I introduced selective sweeps and explored their impact in a generalised 
bacterial population. The results from these models predict that when an advantageous allele arises 
in a population it will sweep to fixation in that bacterial population. Of course this model was 
concerned with a very simplistic scenario and when an advantageous allele (or set of alleles) like 
antibiotic resistance arises in the pneumococcal population, the impact of selection has not been as 
predictable. In Chapters 3 and 4 I explored why certain serotypes did not develop antibiotic 
resistance as a consequence of the associated cost of resistance. However, the question remains as 
to why, within these serotypes, sensitive strains persist in the population. Some attempt has been 
made to resolve this question and reconcile the empirical evidence of coexistence with the 
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predictions of the simple model of selection and transmission (84). However, the results from the 
model presented by Colijn et al. allowed coexistence only under a small range of parameters (85), 
thus further work is needed to explore the phenomenon of coexistence in pneumococcal serotypes. 
Ultimately the answer to this question is likely to be found using a synthesis of parameter estimation 
from natural populations of bacteria, mathematical models to simulate and test hypotheses and 
large datasets, preferably collected from carriage.  
8.3 Concluding remarks 
In conclusion the research in this thesis has demonstrated that if treated with penicillin, a patient 
infected with penicillin non susceptible meningitis is twice as likely to die as a patient with penicillin 
susceptible meningitis. This demonstrated that understanding how and why antimicrobial resistance 
occurs in the pneumococcal population has a clinical impetus. I showed that the development of 
resistance is not an inevitable result of antibiotic use. As there is a cost of resistance, antibiotic 
resistance is unlikely to persist in serotypes which have a short duration of carriage. I demonstrated 
that rates of recombination in bacterial populations are not sufficiently high to prevent the loss of 
genetic diversity as a consequence of the selective sweep of a novel genotype carrying an 
advantageous allele. Finally I showed that the impact of vaccination can be detected by examining 
changes in the population genetic structure of S. pneumoniae in carriage. 
Throughout this research I have shown that mathematical models can be used to develop an 
understanding of a system and develop and formalise hypotheses. These hypotheses can then be 
examined in data from natural populations of bacteria. Finally, I have demonstrated that to 
understand the impact of treatment and prevention of disease, it is essential to understand the 
population genetics of an organism. 
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Appendix A: Glossary of laboratory techniques 
 
Acetyl Co-A synthetase Acetyl Co-A synthetase is an enzyme involved in metabolism of carbon 
sugars. It is in the ligase class of enzymes, meaning that it catalyzes the formation of a new chemical 
bond between two large molecules (1). 
Cell density Cell density can be determined using optical techniques based on the absorbance of 
light by cells using a spectrophotometer or colorimeter (2). With cultures well dispersed it is found 
that optical density remains proportional to cell density throughout the positive growth stages of 
cultures (3).  
Cell mass Both viable and total cell counts do not measure increases in cell mass during the cell 
division cycle. Growing bacterial cells increase their mass before division; therefore even though the 
number of cells may not have increased growth is occurring. Cell mass can be determined directly by 
measuring cell weight after they have been isolated and dried.  
Chemostat A chemostat is a continuous culture device used for growing and harvesting microbes. 
Chemostats are open systems where media is continually added and spent media and cells removed. 
The media is constructed so that one of the nutrients in the media is added in amounts that limit the 
number of bacteria. As media is constantly added and waste removed, limiting conditions do not 
occur and so growth never slows (4). The chemostat consists of three primary parts, the nutrient 
reservoir, the growth chamber and an efflux reservoir for exhausted medium, living cells and cellular 
debris (5). The most important feature of the chemostat is that all fermentation parameters such as 
growth chamber volume, nutrient concentrations and pH remain constant throughout an 
experiment (6). The rate of cell division can be manipulated by varying the input of nutrient from the 
nutrient reservoir until the desired cell density is reached. The equilibrium cell density is maintained 
as the number of new cells created by division is balanced by the number of cells siphoned off in the 
outflow. The equilibrium cell density is determined by the concentration limiting nutrient in the 
reservoir (4).  
An assumption of the chemostat and much of the analytical and computational work attached to it is 
that there is a constant relationship between the amount of limiting nutrient inputted into the 
system and the population size. This leads to the further assumption that the population size can be 
maintained constant throughout the experiment. The assumption that reproduction is proportional 
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to nutrient uptake is a simplification and the evidence for this assumption is based on experimental 
evidence rather than resting on any physiological basis (5).  
Fitness assays The fitness of a bacterial type is measured relative to its ancestor. Relative fitness is 
measured by allowing an evolved type to compete with its ancestor. The two types are grown 
separately in the competition environment in order to ensure that they are equally acclimatised to 
test conditions. They are then mixed, usually at the ratio 1:1 and grown in the competition 
environment. Initial and final numbers of cells are assessed by the pour plate method [defined 
below] to estimate a count of viable cells using an agar containing an indicator substrate. The growth 
rate of each competitor is calculated as the natural logarithm of the ratio of its final density to its 
initial density. Relative fitness is the ratio of the growth rates of the evolved and ancestral types (6).  
gap A is a gene which codes for an enzyme in the glycolysis pathway (1).  
Lac operon encodes proteins which utilize lactose and other β-galactosides (1).  
lacY is a gene which codes for the LacY protein responsible for the membrane transport of lactose 
and other β-galactosides (1).  
malT is the gene which encodes activator proteins in the mal gene system, which codes for proteins 
necessary to utilize maltose a type of sugar (1).  
Metabolite measures Growth can also be estimated indirectly by monitoring the consumption of a 
substrate by the bacteria. This techniques measure a result of growth rather than cell number. 
Assays that measure the depletion of a substrate like glucose are used, as are those that monitor the 
utilization of oxygen during respiration (9).  
mgl locus is a cluster of genes which code for proteins involved in the uptake and utilization of 
galatose which is a type sugar (1). 
mlc is a gene which codes for a global repressor affecting sugar transport genes (1).  
pho A is a gene on the Pho regulon which codes for an enzyme in the pathway of phosphate 
assimilation from environmental organophosphate (1). 
Pho regulon is a system of genes which code for proteins necessary to uptake and utilise phosphorus 
sources for growth (1).  
Serial transfers of batch culture An inoculum of non-growing bacterial cells is added to fresh 
medium. A lag period occurs initially, where there is little or no growth in the culture as cells adapt 
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to the new culture conditions. Shortly after growth starts, cells begin to grow exponentially, at a 
maximum growth rate until some component of the medium becomes limiting. When nutrients 
become exhausted or toxic waste products build up bacterial growth is inhibited (2). The cells then 
enter the stationary phase where the growth rate is null (4). The progress of bacteria through the 
growth stages is monitored through the calculation of changes in cell density; by using optical cell 
density techniques and impedance counting or calculating cell concentrations determined by 
performing indirect viable cell counts. When the bacteria reach stationary phase, the inoculum of 
bacteria for the next flask of fresh medium and this can be repeated for the desired number of 
generations (4).  
Techniques to monitor the change in the prevalence of a neutral marker Periodic selection was first 
observed when the frequencies of mutants carrying neutral markers observed in culture were 
altered by selection for an unrelated and unknown mutation at another locus (7,5). The sweep of the 
advantageous mutant types through the population are tracked by monitoring the fluctuations of a 
neutral marker in the population.  
The densities of the different types are estimated by performing viable cell counts using an indicator 
agar which identifies the neutral marker by sight alone. For example, if the neutral marker on the 
wildtype cell was T5 phage resistance, one plate of culture medium would be inoculated with T5 
phage so that only those containing the neutral marker could grow. A phenotype that is selectively 
neutral, such as T5 phage resistance, when phage is not present, should increase linearly in the 
population as mutations to generate this phenotype occur at a constant rate. Compared to the size 
of the population the T5 resistant phenotype is rare, so it is unlikely that an advantageous mutation 
will occur in a cell with this phenotype. A fall in the frequency of T5 resistant cells in the population 
can be interpreted as an increase in the frequency of an advantageous mutant (6). 
Total cell count The total cell count is the number of cells, living and dead, that are present in a 
sample. This can be estimated by using a direct cell count which measures all the cells present. Cell 
counts can be measured using a counting chamber, where cells are directly observed under the 
microscope or using impedance counting, where cells passing through a narrow chamber disrupting 
the flow of an electrical current (8).  
Viable cell count Using the pour plate method, an inoculum of cells in a suitable dilution is mixed 
with tubes of melted growth medium. The mixture is poured into a petri dish and the number of 
colonies counted is taken as the number of viable cells in the original inoculum of culture medium. 
An alternative method is the spread plate method where a small amount of cells in culture medium 
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is spread over the surface of a solid plate of growth medium. In both methods the plates are 
incubated and the number of colonies formed on the plate counted (9). One limitation of this 
method is that it assumes that each colony is descended from one cell. Another is that colonies must 
be visible to the naked eye before they are counted so a bacterium could have produced hundreds 
of thousands of descendants and still be classed as unviable cell by this method and therefore not 
counted by a viable cell count method.  
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